



**Jéssica Fabiana  
Moreira de Sousa**

**Caracterização das alterações do envelope nuclear  
no envelhecimento**

**Characterization of the nuclear envelope alterations  
during ageing**



Jéssica Fabiana  
Moreira de Sousa

## Caracterização das alterações do envelope nuclear no envelhecimento

### Characterization of the nuclear envelope alterations during ageing

Dissertação apresentada à Universidade de Aveiro para cumprimento dos requisitos necessários à obtenção do grau de Mestre em Biomedicina Molecular realizada sob a orientação científica da Doutora Sandra Maria Tavares da Costa Rebelo, Professora Auxiliar Convidada do Departamento de Ciências Médicas da Universidade de Aveiro e coorientação da Doutora Filipa de Sá Martins, Investigadora de pós-doutoramento do Departamento de Ciências Médicas da Universidade de Aveiro

Este trabalho é financiado pelo Instituto de Biomedicina – iBiMED (UID/BIM/04501/2013 e POCI-01-0145-FEDER-007628), e pelo programa integrado de SR&TD “pAGE – Protein aggregation across Lifespan” (referência CENTRO-01-0145-FEDER-000003), co-financiado pelo programa Centro 2020, Portugal 2020, União Europeia, através do Fundo de Desenvolvimento Regional Europeu.

CENTRO



## **o júri**

presidente

**Prof. Doutora Ana Margarida Domingos Tavares de Sousa**  
Professora Auxiliar Convidada do Departamento de Ciências Médicas da Universidade de Aveiro

**Prof. Doutora Sandra Maria Tavares da Costa Rebelo**  
Professora Auxiliar Convidada do Departamento de Ciências Médicas da Universidade de Aveiro

**Doutora Mariana Santos Moreda Graça**  
Investigadora de Pós-Doutoramento do Instituto de Biologia Molecular e Celular da Universidade do Porto

## **Agradecimentos**

Começo por agradecer à minha orientadora, a professora Sandra Rebelo, por toda a orientação científica prestada na realização desta dissertação.

Gostaria também de agradecer imenso à Filipa Martins. Escreva eu o que escrever, nunca será o suficiente. Obrigada por toda a ajuda prestada diariamente, por tudo o que me ensinaste a nível laboratorial e por toda a amizade criada neste ano de trabalho em conjunto. Sem ti e todos os ensinamentos que me passaste, nada seria igual.

Agradeço também à Cátia, minha colega de grupo de investigação que, à sua maneira, esteve sempre lá para dar uma mão quando foi necessário.

À professora Odete Cruz e Silva pelos materiais e recursos fornecidos para que esta dissertação fosse possível.

*Ao Neuroscience and Signalling Group* por todo o auxílio prestado.

Ao grupo de investigação *STL* que, em diversos momentos, me ajudaram com tudo o que podiam.

À melhor pessoa que Aveiro me deu a conhecer, Catarina Ruivo, que fez com que todos os momentos mais difíceis fossem suportáveis. Obrigada do fundo do meu coração.

A todos os meus colegas e amigos do mestrado que alegraram de uma maneira ou de outra os meus dias durante todo o mestrado, em que o ano de dissertação não foi exceção.

E por último, mas não menos importante, à minha família que sempre me apoiou, mas em especial aos meus pais, sem os quais nada seria possível.

## palavras-chave

Envelhecimento, senescência, funções nucleares, proteínas do envelope nuclear, interações proteína-proteína, ratinhos envelhecidos, fibroblastos humanos

## resumo

O envelhecimento é caracterizado por um decréscimo generalizado da condição física durante o curso de vida. Assim, com a idade, aumenta o risco de desenvolver doenças neurodegenerativas, diabetes, cancro e doenças cardiovasculares. Vários estudos foram realizados no sentido de determinar as alterações moleculares e celulares adjacentes ao envelhecimento, contudo, os mecanismos moleculares exatos que regulam o processo de envelhecimento continuam pouco conhecidos. Ainda assim, a regulação de proteínas na periferia do envelope nuclear, nomeadamente da lamina e de proteínas nucleares associadas à lamina têm sido sugeridas como intervenientes no processo de envelhecimento. De facto, em modelos de envelhecimento prematuro, algumas alterações em proteínas do envelope nuclear foram reportadas. Neste trabalho, foi realizada uma análise bioinformática que nos permitiu elaborar um estudo amplo do processo do envelhecimento. Com recurso a duas bases de dados públicas, identificamos uma lista de genes relacionados com o envelhecimento. A análise dos dados evidenciou que mais de metade dos genes relacionados com o envelhecimento correspondem a proteínas nucleares, o que sugere um papel para a função nuclear no processo de envelhecimento. Ainda, a construção de redes de interação proteína-proteína levou-nos à identificação de clusters funcionais relacionados com regulação transcricional, remodelação da cromatina, processos metabólicos e reparação do DNA. Adicionalmente, investigamos as alterações dos níveis e de localização de proteínas do envelope nuclear durante o envelhecimento, em tecidos de ratinho e fibroblastos humanos. Os nossos resultados indicam claramente que os níveis da proteína lamina A/C e da proteína SUN1 aumentam com a idade tanto em modelos humanos como em ratinhos. Os níveis da nesprina-2, da emerina, da LAP1 e da lamina B1 aumentam com a idade em ratinhos, enquanto que os níveis da NUP133 e da NUP93 diminuem com a idade em fibroblastos humanos. Foi ainda evidenciada uma perda da integridade nuclear em fibroblastos humanos, assim como uma diminuição da fração nucleocitoplásmica da lamina A/C. Também observámos um aumento de *speckles* nucleares de emerina com a idade em fibroblastos humanos. Para concluir, a arquitetura nuclear e as proteínas do envelope nuclear parecem sofrer alterações durante o processo do envelhecimento. Assim, estudos futuros deveriam explorar e elucidar a sua contribuição para o processo de envelhecimento.

**Keywords**

Ageing, senescence, nuclear functions, nuclear envelope proteins, protein-protein interaction, aged mice, human fibroblasts

**Abstract**

Ageing is characterized by an overall organismal fitness decrease across lifespan. Hence, the risk of developing complex diseases as neuropathologic disorders, diabetes, cancer and cardiovascular diseases increases with age. Despite a huge effort to determine the underlying molecular and cellular changes, the precise molecular mechanisms that regulate the ageing process remain elusive. Although, in the last few years, the protein regulation at the nuclear periphery, particularly of the nuclear lamina and lamina-associated proteins, has been pointed out as a major contributor to the ageing process. In fact, in premature ageing models, some nuclear envelope proteins have been mentioned to be altered. In this work, we performed a bioinformatic analysis that allowed us to develop an intricate study of the ageing process. Briefly, we assembled a list of age-related genes by combining the data of two public databases. Remarkably, the analysis of the data places the nucleus in the spotlight of the ageing process, given that almost half of the age-related genes are associated to nuclear functions. Moreover, protein-protein interaction network construction led us to the identification of prominent age-related functional clusters related with transcription regulation and chromatin remodelling, and DNA metabolic process and DNA repair. Further, in order to unravel the nuclear envelope proteins alterations during ageing, we performed immunoblotting and immunocytochemistry analysis in mice tissues and human fibroblasts. Our results clearly indicate that lamin A/C and SUN1 protein levels increases during ageing in both human and mice models. Moreover, nesprin-2, emerin, LAP1, and lamin B1 protein levels increase with age in mice models, whereas lamin B1, NUP133 and NUP93 protein levels decreases with age in human fibroblasts. Moreover, in aged human fibroblasts it is observable a loss of the nuclear integrity, combined with a decrease of the nucleocytoplasmic fraction of lamin A/C. Also, an increase of emerin nuclear speckles is noticeable in aged fibroblasts. To conclude, the nuclear architecture and the nuclear envelope proteins seems to be affected during the ageing process and further studies should be performed in order to elucidate their relative contribution to ageing.

## Index

|  |    |
|--|----|
| List of Abbreviations .....  | v  |
| CHAPTER I: General introduction and aims .....   | 1  |
| 1. Introduction .....  | 3  |
| 1.1. The Nuclear Envelope .....  | 3  |
| 1.1.1. The Nuclear Envelope Proteins .....   | 5  |
| 1.2. The Ageing Process .....  | 16 |
| 1.3. The NE dysfunction in the ageing process .....  | 22 |
| 1.4. Ageing models .....   | 28 |
| Aims .....   | 30 |
| CHAPTER II: Bioinformatic analysis of interaction networks in ageing .....                                   | 31 |
| 2.1. Introduction .....  | 33 |
| 2.2. Methodology .....   | 33 |
| 2.2.1. Collection of the human age-related proteins/genes .....  | 33 |
| 2.2.2. Functional enrichment analysis of Gene Ontology .....   | 34 |
| 2.2.3. Construction of an interaction network of ageing .....  | 34 |
| 2.3. Results .....   | 35 |
| 2.4. Discussion .....  | 45 |
| Supplementary Data .....   | 47 |
| CHAPTER III: Characterization of the nuclear envelope protein alterations during ageing in mice models ..... | 63 |
| 3.1. Introduction .....  | 65 |
| 3.2. Materials and Methodology .....   | 66 |
| 3.2.1. Animals .....   | 66 |
| 3.2.2. Protein extraction .....  | 67 |
| 3.2.3. Protein Quantification .....  | 67 |
| 3.2.4. SDS-Polyacrylamide Gel Electrophoresis .....  | 68 |
| 3.2.5. Immunoblotting .....  | 68 |
| 3.2.6. Data Analysis and Statistics .....  | 70 |
| 3.3. Results .....   | 70 |
| 3.4. Discussion .....  | 75 |
| Supplementary Data .....   | 78 |
| CHAPTER IV: Characterization of the nuclear envelope protein alterations during ageing in human models ..... | 79 |
| 4.1. Introduction .....  | 81 |
| 4.2. Materials and Methods .....   | 82 |
| 4.2.1. Samples .....   | 82 |

|  |   |     |
|--|---|-----|
| 4.2.2.   | Cell Culture .....  | 82  |
| 4.2.3.   | Flow Cytometry .....  | 83  |
| 4.2.4.   | Antibodies .....  | 84  |
| 4.2.5.   | Western Blotting .....                                      | 84  |
| 4.3.   | Results.....  | 86  |
| 4.3.1.   | Characterization of our human ageing model.....             | 86  |
| 4.3.2.   | Evaluation of Nuclear Envelope Proteins during ageing ..... | 88  |
| 4.2.3.   | Nuclear Envelope Proteins localization during ageing .....  | 91  |
| 4.4.   | Discussion .....  | 100 |
| CHAPTER V: General discussion and concluding remarks ..... |   | 107 |
| Bibliographic references .....                             |   | 113 |
| Appendix .....   |   | 131 |

## List of Figures

|   |    |
|---|----|
| Figure I.1 – Schematic representation of the nuclear envelope.....  | 3  |
| Figure I.2 – The Nuclear Pore Complex structure and composition. ....   | 5  |
| Figure I.3 – Structure of the nuclear envelope and associated proteins.....   | 6  |
| Figure I.4 – Schematic representation of the prelamin A maturation process.....   | 7  |
| Figure I.5 – Schematic representation of Emerin.....  | 9  |
| Figure I.6 – The LINC complex.....  | 11 |
| Figure I.7 – Schematic representation of the NPCs and the different nucleoporins categories.....  | 13 |
| Figure I.8 – The hallmarks of ageing.....   | 17 |
| Figure I.9 – The three core groups of the hallmarks of ageing.....  | 18 |
| Figure II.1. – Methodological workflow overview.....  | 35 |
| Figure II.2 – Functional annotation cellular component clustering analysis (clusters 1 and 2) of the age-related genes using DAVID online resource. The percentage of the age-related genes was calculated and plotted..... | 36 |
| Figure II.3 – Protein-protein interaction network of the nuclear age-related genes. Node size according to the degree (number of neighbours) in the network.....  | 40 |
| Figure II.4 – Nuclear age-related PPI network clusters produced using the Cytoscape plugin clusterMaker (GLay).....   | 41 |
| Figure II.5 – Nuclear age-related PPI network cluster 1 (A) and cluster 2 (B) produced using the Cytoscape plugin clusterMaker (GLay). Node size corresponding to node degree.....  | 42 |
| Figure III.1 - Life phase equivalencies between mice and human.....   | 65 |
| Figure III.2 – Illustrative scheme of the tissues (liver and kidney) collected of four different mice at different ages of 6, 18 and 24 months old.....   | 66 |



|  |     |
|--|-----|
| Figure III.3- Protein levels of specific nuclear envelope proteins during ageing in mice liver.....  | 72  |
| Figure III.4 - Protein levels of specific nuclear envelope proteins during ageing in mice kidney..   | 74  |
| Figure SIII.1 – Ponceau S scans used to normalize the mice samples.....  | 78  |
| Figure IV.1 – Schematic representation of the hallmarks of ageing, confirmed <i>in vitro</i> by using aged fibroblasts as model.....   | 81  |
| Figure IV.2 – Categorization of the fibroblasts samples across lifespan. Biopsies were performed on healthy Caucasian women with ages between 24yo (years old) to 80yo.....  | 82  |
| Figure IV.3. – H3K9me3 protein levels evaluated by immunoblotting in human fibroblasts lysates from 5 different patients analysed separated or grouped into 2 groups: young (24, and 25yo) and aged (46, 69 and 89yo)..... | 87  |
| Figure IV.4. – Percentage of fibroblasts of four different donors (24, 46, 69 and 80 yo) annexin V positive/PI negative stained (black bars) and annexin V positive/PI positive stained (grey bars).....                   | 88  |
| Figure IV.5 – Lamin A/C protein levels during ageing in human fibroblasts.....   | 89  |
| Figure IV.6 – The inner nuclear membrane proteins levels during ageing in human fibroblasts...   | 90  |
| Figure IV.7 – Nuclear Pore Complex Proteins levels during ageing in human fibroblasts.....   | 91  |
| Figure IV.8. – Subcellular distribution of lamin A/C in fibroblasts from donors’ samples with 24 (A), 46 (B), 69 (C) and 80 yo (D).....  | 92  |
| Figure IV.9. – Subcellular distribution of lamin A/C in fibroblasts from donors’ samples with 24 yo at PN10 and 24 yo at PN20.....   | 93  |
| Figure IV.10. – Subcellular distribution of Lamin B1 in fibroblasts from donors’ samples with 24 (A), 46 (B), 69 (C) and 80 yo (D).....  | 95  |
| Figure IV.11 – Subcellular distribution of emerin in fibroblasts from donors’ samples with 24 (A), 46 (B), 69 (C) and 80 yo (D).....   | 96  |
| Figure IV.12 – Subcellular distribution of SUN1 in fibroblasts from donors’ samples with 24 (A), 69 (B) and 80 yo (C).....   | 98  |
| Figure IV.13 – Subcellular distribution of LAP1 in fibroblasts from donors’ samples with 24 (A), 46 (B), 69 (C) and 80yo (D).....  | 99  |
| Figure IV.14 – Schematic summary of the main results obtained by immunoblotting and immunocytochemistry analysis of lamin A/C, lamin B1, emerin, SUN1, LAP1, NUP133, and NUP93 in human fibroblasts.....                   | 102 |
| Figure V.1 – Schematic summary of the main results obtained with both ageing models studied in this work (mouse model left, and human fibroblast model right).....   | 109 |

## List of Tables

|  |    |
|--|----|
| Table I.1 – Classes of nucleoporins.....   | 14 |
| Table I.2 - Nuclear envelope proteins involved in the ageing process.....  | 27 |
| Table II.1 – Cellular component functional annotation clustering enrichment analysis of the age-related genes network using DAVID online resource. Enriched categories are those with Bonferroni adjusted p value <0.05..... | 37 |
| Table II.2. – Biological processes functional annotation enrichment analysis of the cluster 1 using Panther online resource. Enriched categories are identified as those with Bonferroni adjusted p value <0.05.....         | 43 |
| Table II.3. – Biological processes functional annotation enrichment analysis of the cluster 2 using Panther online resource. Enriched categories are identified as those with Bonferroni adjusted p value <0.05.....         | 44 |
| Table SII.1 – Age-related genes obtained from the online databases GenAGE and GENEID. Uniprot accession numbers, gene and protein names are listed.....  | 47 |
| Table III.1 – Primary antibodies used in order to detect the proteins analysed by immunoblotting.....  | 69 |
| Table IV.1 – Primary antibodies used in order to detect the multiple proteins. WB, Western Blotting; ICC, immunocytochemistry.....   | 84 |

## List of Abbreviations

A.U. – Arbitrary Units  
AGEID – Aging Genes/Interventions Database  
ANOVA – Analysis of variance  
APC – Allophycocyanin  
APS – Amonium persulfide  
A-T – Ataxia Telangiectasia  
ATP – adenosine triphosphate  
BAF – barrier to autointegration factor  
BCA – bicinchoninic acid  
BMP – bone morphogenic protein  
BSA – bovine serum albumin  
Btf – death promoting transcriptional repressor  
CEDCM-BEA – Animal welfare body of the Department of Medical Sciences of the University of Aveiro  
DAPI – 4',6-diamidino-2-phenolyde  
DAVID – The Database for Annotation, Visualization and Integrated Discovery  
dH2O – distilled water  
DMEM – Dulbecco's Modified Eagle Medium  
DNA – deoxyribonucleic acid  
DTT – Dithiothreitol  
ECM – extracellular matrix  
EDMD – Emery-Dreifuss muscular dystrophy  
EDTA – Ethylenediamine tetraacetic acid  
EGTA – Ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid  
ELB – extraction lysis buffer  
ER – endoplasmic reticulum  
FBS – Fetal Bovine Serum  
FG – phenylalanine-glycine  
g – times gravity  
GCL – germ cell less  
GO – Gene Ontology  
h – hours

H3K27 – Histone H3 lysine 27  
H3K4 – Histone H3 lysine 4  
H3K9 – Histone H3 lysine 9  
H4K20 – Histone H4 lysine 20  
HEPES – N-2-Hydroxyethylpiperazine-N'-2-Ethanesulfonic Acid  
HGPS – Hutchinson-Gilford progeria syndrome  
HRP – Horseradish peroxidase  
iBiMED – Institute for Biomedicine of University of Aveiro  
ICC – immunocytochemistry  
ICMT – isoprenylcysteinecarboxylmethyltransferase  
INM – inner nuclear membrane  
iPSCs – induced pluripotent stem cells  
KASH – Klarsicht/ANC-1/SYNE homology  
LAP1 – Lamina-associated polypeptide 1  
LAP2 – Lamina-associated polypeptide 2  
LAP2 – lamina-associated polypeptide 2  
LB – loading buffer  
LBR – Lamin B receptor  
LINC – Linker of Nucleoskeleton and Cytoskeleton  
mAb – monoclonal antibody  
MAN1 – Inner nuclear membrane protein Man1  
MAPK – mitogen activated protein kinases  
min – minutes  
Na<sub>3</sub>VO<sub>4</sub> – Sodium orthovanadate  
NaCl – sodium chloride  
NAD – nicotinamide adenine dinucleotide  
NE – Nuclear envelope  
nm – nanometre  
NPC – nuclear pore complexes  
Nrf2 – nuclear factor erythroid-2-related factor 2  
NUP – nucleoporin  
°C – degrees Celsius  
ONM – outer nuclear membrane  
PANTHER – Protein ANalysis THrough Evolutionary Relationships

PBS – phosphate buffered saline  
PCNA – proliferating cell nuclear antigen  
PI – propidium iodide  
PN – passage number  
PNS – perinuclear space  
PP1 – protein phosphatase 1  
PPI – protein-protein interaction  
PTMs – Post-translational modifications  
Rb – retinoblastoma  
RNA – ribonucleic acid  
ROS – reactive oxygen species  
rpm – rotations per minute  
RT – room temperature  
SDS – sodium dodecyl sulfate  
SDS-PAGE – sodium dodecyl sulfate polyacrylamide gel electrophoresis  
SEM – standard error  
siRNA – small interfering RNA  
SIRT – sirtuin  
SUN – Sad1/UNC-84  
TBS – Tris-buffered saline  
TBS-T – Tris-buffered saline with Tween 20  
TEMED - N,N,N',N'-Tetramethylethylenediamine  
TERT – telomerase reverse transcriptase  
TGF $\beta$  – transforming growth factor beta  
TOR1AIP1 – Torsin-1A-interacting protein 1  
TPR – Nucleoporin TPR  
TRF – telomere restriction fragment  
VSMC – vascular smooth muscle cells  
WB – western blotting  
WT – wild type  
YO – years old  
ZMPSTE24 - Zinc Metallopeptidase STE24



# **CHAPTER I**

## **General introduction and aims**






# 1. Introduction

## 1.1. The Nuclear Envelope

The nuclear envelope (NE) is a very specialized double membrane that encloses the eukaryotic nuclear content (D'Angelo and Hetzer, 2006). The NE is crucial to keep the individuality of the nucleus and the cytoplasm as it represents the only barrier between these two compartments (Postberg *et al.*, 2010). The NE is composed by the nuclear pore complexes (NPCs), the nuclear lamina, and two nuclear membranes, each of which is a lipid bilayer, namely the outer nuclear membrane (ONM) and the inner nuclear membrane (INM) (Watson, 1955; Yang *et al.*, 2017). These membranes are separated by the perinuclear space (PNS) which corresponds to a 30 to 50nm gap (Stewart *et al.*, 2007) (figure I.1).




**Figure I.1** – Schematic representation of the nuclear envelope. The nuclear envelope encloses the nucleus and is composed by a double nuclear membrane (the inner and the outer nuclear membrane). The perinuclear space is enclosed between the INM and the ONM. The nuclear lamina is localized close to the inner side of the nuclear membrane. The ONM is contiguous with the endoplasmic reticulum. The nuclear pore complexes go through the nuclear membranes.

The ONM is continuous with the rough endoplasmic reticulum (ER), which explains the presence of ribosomes on its cytoplasmic surface (D'Angelo and Hetzer, 2006; Newport

and Forbes, 1987) which are involved in protein synthesis (Alberts *et al.*, 2008). The ONM also offers attachment sites for structural elements of the cytoplasm (Burke and Ellenberg, 2002). The link between the cytoskeleton and the ONM is vital to the NE integrity and to the location of the nucleus (Fernández-Álvarez and Cooper, 2017).

The INM is particular and encompasses many integral membrane-associated proteins (D'Angelo and Hetzer, 2006; Katta *et al.*, 2014; Stewart *et al.*, 2007). The INM contains many proteins that are involved in processes like genome regulation, inheritance and protection, counting peripheral and integral proteins (Ungricht and Kutay, 2017). The INM nucleoplasmic layer is closely associated with the nuclear lamina, which is a network of fibrous intermediate filaments that guarantees the integrity and supports the nuclear structure (Senior and Gerace, 1988; Alberts *et al.*, 2008; Yang *et al.*, 2017). Furthermore, the nuclear lamina is a thin matrix of ~10-20nm with multiple proteins constituted by A- and B-type lamins that are associated with proteins from the INM, establishing connections between the cytoskeleton, the nucleoskeleton, and the genome (Lee and Burke, 2017; Brady *et al.*, 2018). It contacts directly with chromatin and might play a role in gene expression, DNA replication, DNA repair, chromosome organization, transcriptional control and heterochromatin maintenance (D'Angelo and Hetzer, 2006; Katta *et al.*, 2014; Fernández-Álvarez and Cooper, 2017).

The NPCs are aqueous multiprotein channels that penetrate both the inner and the outer nuclear membranes at many sites (Liu *et al.*, 2012; Rothballer and Kutay, 2013). According to Hetzer (2010), these channels have an outer diameter of ~100 nm and a central transport channel measuring 40 nm in diameter (Hetzer, 2010). The main structure of NPCs can be represented by three rings, namely the nucleoplasmic ring at the top, the cytoplasmic ring at the bottom and in the middle: the inner ring. Some cytoplasmic filaments spread from the cytoplasmic ring. Below the nucleoplasmic ring, there is the nuclear basket which is connected with it (figure I.2) (De Magistris and Antonin, 2018).




**Figure I.2** – The Nuclear Pore Complex structure and composition. The nuclear pore complex is formed by cytoplasmic fibrils, the cytoplasmic ring, the central pore, the nuclear ring and the nuclear basket. Taken from Fu *et al.*, (2018).

The NPCs are formed by several complexes composed of nuclearporins. The main function of the NPCs is to enable the nucleocytoplasmic transport of small molecules (<40kDa and <5nm) (Patel *et al.*, 2007) and some larger protein complexes containing important signalling sequences (Robijns *et al.*, 2018). The NPC transport is arbitrated by a transient interaction between the NPC and karyopherins. Karyopherins are a transport receptors superfamily that links to their cargoes by recognizing precise nuclear localization or export signals. This link is controlled by the Ras-related GTPase Ran. Protein regulators of the GTPase cycle and subcellular localization supports Ran in this regulation (Pemberton and Paschal, 2005). Several proteins have been associated with this nucleocytoplasmic shuttling process, namely transcription factors, translation initiation factors, cell proliferation regulators, RNA binding proteins, and hormone receptors (Gama-Carvalho and Carmo-Fonseca, 2001; Hetzer, 2010; Liu *et al.*, 2012; Fu *et al.*, 2018).

### 1.1.1. The Nuclear Envelope Proteins

The NE proteins work together to perform individual structural, functional, and regulatory roles between the genome and the cytoskeleton, allowing the metazoan cells to answer various mechanical, chemical and inflammatory stimuli in a proper and timely manner (Brady *et al.*, 2018). The main NE proteins are represented in figure I.3.




**Figure I.3** – Structure of the nuclear envelope and associated proteins. LAP1, LAP2, BAF, Emerin, SUN1/2, Nesprin 1/2, LBR and MAN1 are the most abundant proteins of the nuclear envelope. Image taken from Stewart *et al.* (2007). INM, inner nuclear membrane; PNS, perinuclear space; ONM, outer nuclear membrane; NPC, nuclear pore complex.

- **Lamins**

The nuclear lamina is composed by members of the family of the intermediate filaments called lamins, which are a complex of proteins located close to the INM in a clear majority of the metazoan cells playing a fundamental role in the nuclear architecture (Reddy and Comai, 2016). The main elements of the nuclear lamina are two types of lamins: the A- and the B-type lamins. A-type lamins can be divided in lamin A, lamin C, lamin C2 and lamin C3, whereas B-type lamins are lamin B1, lamin B2 and lamin B3. Furthermore, the A-type lamins are encoded by a unique gene, the *LMNA*, by alternative splicing. B-type lamins are derived from two different genes: *LMNB1* that encodes lamin B1 and *LMNB2* that encodes lamins B2 and B3 (Schreiber and Kennedy, 2013). Lamins A/C are expressed only in differentiated cells, but C2 is uniquely expressed in germ cells. Recent studies reported the presence of low levels of lamin A/C in mouse embryonic stem cells (Eckersley-Maslin *et al.*, 2013). Lamin B3 is specific of the testis tissue (Schütz *et al.*, 2005).

Lamins comprise a globular N-terminal head domain, a coiled-coil central rod domain, and a C-terminal tail domain. Lamins present singularities at the tail domain like a nuclear localization signal, an immunoglobulin fold domain, and a CaaX motif (C=Cysteine;

A= Aliphatic residue; X= any residue) (de Leeuw *et al.*, 2018). These proteins go through a long process of post-translational modifications (PTMs; figure I.4). A-, B1- and B2-lamin types are synthesised as prelamins containing a CaaX motif at their carboxy-terminal tails (Dittmer and Misteli, 2011).



**Figure I.4** – Schematic representation of the prelamina maturation process. Prelamin, the precursor to mature lamin A, lamin B1, and lamin B2 comprise a carboxyl-terminal *CaaX* motif that activates farnesylation and methylation of a carboxyl-terminal cysteine. Prelamin A undertakes one extra processing step: the last 15 amino acids of the protein, including the farnesylcysteine methyl ester, are removed, releasing the mature lamin A. Taken from Dechat *et al.* (2008).


The complex processing of the CaaX motif starts with an incorporation of the hydrophobic farnesyl group to the cysteine residue by farnesyltransferase and it is followed by the cleavage of the final three amino acids (-AAX) by an AAX endopeptidase like Zmpste24 or FACE1 metallopeptidases. An isoprenylcysteinecarboxylmethyltransferase (ICMT) adds a methyl group to the carboxylic acid group (-COOH) of the C-terminal cysteine (Dechat *et al.*, 2008). In order to produce a mature Lamin A, another cleavage of 15 amino acids upstream of the farnesylated and methylated cysteine by Zmpste24 is needed (Carrero *et al.*, 2016).

Defects or failures in the removal of the farnesylated and methylated cysteine result in serious conditions and diseases like Hutchinson-Gilford progeria syndrome (HGPS) which is a very rare genetic disorder that presents clinical traits that mimic physiological ageing (Carrero *et al.*, 2016; de Leeuw *et al.*, 2018). This disorder occurs due to an accumulation of a permanently farnesylated and carboxy methylated prelamin A variant called progerin that results from the deletion of the second cleavage site (Reddy and Comai, 2016). The most frequent HGPS mutation occurs at codon 608 (G608G) and results in a cryptic splice site in the exon 11, excluding a proteolytic cleavage site in the expressed mutant lamin A (Pollex and Hegele, 2004). Other genetic disorders can be caused by mutations in the nuclear lamins or other NE proteins. These disorders are known as laminopathies and display various phenotypes and symptoms that can vary from muscular dystrophy to neuropathies to premature ageing syndromes (Schreiber and Kennedy, 2013).

- **Emerin**

Emerin is a nuclear protein encoded by the *EMD* gene and is attached to the inner nuclear membrane through its hydrophobic C-terminal domain (Samson *et al.*, 2017). Emerin is expressed in various tissues but it seems to play a prominent role in maintaining the regular function in skeletal and cardiac muscle (Wilson *et al.*, 2008). Emerin interacts with lamin A/C and mutations in any of these proteins can cause Emery-Dreifuss muscular dystrophy (EDMD) (Wilkinson *et al.*, 2003). EDMD is a disorder that influences skeletal and cardiac muscle, resulting in contractures, movement restriction, muscle weakness and wasting with propensity to get worse over time, heart conditions and a higher risk of unexpected death (Fairley *et al.*, 1999). Emerin is a member of the LEM-domain protein family. The LEM domain is found in LAP2 $\beta$ , emerin, and MAN1 (Lin *et al.*, 2000) proteins, is a 40-residue LEM-domain and also a conserved chromatin domain that connects with the BAF (barrier to autointegration factor)(Koch and Holaska, 2014) (figure I.5). Moreover, emerin binds to transcriptional repressors like GCL (germ cell less), Btf (death promoting transcriptional repressor) and the RNA-associated splicing factor YT521-B. Emerin also interacts with many other NE proteins, such as nesprin-1 and -2, MAN1, nuclear actin, nuclear myosin I, nuclear  $\alpha$ II spectrin and lamins A, B and C (Bengtsson and Wilson, 2004). Collectively, these proteins are important in processes like the regulation of some genes,

nuclear assembly during cell division, supervising chemical signalling, aid chromatin tethering and sustaining the nuclear structure and stability (Berk *et al.*, 2013).



**Figure I.5** – Schematic representation of emerin. Emerin is attached at the inner nuclear membrane, interacts with lamin A, GCL (germ cell less), BAF (barrier to autointegration factor), actin and a nesprin dimer. IM, inner nuclear membrane. Taken from Bengtsson and Wilson (2004).

- **LAP1 and LAP2**

Lamina-associated polypeptide 1 (LAP1) is a type II transmembrane protein of the INM and it is encoded by the *TOR1AIP1* gene (Senior and Gerace, 1988). LAP1 was one of first proteins to be associated with lamins (Foisner and Gerace, 1993). Historically, LAP1 was first identified in rat liver nuclei using a monoclonal antibody against lamina-enriched fractions (Senior and Gerace, 1988). Studies with null LAP1 fibroblasts show that it is essential for normal localization of emerin and A-type lamins in the INM (Shin *et al.*, 2014). The association between LAP1 and lamins seems to be a key for lamins attachment to the NE during the interphase, playing a role in the preservation of the NE architecture (Foisner and Gerace, 1993; Rebelo *et al.*, 2015; Santos *et al.*, 2015).

LAP1 has different species-specific isoforms described so far. There are three different LAP1 isoforms described in rats namely LAP1A, LAP1B and LAP1C with molecular weights of 75, 68, and 55kDa, respectively (Senior and Gerace, 1988). These isoforms only differ in the nucleoplasmic region. On the other hand, only two human LAP1 isoforms have been identified: LAP1B with a molecular weight of 68kDa and the more

recently reported LAP1C, a N-terminally truncated isoform of LAP1 with 55kDa (Santos *et al.*, 2014). Three mouse LAP1 isoforms have been described: LAP1A with 64.7kDa, LAP1B with 58.3kDa and LAP1C with 43.9kDa (Shin *et al.*, 2014).

The precise functions of LAP1 are not fully known yet. So far, some interactors of LAP1 have been uncovered like torsinA, emerin and protein phosphatase 1 (PP1) leading to the attribution of some functions to LAP1, such as nuclear architecture preservation and chromatin regulation (from the LAP1-lamins interaction) (Schirmer and Foisner, 2007), management of the torsinA ATPase activity, NE localization of torsinA and NE dynamics (from the LAP1-torsinA interaction) (Brown *et al.*, 2014; Sosa *et al.*, 2014) and the NE integrity and skeletal muscle maintenance (from the LAP1-emerin interaction) (Shin *et al.*, 2013). The interaction between LAP1 and PP1 is reported to be involved in the control of the cell cycle progression (Santos *et al.*, 2015). LAP1 has also been recently appointed as an important factor in the production of healthy sperm cells (Serrano *et al.*, 2017).

Lamina-associated polypeptide 2 (LAP2) is a family of six proteins obtained by alternative splicing. Four of these proteins (LAP2  $\beta$ ,  $\gamma$ ,  $\delta$ , and  $\epsilon$ ) are type II membrane proteins. LAP2 $\beta$  binds to lamin B (Foisner, 2003). LAP2 $\alpha$  is distributed in the nucleoplasm and interacts with lamin A/C, forming a LAP2 $\alpha$ -lamin A/C complex that display a negative effect in cell proliferation and might be involved in cell differentiation and in chromatin organization and stabilization in the nucleus (Gesson *et al.*, 2014). Regardless of lamins A/C, LAP2 $\alpha$  is able to control extracellular matrix (ECM) components (Gesson *et al.*, 2014; Vidak *et al.*, 2015).

- **SUN1 and Nesprin-2**


SUN proteins are type II membrane proteins, normally encountered in the INM. They are conserved virtually in the entire eukaryotes' group, especially in mammalian somatic cells. They are composed of an N-terminal variable nucleoplasmic region that interacts with A- and B-type lamins and a transmembrane helix linked with a predicted coiled-coil C-terminal segment placed in the perinuclear space (Razafsky and Hodzic, 2009; Sosa *et al.*, 2013).

SUN proteins are part of the Linker of Nucleoskeleton and Cytoskeleton (LINC) Complex (figure I.6). LINC complexes are composed by the Sad1/UNC-84 (SUN) INM



proteins and Klarsicht/ANC-1/SYNE homology (KASH) proteins (also known as nesprins, nuclear envelope spectrin repeat proteins) located in the ONM (Lee and Burke, 2017). These proteins interact with each other through the short KASH peptide and the SUN domain in the luminal space (Zhu *et al.*, 2017).

Similarly to the SUN proteins, KASH proteins are type II membrane proteins that have several spectrin-repeat-containing N-termini anchored to the ONM interacting with the cytoskeleton and other cytoplasmic proteins (Jahed *et al.*, 2018) followed by an highly conserved region of 35 aa rooted in the PNS (Razafsky and Hodzic, 2009). This short peptide connects with KASH binding sites on single SUN protein trimers (Lee and Burke, 2017).



**Figure I.6** – The LINC complex. LINC complexes are composed by the Sad1/UNC-84 (SUN) INM proteins and Klarsicht/ANC-1/SYNE homology (KASH) proteins located in the outer nuclear membrane. ONM, outer nuclear membrane; INM, inner nuclear membrane. Taken from Puckelwartz (2017) and Razafsky and Hodzic (2009).

The number of SUN proteins increases depending on the complexity of the organism. Simpler organisms, like unicellular ones, only have one SUN domain protein. However, more evolved organisms like mammals display at least five different members of the SUN protein family (Sosa *et al.*, 2013; Horn, 2014).

Likewise, at least six genes corresponding to KASH proteins are encoded in mammals, namely nesprins 1-4, lymphoid-restricted membrane protein and KASH5. The members of these protein families are expressed differently in various tissues due to

alternative splicing (Horn, 2014; Lee and Burke, 2017; Jahed *et al.*, 2018).

Nevertheless, the most commonly expressed SUN proteins in mammals are SUN1 and SUN2 while the most expressed KASH proteins in mammals are nesprins 1-4. These SUN and KASH proteins interact with each other. (Jahed *et al.*, 2018).


The LINC complex might play a role in the spread of signals from the cytoplasm to the nucleus and it is possibly involved in several functions like moving and shaping the nucleus, signal transduction, chromatin localization (Puckelwartz, 2017), and spermatogenesis (Horn, 2014). There is a certain redundancy of the ligation between SUN1 or SUN2 to KASH proteins, leading to interchangeable functions between them of coupling the nucleus of centrosomes in neuronal precursors in the developing brain, repairing DNA damage, nuclear positioning in the skeletal muscle, among other functions. SUN1 alone has been described as necessary for DNA double-strand break repairs, pairing meiotic chromosomes, taking part in RNA export as a messenger, nucleolar morphogenesis, etc. On the other side, SUN2 alone is responsible for the formation of actin cables that are able to move the nucleus (Jahed *et al.*, 2018).

Nesprins have been associated with many diseases like myopathies, neurological disorders, cancer, hearing loss and arthrogyrosis. Nesprin-1 and -2 are linked with EDMD and EDMD-like phenotypes. Lamin A/C mutations affect the LINC complex, altering nesprin-1, nesprin-2 and SUN2 localization. In progeroid syndromes regulated by lamin A/C, nesprin-2 giant is down-regulated, while SUN1 is significantly upregulated. In this case, nesprin-2 giant acts as a compensatory mechanism since its presence *in vitro* improves the deleterious progerin defects. Nevertheless, SUN1 tend to extend the lifespan of lamin A/C deficient and progeroid mice and nesprin-2 giant knock-out mice do not present an ageing phenotype (Cartwright and Karakesisoglou, 2014; Puckelwartz, 2017). Nesprin is also implicated in mRNA export, opening the possibility that nesprin helps anchoring SUN1 close to the NPC aiding and enabling it to accomplish its duty in mRNA export (Li *et al.*, 2017).

- **Nucleoporins**

The NPCs are very large complexes with a molecular weight of approximately 120 MDa. Nevertheless, the NPCs are only constituted by ~30 nucleoporins (NUPs) highly

conserved during the evolution of the eukaryotes (DeGrasse *et al.*, 2009; Kabachinski and Schwartz, 2015). Most of NUPs are named with a number that corresponds to their molecular weight. However, given that NUPs molecular weight changes between species there is no universal nomenclature for NUPs. NUPs can be divided according to their localization in the NPC. Commonly, they are divided in six principal categories: (1) Transmembrane NUPs; (2) Membrane-apposed coat NUPs; (3) Adapter NUPs; (4) Channel NUPs; (5) Nuclear Basket NUPs; and, (6) NPC cytoplasmic filaments (Figure I.7 and Table I.1) (Hoelz *et al.*, 2011; Nofrini *et al.*, 2016).



**Figure I.7** – Schematic representation of the NPCs and the different nucleoporins categories (Adapted from Nofrini *et al.* (2016)).

**Table I.1** – Classes of nucleoporins (Adapted from Nofrini *et al.* (2016)).

| <b>Transmembrane NUPs</b> | <b>Coat NUPs</b>   | <b>Adapter NUPs</b>                          | <b>Channel NUPs</b>              | <b>Nuclear basket NUPs</b> | <b>Cytoplasmic filament NUPs</b>                              |
|---------------------------|--|--|----------------------------------|----------------------------|---|
| NUP210<br>NDC1<br>POM121  | NUP160<br>NUP133<br>NUP107<br>NUP96<br>NUP85<br>SEH1L<br>NUP43<br>NUP37<br>SEC13<br>ELYS | NUP205<br>NUP188<br>NUP155<br>NUP93<br>NUP35 | NUP62<br>NUPL1<br>NUP45<br>NUP54 | NUP153<br>TPR<br>NUP50     | RANBP2<br>NUP214<br>NUP98<br>NUP88<br>ALADIN<br>NUPL2<br>RAE1 |

The transmembrane NUPs are integral membrane proteins, which have been associated with NPC assembly and anchorage to the NE (Hoelz *et al.*, 2011). The coat NUPs form a Nup107–160 complex, which comprehends the largest NPC subunit in size and complexity. This complex is necessary in the first stages of NPC assembly. The adapter NUPs form the NUP93 complex, the second largest NPC structural unit. NUP188 and NUP93 are part of the NUP93 complex and play a key role in delimiting the NE sub-compartments, creating a blockade that avoids the movement of membrane proteins from ONM to the INM. NUP155 also belongs to this complex and guarantee the right localization of the INM proteins. The channel NUPs are the ones in the deepest cylindrical layer of the NPC. NUP54 and NUP58 are part of these NUPs category and play a part in regulating nucleocytoplasmic traffic by establishing a ring in middle of the NPC that has the capacity of expanding reversibly (Solmaz *et al.*, 2011). The nuclear basket NUPs are constituted by NPC nucleoplasmic filaments, namely NUP153, NUP50 and TPR associated with nuclear import/export processes. NUP153 and NUP50 make a ring that links the TPR protein filaments, creating a basket structure that aids in nucleocytoplasmic traffic. NPC cytoplasmic filaments are made of seven proteins that works as fundamental interaction sites to the nucleocytoplasmic trafficking machinery. The mRNA export factor GLE1 and DEAD-box-

containing RNA helicase DDX19 are linked with cytoplasmic filaments and are described as part of the NPC. These two proteins are also involved in the mRNA transport (Hoelz *et al.*, 2011; Nofrini *et al.*, 2016).

Some nucleoporins have a domain with several phenylalanine-glycine (FG) motifs. FG NUPs act as binding sites for transport receptors, being fundamental for translocation within the NPC. Some FG NUPs are thought to associate and create the permeability barrier of the pore (Wente and Rout, 2010; Xu and Powers, 2013).

NPCs have been proposed to directly regulate transcriptional programs and to interact in the nuclear compartmentalization of the genome. Some interactions between the NPC and non-transcribing genomic regions and silencing machinery have also been reported. NUPs mutations have been linked to various human diseases that go from neurological disorders to cardiac diseases and cancer. NUPs differ according to the tissue we are looking at and have been described to alter tissue-specific embryonic development like differentiation of neurons and muscle (Pascual-Garcia and Capelson, 2014). Furthermore, NUPS and NPCs have been reported to play a diverse role in cellular functions like chromatin organization, regulation of gene expression and cell division (Hoelz *et al.*, 2011).

- **MAN1**

MAN1 is an INM that has been reported as an important factor in transforming growth factor beta/bone morphogenic protein (TGF $\beta$ /BMP) signalling. Three autosomal dominant diseases related with increased bone density have been associated with loss of MAN1 (Bengtsson and Wilson, 2004).

- **LBR**

Lamin B receptor (LBR) is an INM protein that is associated with the nuclear lamina. LBR is crucial for cholesterol synthesis and LBR mutations are implicated in congenital disorders such as Greenberg skeletal dysplasia or Pelger-Huët anomaly where it fails to rescue the cholesterol auxotrophy because of a loss-of-function mechanism (Tsai *et al.*,

2016). LBR contributes to the profile of the interphase nuclear architecture (Nikolakaki *et al.*, 2017).

## **1.2.The Ageing Process**


All the organisms age. How cells and tissues age is still far from being fully understood and exploited. It is commonly accepted that there is no genetic program that determine the ageing process. Nevertheless, it is undeniable that a crossover between genetics and environmental factors has a tremendous impact on the degree and rate of ageing in same species-individuals and in the variances among species (Rando, 2013).

The lifespan seems to be affected by anatomical and physiological characteristics like size and metabolic rate possibly leading to primary mechanisms, but there are many crucial exceptions that teach us how difficult and complex is understanding the ageing process. Between species, there is a narrow variability of lifespan which points out to the strength of the physiological signalling networks behind the maintenance of cells and tissues. Whenever these signalling networks fail, ageing phenotypes arise. This lifespan variability within the same species can be explained by the environmental stress impact on cell, tissues and organism's responses changing the timing of the failure of homeostatic mechanisms that end up in ageing phenotypes. Caloric restriction and several genes and signalling pathways have been reported as successful options for extending the lifespan (Rando, 2013).

The ageing process is a high-risk factor for the most frequent diseases like cancer, diabetes, heart disorders and Alzheimer's disease. Over the years, lifespan expectancy has increased, but 100 years old seems to be the upper limit of the human ageing process. Understanding the underlying molecular signalling pathways might help us in our quest for increasing lifespan (Aunan *et al.*, 2016).


It is widely accepted that the general characteristic of ageing is an accumulation of genetic material damage (Gems and Partridge, 2013; Moskalev *et al.*, 2013). General accumulation of genetic damage happens in different species, namely in yeast, mice, and humans (Pitt and Kaerberlein, 2015). Cancer is a consequence of an abnormal gain of cellular fitness, and ageing is quite the opposite, being characterized by a loss of fitness. An accumulation of cellular damage is observed in many of pathologies linked with ageing involving unrestrained cellular overgrowth or hyperactivity like in atherosclerosis and inflammation (Blagosklonny, 2008). Similarly to cancer, in the last few years, ageing has

gained a new research interest with the publication of the nine postulated “Hallmarks of Aging” (López-Otín *et al.*, 2013). The hallmarks of ageing were reported by López-Otín *et al.* (2013) as: genomic instability; telomere attrition; epigenetic alterations; loss of proteostasis; deregulated nutrient-sensing; mitochondrial dysfunction; cellular senescence; stem cell exhaustion and altered intercellular communication (figure I.8).



**Figure I.8** – The hallmarks of ageing. Genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion and altered intercellular communication. Taken from López-Otín *et al.* (2013).

The hallmarks can be organized into three main groups: the first group comprises the ones that are thought to be the real primary hallmarks, which directly causes the damage; the second group corresponds to antagonistic hallmarks, that try to respond to the damage; and the integrative ones, which are resultant of the ageing phenotype itself (figure I.9). Every one of the hallmarks of ageing should preferably achieve the subsequent principles: being present in normal ageing processes; resulting from deterioration of the ageing condition when it is intensified and when experimentally ameliorated it should slow down the normal ageing process and increase healthy lifespan. This last criteria is quite difficult to achieve, some of the hallmarks do not fulfil this requirement to the fullest (López-Otín *et al.*, 2013).



**Figure I.9** – The three core groups of the hallmarks of ageing. The hallmarks of ageing can be grouped into three core groups: the primary hallmarks that are considered caused of damage; the antagonistic hallmarks, that are considered responses to damage; and the integrative hallmarks, that are considered the culprits of the phenotype. Adapted from López-Otín *et al.* (2013) and <http://www.revgenetics.com/wp/hallmarks-aging-interventions>.

Through lifetime, humans and other organisms are constantly exposed to external (like radiation, diet, etc.) and internal risk factors (like failure in replicating DNA, etc.) that causes damages at a molecular level, resulting in diseases and in a decline of the overall organ/tissue function. This accumulation of damage include hallmarks such as genomic instability, telomere attrition, epigenetic changes and loss of proteostasis (Aunan *et al.*, 2016).

- **Genomic instability**

During lifespan there are numerous opportunities for the cell to accumulate genetic damage. Possible mutagens include radiation, chemicals, free radicals, etc. The DNA repair machinery is highly effective way and may reverse many of these damages (Friedberg, 2003; Lord and Ashworth, 2012). Nevertheless, chromosomes get less stable during ageing, and mutations and damage accumulate through time (Moskalev *et al.*, 2013). The older the cell the higher the possibility of having more genetic instability. The endogenous and environmental harmful effects can vary from small point mutations to more serious insults like retrotransposon movement and large chromosome rearrangements that play a bigger role in this process (Hoeijmakers, 2009). There is a variety of reports associating genomic and



epigenomic alterations to premature accelerated ageing, but it is not easy to relay and co-relate these alterations to the physiological ageing process once it only shows some features of normal ageing (Burtner and Kennedy, 2010).

Accumulated DNA damage, epigenetic alterations and microsatellite unsteadiness are more frequently found in older individuals. Genomic instability including DNA damage is currently linked with carcinogenesis and other age-related diseases like neurodegenerative disorders (Lombard *et al.*, 2005; van Heemst *et al.*, 2007; Kryston *et al.*, 2011; Ogino *et al.*, 2012). Compromised and decreased DNA repair systems is the main feature of genomic instability but there is no broad consensus whether this is the cause or a consequence of the ageing process. Nonetheless, increasing the DNA repair systems activity and reducing DNA damage could be positive and it could potentially be achieved through caloric and dietary restriction (Heydari *et al.*, 2007; Michan, 2014)

- **Telomere attrition**

One of the most known paradigm of cell division is that telomers get shorter in each cellular division. Ultimately, the telomerase is silenced and telomeres get too short for the division process to continue (Blackburn *et al.*, 2015). Telomeres are prone to DNA damage and contrasting with the rest of the chromosome, this DNA damage is not fixed by DNA repair systems in order to avoid fused chromosome and genomic instability. Telomerase works in this particular process but it seems to be silent in several adult cells in an attempt to control extensive cell proliferation and carcinogenesis (Olovnikov, 1996). The shortening of the telomeres is associated with many age-related disorders such as atherosclerosis, atrial fibrillation, osteoarthritis and coronary heart disease (Hunt *et al.*, 2015; Kuszel *et al.*, 2015; Carlquist *et al.*, 2016).

- **Epigenetic alterations**

As stated in the genomic instability section, environmental factors contribute to alterations in epigenetic mechanisms in the cells. Epigenetic alterations are alterations in the gene expression, which result from nucleotide sequence alteration, such as DNA methylation. These kind of alterations accumulate with time and have been associated with ageing (Aunan *et al.*, 2016). Among other changes, decreased trimethylation of H3K9 and H3K27 and an increased trimethylation of H4K20 and H3K4 are associated with a reduction

in the quantity of heterochromatin and a higher state of chromosome fragility and transcriptional noise (D'Aquila *et al.*, 2013).

- **Loss of proteostasis**

The variety of cellular systems and mechanisms responsible for keeping the homeostasis of the proteasome, the synthesis and turnover of human proteins are called proteostasis (Eisenstein, 2014). The accumulation and aggregation of misfolded proteins can be avoided by proteostasis. Therefore, the loss of this set of mechanisms results in failure of autophagy processes, unstable and misfolded proteins accumulation, which leads to a variety of age-associated diseases in human, such as Alzheimer's and Parkinson's disease and others diseases like cataracts (Clark *et al.*, 2012; Labbadia and Morimoto, 2015). The reduced capacity of keeping homeostasis of the proteins with age along with protein aggregation are encountered in almost all tissues in older organisms (Koga *et al.*, 2011).

Inflammaging, the decrease of successful autophagy processes, and a worse removal of vesicles holding cellular waste by lysosomes result in a rise of intracellular ROS which lead to low levels of chronic inflammation generated by the inflammasome damage sensing mechanism, and ultimately result in additional accelerating ageing (Glick *et al.*, 2010; Franceschi and Campisi, 2014). Upregulation of autophagy can lead to an extension of nematodes, flies and mice lifespan (Madeo *et al.*, 2015).

- **Deregulated nutrient sensing**

Human cells rely on their capacity to use nutrients and fluids in a sensitive manner in order to keep the body functioning and growing. However, through age, several of these sensors and molecular targets disappear or are downregulated (Barzilai and Ferrucci, 2012). The most frequent traits of human ageing embrace increase of visceral fat mass, diminishing lean mass, decreased sensitivity to insulin that results in an intolerance to glucose and muscle ragged red fibres (Pesce *et al.*, 2001).

Metabolic decline causes an accelerated ageing rate in cells. This decline can be translated into cellular damage caused by oxidative and ER stress, mitochondrial and calcium signalling dysfunction (Riera and Dillin, 2015). A dysfunctional nutrient sensing system might result for instance in a greater intake of food and calories than the ones that are needed. Therefore, obesity, diabetes and other metabolic disorders happen to be linked

to the ageing process. Furthermore, diabetes and obesity have an associated chronic inflammation that can additionally decontrol this nutrient sensor by itself. Up to now, the only effort towards expanding human lifespan that seems to work is the intermittent caloric restriction (also known as fasting) (Lee and Longo, 2011).

- **Mitochondrial dysfunction**

The constant exposure of the mitochondrial DNA to reactive oxygen species (ROS) makes the probability of oxidative damage and ageing happen very plausible and common. This is called the mitochondrial free radical theory of ageing (Harman, 2009). ROS can oxidize and insult proteins, lipids and nucleic acids. There is a reported increase of ROS linked with the loss of mitochondrial integrity since the mitochondria is the main manufacturer of ROS. An increase in the induced apoptosis has also been described to be associated with age. Below a certain level of ROS, they may function as an activator of cellular homeostasis signalling pathways, and it decelerates the ageing process. Nonetheless, above a certain limit, ROS are toxic and cause accelerating ageing or even cell death. Some molecules like metformin increase the overall fitness of the organism and might ameliorate the ageing phenotype (Hekimi *et al.*, 2011; Aunan *et al.*, 2016).

- **Cellular senescence**

Cellular senescence can be defined as the moment that cells stop to divide and to grow permanently, suffering of chromatin and secretome alterations. Senescence can be caused by the lack or damage of essential components (Kuilman *et al.*, 2010). Young senescent cells are probably cleared by the immune system. On the contrary, older cells wonder around, staying and producing injurious proinflammatory signals such as interleukins that persist in damaging our organisms (Kuilman *et al.*, 2010; Van Deursen, 2014). Other hallmarks that involve DNA damage, telomere shortening, and oxidative stress contribute to this senescence process (Collado *et al.*, 2007; Van Deursen, 2014).

- **Stem cell exhaustion**

As we get older, the cell stemness state capacity is lost, and the organism become incapable of substituting stem cells that migrated, differentiated or died, given that the stem cells are unable to divide. A decrease of the regeneration of stem cells play a fundamental

role in ageing. For instance, a decline in haematopoietic stem cell results in anaemia, mesenchymal stem cell exhaustion lead to osteoporosis and fractures, intestinal epithelial stem cell reduction results in perturbed intestinal function, and muscle stem cell loss is linked with ageing (López-Otín *et al.*, 2013; Aunan *et al.*, 2016).

- **Altered intercellular communication**

Age-related alterations that occur in a single tissue can affect and damage other tissues due to a complex system of intercellular communication of the ageing phenotype. Senescent cells seem to be able to induce senescence in proximal cells through gap-junction-mediated cell-cell contacts and processes concerning ROS. It is called the “bystander effect” (Nelson *et al.*, 2012). Then, aiming a unique gene or protein can have an effect in other tissues (Durieux *et al.*, 2011). Systems like renin-angiotensin or the insulin-to-insulin growth factor response can be deregulated by the changes in the intracellular communication. Immunosenescence (age related changes of the immune system) and inflammaging (chronic low-grade systemic inflammation) due to an increase secretion of cytokines by adipose tissue are in the origin of several age-related disorders like diabetes, arthritis, metabolic syndrome and cardiovascular diseases (Sergio, 2008; Capri *et al.*, 2014; Szarc Vel Szic *et al.*, 2015) leaving the organism more fragile and prone to morbidity and mortality in aged individuals (Aunan *et al.*, 2016).

### **1.3.The NE dysfunction in the ageing process**

There are some limitations in using animal ageing models once it does not completely mimic the human ageing phenotype in some aspects, as is the cases of telomeres that do not get as short in these animal models through ageing as in humans (Blackburn *et al.*, 2015). The long human lifespan and other limitations poses difficulties to study human normal ageing at a practical level. Ethical considerations are also a drawback (Mitchell *et al.*, 2015).

The premature ageing disorders, also known as progerias, provide us with a unique opportunity to unravel the mechanisms inherent to physiological ageing (Kubben and Misteli, 2017). Nevertheless, it is important to remember that no premature ageing disorder is able to present all the physiological ageing phenotype and features, so they should be seen as segmental progerias (Van De Ven *et al.*, 2006; Reddy and Comai, 2016).

Many premature ageing disorders have been associated with defects and alterations in the nuclear proteins, leaving the prospect of nuclear lamina and the INM as major regulators of the ageing phenotype (Serebryanny and Misteli, 2018). Many indications that pose the nuclear periphery as a prospective controller of the ageing phenotype were obtained from studies in HGPS (Serebryanny and Misteli, 2018). As previously described, this is a rare genetic disorder that causes systemic accelerated ageing in children due to a single mutation in the *LMNA* gene that leads to the synthesis of a truncated and toxic form of lamin A called progerin. Progerin assimilation into the nuclear lamina is supposed to alter negatively the lamin A and B grids, causing an overall structural and signalling defects (Delbarre *et al.*, 2006; Lee *et al.*, 2016). HGPS fibroblast cells present a poor and defective nuclear shape, DNA damage, down-regulation of various nuclear proteins and a different histone modification pattern (Scaffidi and Misteli, 2006a).

The nuclear integrity seems to be affected by ageing in human fibroblasts where telomere attrition and radiation damage induce progerin expression (Cao *et al.*, 2011; Takeuchi and Runger, 2013). In fact, an accumulation of prelamin A or progerin has been described in the past few years associated with the normal ageing phenotype (Scaffidi and Misteli, 2006a; Ragnauth *et al.*, 2010; Sieprath *et al.*, 2015). Mutations in *LMNA* gene are linked with older individuals (Conneely *et al.*, 2012). The expression of altered isoforms of lamin A has been widely mentioned in the literature in physiological ageing models, such as fibroblast from skin biopsies (Scaffidi and Misteli, 2006a; McClintock *et al.*, 2007; Rodriguez *et al.*, 2009), fibroblasts extensively passaged (Cao *et al.*, 2011), fibroblasts from centenarians (Lattanzi *et al.*, 2014), cardiovascular tissues (Olive *et al.*, 2010) and normal and aged vascular smooth muscle cell (VSMC) (Ragnauth *et al.*, 2010).

According to Serebryanny and Misteli (2018), the concept of sequestration of proteins at nuclear periphery, or loss thereof, may be responsible for prominent defects associated with premature and physiological ageing like diminished cell stemness, dysfunctional cytotoxicity, inhibition of proliferation, altered chromatin and telomere preservation (Serebryanny and Misteli, 2018)

- **Cell stemness**

The capacity of the tissues regenerate (cell stemness) is compromised during ageing (Lopez-Otın *et al.*, 2013). Notch activation controls proliferation, migration, and

differentiation, and it is vital to maintain stem cell homeostasis (Bray, 2016). The renovation of muscle stem cells is prevented by the loss of Notch signalling pathway which also plays a role in cardiovascular dysfunctions. On the other side, an upregulation of the Notch signalling is involved in carcinogenesis and inflammation processes through MAPK and TBF $\beta$  (Balistreri *et al.*, 2016). Notch target genes are activated by progerin expression in human mesenchymal stem cells leads to aberrant stem cells and differentiation flaws (Scaffidi and Misteli, 2008). WNT seems to have a similar pathway that is implicated in stem cell proliferation and differentiation (Borggreffe *et al.*, 2016).

- **Dysfunctional cytotoxicity**

Mitochondrial dysfunction is present in HGPS fibroblast cells as well as elevated ROS levels, meaning that the nuclear periphery can play a role in mitochondria homeostasis (Serebryanny and Misteli, 2018). Nuclear factor erythroid-2-related factor 2 (Nrf2) is a transcriptional activator of resistance to ROS stress and other chemical insults (Ma, 2013). Noticeable, Nrf2 levels are altered through ageing and show a specific profile in different tissues and different models (Zhang *et al.*, 2015a).

Nrf2 is inadequately sequestered to the nuclear periphery in HGPS fibroblasts by progerin, resulting in a decrease of its cytoprotective activity against ROS stress and a reduced concentration at the nucleus (Kubben *et al.*, 2016).

- **Proliferation**

Immunosenescence has been associated with loss of functions related to ageing. This can be related with a proliferation suppression of stem cells and an increase of senescent cells (Van Deursen, 2014). The cellular proliferation capacity can be controlled by a group of intrinsic checkpoints, signalling pathways in a close connection with the nuclear periphery according to results obtained in HGPS models (Varela *et al.*, 2005).

A good example is PCNA, a crucial part of the DNA replication apparatus. It is associated with DNA damage repair systems, and telomere steadiness (Choe and Moldovan, 2017). With age, PCNA expression is reduced (Tanno *et al.*, 1996). PCNA localization is partly defined by A- and B-type lamins. Therefore, the loss of the nuclear lamina integrity due to lamin mutants or progerin leads to PCNA sequestration and aggregation at the nuclear periphery disrupting replication (Hilton *et al.*, 2017). The contrary is also true: expression of

prelamin A or progerin conduct to the loss of PCNA correct functions, resulting in DNA damage (Cobb *et al.*, 2016). Having all that stated, it is not surprising that PCNA is being implicated in the ageing process.

- **Chromatin remodelling**

Modifications in DNA methylation, histone alteration, chromatin structure and epigenetic controlling systems are important ageing features (Zane *et al.*, 2014). Human sirtuin1 (SIRT1) is a NAD<sup>+</sup> dependent protein deacetylase that play a part in many cellular processes, such as ageing, metabolism, cancer and stress responses. SIRT1 is connected and activated by lamin A. Resveratrol is an activator of SIRT1 by increasing SIRT1-Lamin A connection, consequently assisting in the localization of SIRT1 in the nuclear lamina. This connection can be jeopardized by prelamin A and progerin. In premature ageing mice and HGPS fibroblasts, resveratrol rescue adult stem cell due to the increased SIRT1-Lamin A binding. This ends up in an extended lifespan and an improvement in the progeroid traits. It can influence other characteristics such as chromatin remodelling, DNA damage combat and stem cell therapy (Ghosh *et al.*, 2013).

- **Telomere maintenance**

Telomeres shortening have been extensively associated with lifespan. There is a class of human telomers that are localized at the nuclear periphery posing the possibility that lamin organization modulate the telomere length and maintenance. Telomeres decline can result in progerin expression and uncontrolled DNA damage.

TRF2 is a binding factor involved in maintaining telomere stability. TRF2 keep the telomere integrity at the nuclear periphery by interaction with the nuclear lamina, LAP2 $\alpha$  and possibly LAP1 (Ludérus *et al.*, 1996; Chojnowski *et al.*, 2015; Serrano *et al.*, 2016). LAP2 $\alpha$  levels decrease in case of progerin expression which might obstruct the TRF2-lamin A/C connection. HGPS cells without lamin A/C being expressed eventually stop having telomeres (Wood *et al.*, 2014). Human fibroblasts carrying a null TERT mutation show high levels of progerin. Fibroblasts expressing TRF2 $\Delta$ B $\Delta$ M result in uncapped telomeres and it is associated with higher progerin synthesis. The connection between aberrant telomere and progerin synthesis might induce cellular senescence (Cao *et al.*, 2011).

SUN1 seems to be upregulated in studies performed in centenarians fibroblasts, but not in an older group of fibroblasts from patients with 65-80 years old. Prelamin A is accumulated in fibroblasts from centenarians. Centenarian fibroblasts show an accumulation of prelamins A in cells that suffer stress and they do not present senescence traits (Lattanzi *et al.*, 2014).

Some studies have reported a decrease in lamin B levels through ageing in *Drosophila* and human. In *Drosophila* the low levels of lamin B result in a general process of inflammaging. Lamin-B diminishing in a single tissue might disturb the role of other tissues through systemic inflammation (Chen *et al.*, 2015). Dysregulation of lamin B1 in human fibroblasts might cause cell senescence (Liu *et al.*, 2012). Studies point out to the fact that when lamin B1 is silenced, cellular ROS levels are decreased (Shimi and Goldman, 2014). Augmented levels of lamin B1 are connected with higher levels of ROS (Barascu *et al.*, 2012a). Lamin B1 seems to be a signalling hub and its response is different according to what senescence pathway is activated (ROS-induced premature senescence, Replicative-induced senescence and Oncogene-induced senescence) (Hutchison, 2012).

There are some studies that mention a disruption in NPC associated with age in *C. elegans* post mitotic cells (D'Angelo *et al.*, 2009). Moreover, using aged VSMCs it was demonstrated that the lamin A precursor, prelamins A, accumulates and induces NE invaginations trapping the Nup153 and consequently compromising the Ran gradient and large cargo transportation to the nucleus (Cobb, *et al.*, 2016). Progerin expression inhibits TPR import, and reduces trimethylation of H3K9 (Kelley, *et al.*, 2011). A reduction of nuclear import rate is observed in Progeria. NPCs clustering mislocate NPC components such as Nup153 and TPR. Additionally, it was also shown that in aged leaky nuclei (where Nup93 was lost) there is also decrease signal of FG-nucleoporins, recognized by the mAb414 antibody that recognizes several nucleoporins including Nup62 (D'Angelo *et al.*, 2009). These authors observed that Nup93 were lost in old and permeable nuclei (D'Angelo, *et al.*, 2009).

Emerin has been reported to be increased and mislocated in aged-iPSCs when mutations in nesprins and lamin A occur (Zhang *et al.*, 2007; Ho *et al.*, 2013; Petrini *et al.*, 2017). Petrini *et al.* (2017) results show that in young iPSCs (early passages) nesprin-2 is faintly detected. However, after passaging iPSCs for about one year (aged iPSCs) the nesprin-2 expression is uniformly increased through the nucleus.



Table I.2 summarizes the NE proteins already described to be involved in the ageing process.

**Table I.2** - Nuclear envelope proteins involved in the ageing process. (INM – Inner Nuclear Membrane, VSMCs - vascular smooth muscle cells, HGPS - Hutchinson–Gilford progeria syndrome, NPC – nuclear pore complex).

| NE protein                         | Alterations in ageing   | Ageing model  | References  |
|------------------------------------|---|---|---|
| <b><i>Nuclear lamina</i></b>       |   |   |   |
| Lamin A/C                          | WT lamin A, mutations in prelamin A and lamin A accumulate with age. Nucleoplasmic lamin A/C seems to be depleted | <ul style="list-style-type: none"> <li>◆ Human VSMCs from old donors</li> <li>◆ Human HGPS coronary arteries</li> <li>◆ Human fibroblasts from old donors</li> <li>◆ Human fibroblasts extensively passaged in culture</li> </ul> | (Candelario et al., 2008; Cao et al., 2011; Lattanzi et al., 2014; McClintock et al., 2007; Olive et al., 2010; Ragnauth et al., 2010; Rodriguez et al., 2009; Scaffidi and Misteli, 2006a) |
| Lamin B1                           | Decrease or increase with age (depending on the senescence pathway being activated)                               | <ul style="list-style-type: none"> <li>◆ Drosophila</li> <li>◆ Human aged fibroblasts</li> </ul>  | (Chen <i>et al.</i> , 2015; Dreesen and Stewart, 2011; Freund <i>et al.</i> , 2012; Lattanzi <i>et al.</i> , 2014; Shimi and Goldman, 2014)   |
| <b><i>INM</i></b>                  |   |   |   |
| LAP2 $\alpha$                      | Decreases in case of progerin expression  | ◆ HGPS fibroblast cells   | (Wood <i>et al.</i> , 2014)   |
| SUN1                               | Upregulated with age and increased in progerias   | <ul style="list-style-type: none"> <li>◆ Human centenarian fibroblasts</li> <li>◆ Human HGPS fibroblasts</li> </ul>   | (Meinke <i>et al.</i> , 2011; Chi <i>et al.</i> , 2012; Lattanzi <i>et al.</i> , 2014)  |
| NPC (Nup93, Nup62, Nup153 and TPR) | Age-related deterioration of NPC  | ◆ <i>C. elegans</i>   | (D'Angelo <i>et al.</i> , 2009)   |
| Emerin                             | Increases and is mislocated with age  | ◆ Human aged-iPSCs  | (Petrini <i>et al.</i> , 2017)  |
| <b><i>ONM</i></b>                  |   |   |   |
| Nesprin-2                          | Increases with age  | ◆ Human aged-iPSCs  | (Petrini <i>et al.</i> , 2017)  |

#### 1.4.Ageing models

To study the ageing process, it is important to define which model is adequate for the intended research. Studying human ageing is tough because of the long lifespan and ethical considerations. Over the years, ageing studies have been conducted in many type organisms including unicellular organisms like the *Saccharomyces cerevisiae*, other organisms such as *Caenorhabditis elegans*, *Drosophila melanogaster*, zebrafish, rodents, and human derived cells were used (Mitchell *et al.*, 2015).

*S. cerevisiae* is a yeast with a highly known and characterized genome and proteome that accepts well genetic manipulation. Its low doubling time (1.25 to 2h) and its 26 cell divisions average lifespan makes it an easier and cheap model. Several age-related genes have been identified using *S. cerevisiae* (Mitchell *et al.*, 2015).

The extensive knowledge about *C. elegans* genome, developmental stages, and its short lifespan (2-3 weeks) makes it also an attractive model to study ageing. *C. elegans* has a translucent body which aids in microscopy studies without interfering or threatening its life course, and allows us to investigate the accumulation of heterochromatin at the nuclear periphery in specific tissues (González-Aguilera *et al.*, 2014).

*D. melanogaster* conserve human disease genes that might be related to ageing disorders such as stem cell exhaustion, cardiovascular decline and Alzheimer's disease. It presents a short lifespan (up to 6 weeks) and a low maintenance cost (Brandt and Vilcinskis, 2012). *Drosophila* and *C. elegans* age differently than humans and they do not have several age-related diseases described in humans. It enlightens the very real possibility of most of the results obtained in these animals not being valid to humans (González-Aguilera *et al.*, 2014; Sinclair, 2002).

Zebrafish is starting to be considered an interesting ageing model since it has been used to study evolutionary and development origins of ageing. Genes linked to senescence phenotype uncovered in zebrafish have been linked with cellular senescence and chronological ageing, but more studies are required to clarify this (Kishi, 2014).

Rodents like mice and rat are considered to be the best ageing model available nowadays. They present a relative short lifespan (up to 3 years), can be genetically modified, and resemble most of the human ageing phenotypes. Moreover, they can be tested on the lab with therapeutic drugs to increase lifespan. There are many different strains available that can mimic many scenarios. So far, the mice model has given new

perspectives in several processes underlying ageing, such as caloric-restriction that ended up having a relevant interest in humans as well (Vanhooren and Libert, 2013).

Nevertheless, human cell cultures studies grow day by day since there are a strong resemble between them and what we aim to study: the human ageing. It is realist to think that at least some of the age-related processes that happen *in vitro* also happens *in vivo* (de Magalhães, 2004). Several ageing studies use fibroblasts obtained from young and old individuals biopsies (Scaffidi and Misteli, 2006; Cao *et al.*, 2011; Lattanzi *et al.*, 2014). Alterations related to ageing occurring in the human body due environmental stresses and intrinsic factors make fibroblasts a good candidate to study intrinsic and extrinsic ageing (Varani, 2010; Tigges *et al.*, 2014).

## **Aims**

Ageing is a multifactorial process characterized by the loss of the overall organismal fitness. Bioinformatic approaches can provide us a unique opportunity to identify new putative players in the ageing phenotype and to uncover the main underlying biological functions and cellular components associated with this process. On the other hand, the nuclear envelope periphery has already been pointed as a potential regulator of the ageing phenotype. Nevertheless, there are still few studies regarding this topic and most of them focus on a single protein and/or are based on premature ageing disease model. Nevertheless, the significance of premature ageing disorders to physiological ageing is still uncertain since they do not fully recapitulate and mimic the physiological ageing.

Therefore, the main aim of this dissertation is to characterize the alterations of the nuclear envelope proteins during the physiological ageing process.

Thus, the specific aims of this dissertation are the following:

- Analyse and characterize age-related interaction networks using bioinformatic tools;
- Characterize the profile of nuclear envelope proteins during ageing using a mice model;
- Characterize the profile of nuclear envelope proteins during ageing using human fibroblasts;
- Evaluate the subcellular localization of nuclear envelope proteins during ageing using human fibroblasts.

## **CHAPTER II**

### **Bioinformatic analysis of interaction networks in ageing**



## **2.1. Introduction**

The physiological ageing is defined as a functional decline at cellular, tissue and organismal level across the lifespan (López-Otín *et al.*, 2013). Ageing impacts many areas and increases the risk of developing several age-related diseases like cancer, diabetes, cardiovascular and neurodegenerative disorders. Despite all the efforts to determine the molecular and cellular changes associated with ageing, the underlying mechanisms remains elusive. Several studies have monitored aspects of the ageing in mammals, namely alterations in gene expression (de Magalhães *et al.*, 2009), transcription (Schumacher *et al.*, 2008) and proteome (Waldera-Lupa *et al.*, 2014; Walther and Mann, 2011). Although these studies have reported some age-specific changes, no substantial alterations were highlighted. In fact, when we look at a single gene or a single protein in a certain research field, whether we are looking into a specific disease or process, we are limiting our investigation. Genes and proteins work together. Biological systems are composed of many components that interact with one another at different levels. A single component of a complex network of interactions can affect the rest of them. Therefore, over the last few years, more integrative and comprehensive approaches have been used, bringing interactomes into the spotlight (Chautard *et al.*, 2010).

Consequently, it urges to look at the bigger picture and network approaches are essential for the understanding of the complex ageing process. This strategy provides important information since it allows for a systems approach of the protein complexes formed, rather than single interactions (Chautard *et al.*, 2010). Here, by building human age-related protein-protein interaction (PPI) networks we aimed to identify the underlying biological processes and the main signalling pathways of ageing.

## **2.2. Methodology**

### **2.2.1. Collection of the human age-related proteins/genes**

Ageing-associated genes already described in the literature were retrieved using the GenAge Human Database and the AGEID (Ageing Genes/Interventions Database) databases. GenAge is a curated database of genes associated to human ageing (de Magalhães and Toussaint, 2004; Tacutu *et al.*, 2018), whereas AGEID is a database of experimental results in any organism related to genes and interventions connected with ageing phenotypes (Kaeberlein *et al.*, 2002). Therefore, the list of genes retrieved in

AGEID from other organisms were extrapolated by homology to *Homo sapiens*. A total of 663 ageing-associated genes were retrieved from both databases (Table SII.1).

### **2.2.2. Functional enrichment analysis of Gene Ontology**


Gene Ontology (GO) provides a system of terms to consistently describe and annotate gene products (Ashburner *et al.*, 2000; Mi *et al.*, 2017; The Gene Ontology Consortium, 2017). Functional annotation clustering analysis was performed online using the DAVID database (The Database for Annotation, Visualization and Integrated Discovery; available at <https://david.ncifcrf.gov/tools.jsp>; version 6.8) (Huang *et al.*, 2008, 2009) to enquire for GO terms that are over-represented using the annotation Cellular Component. Briefly, the 663 genes were submitted to analysis, and a classification stringency of 4 was used. The output retrieved was a table that lists and groups in clusters the significant shared GO terms (or parents of GO terms) used to describe the set of genes submitted to analysis, the fold enrichment (%) and the p-value. The statistical analysis included Bonferroni's correction for multiple testing and a term was considered as enriched if the adjusted p-value is below a significance threshold of 0.05.

### **2.2.3. Construction of an interaction network of ageing**

The 308 proteins/genes assembled in the two first clusters of the cellular component enrichment analysis (Table II.1) were further used to construct a PPI network using the STRING database (Version 10.5) (Szklarczyk *et al.*, 2017), considering only physical contacts and co-expression as interaction sources. The network was visualized using the freely available Cytoscape software (version 3.7.0) and further analysed using the NetworkAnalyzer plugin version 3.3.1. Cluster analysis was carried out using the Cytoscape plugin clusterMaker (GLay), a specific tool which provides numerous algorithms for clustering nodes within a network. This network visualization approach allows the analysis of complex networks in a biological context. The PANTHER (Protein ANalysis THrough Evolutionary Relationships) classification system was used to perform a statistical overrepresentation test of the biological processes (Thomas *et al.*, 2006; Mi *et al.*, 2013, 2017) in order to analyse the genes retrieved from the first two clusters produced by clusterMaker.



A schematic representation of the followed methodology is presented in figure II.1.



**Figure II.1.** – Methodological workflow overview. Schematic representation of the methodological workflow applied in the bioinformatic approach.


### 2.3. Results

The identification of genes that were associated to ageing, longevity or senescence was achieved using GenAge and AGEID databases. A total of 663 age-associated genes were identified as described in the methods section, several being human orthologs established in model organisms.

A functional annotation clustering analysis according to GO cellular component annotation using the DAVID online resource was performed. The resulting cellular component enrichment clusters are listed in Table II.1. The clusters with higher enrichment scores correspond to clusters 1 and 2 (enrichment scores of 28.28 and 27.42, respectively). Interestingly, the main cellular components were related to nucleus (chromosomal part, nuclear chromosome part, nuclear chromosome, intracellular

organelle lumen, nuclear part, nucleoplasm, and nuclear lumen). The remaining clusters have enrichment scores of 3.21 and lower (Table II.1).

The main cellular component categories of the first two clusters are shown in Figure II.2.



**Figure II.2** – Functional annotation cellular component clustering analysis (clusters 1 and 2) of the age-related genes using DAVID online resource. The percentage of the age-related genes was calculated and plotted.


**Table II.1** – Cellular component functional annotation clustering enrichment analysis of the age-related genes network using DAVID online resource. Enriched categories are those with Bonferroni adjusted p value <0.05.

|  | <b>GO Term</b>                               | <b>Nr. Genes</b> | <b>% of genes</b> | <b>p-value</b> |
|--|--|------------------|-------------------|----------------|
| <b>Cluster 1</b><br><b>Enrichment Score: 28.28</b> | chromosomal part                             | 105              | 16.06             | 1.53E-26       |
|  | nuclear chromosome part                      | 82               | 12.54             | 1.95E-26       |
|  | nuclear chromosome                           | 84               | 12.84             | 8.04E-26       |
| <b>Cluster 2</b><br><b>Enrichment Score: 27.42</b> | intracellular organelle lumen                | 287              | 43.88             | 2.14E-26       |
|  | nuclear part                                 | 270              | 41.28             | 9.99E-26       |
|  | Nucleoplasm                                  | 223              | 34.10             | 3.58E-25       |
|  | nuclear lumen                                | 249              | 38.07             | 2.39E-24       |
| <b>Cluster 3</b><br><b>Enrichment Score: 3.21</b>  | cytoplasmic vesicle                          | 71               | 10.86             | 2.66E-01       |
|  | intracellular vesicle                        | 71               | 10.86             | 2.78E-01       |
|  | cytoplasmic, membrane-bounded vesicle        | 66               | 10.09             | 3.23E-01       |
| <b>Cluster 4</b><br><b>Enrichment Score: 2.79</b>  | respiratory chain complex                    | 11               | 1.68              | 3.63E-01       |
|  | mitochondrial respiratory chain              | 11               | 1.68              | 5.43E-01       |
|  | inner mitochondrial membrane protein complex | 13               | 1.99              | 8.66E-01       |
| <b>Cluster 5</b><br><b>Enrichment Score: 2.66</b>  | RNA polymerase complex                       | 14               | 2.14              | 4.69E-01       |
|  | nuclear DNA-directed RNA polymerase complex  | 13               | 1.99              | 8.11E-01       |
|  | DNA-directed RNA polymerase complex          | 13               | 1.99              | 8.11E-01       |
| <b>Cluster 6</b><br><b>Enrichment Score: 2.53</b>  | terminal bouton                              | 10               | 1.53              | 2.24E-01       |
|  | neuron projection terminus                   | 12               | 1.83              | 9.70E-01       |
|  | axon terminus                                | 11               | 1.68              | 9.92E-01       |
| <b>Cluster 7</b><br><b>Enrichment Score: 1.72</b>  | muscle myosin complex                        | 5                | 0.76              | 9.15E-01       |
|  | myosin filament                              | 5                | 0.76              | 9.86E-01       |
|  | myosin II complex                            | 5                | 0.76              | 1.00           |
|  | myosin complex                               | 5                | 0.76              | 1.00           |
| <b>Cluster 8</b><br><b>Enrichment Score: 1.06</b>  | Z disc                                       | 9                | 1.38              | 1.00           |
|  | sarcomere                                    | 12               | 1.83              | 1.00           |
|  | I band                                       | 9                | 1.38              | 1.00           |
| <b>Cluster 9</b>                                   | contractile fiber part                       | 13               | 1.99              | 1.00           |

|  |   |    |      |      |
|--|---|----|------|------|
| <b>Enrichment Score: 1.03</b>                      | sarcomere   | 12 | 1.83 | 1.00 |
|  | contractile fiber   | 13 | 1.99 | 1.00 |
| <b>Cluster 10</b><br><b>Enrichment Score: 0.94</b> | nuclear outer membrane-endoplasmic reticulum membrane network | 49 | 7.49 | 1.00 |
|  | endoplasmic reticulum membrane                                | 44 | 6.73 | 1.00 |
|  | endoplasmic reticulum part                                    | 50 | 7.65 | 1.00 |
| <b>Cluster 11</b><br><b>Enrichment Score: 0.27</b> | respiratory chain complex I                                   | 3  | 0.46 | 1.00 |
|  | NADH dehydrogenase complex                                    | 3  | 0.46 | 1.00 |
|  | mitochondrial respiratory chain complex I                     | 3  | 0.46 | 1.00 |
| <b>Cluster 12</b><br><b>Enrichment Score: 0.21</b> | microbody lumen   | 3  | 0.46 | 1.00 |
|  | peroxisomal membrane  | 3  | 0.46 | 1.00 |
|  | microbody membrane  | 3  | 0.46 | 1.00 |
|  | peroxisomal part  | 4  | 0.61 | 1.00 |
|  | microbody part  | 4  | 0.61 | 1.00 |
| <b>Cluster 13</b><br><b>Enrichment Score: 0.12</b> | synaptic vesicle membrane                                     | 3  | 0.46 | 1.00 |
|  | exocytic vesicle membrane                                     | 3  | 0.46 | 1.00 |
|  | transport vesicle membrane                                    | 3  | 0.46 | 1.00 |


Remarkably, 308 genes are associated with the categories of cluster 1 and 2, which correspond to almost half of the age-related genes identified. Hence, the protein-protein interactions of these 308 age-related genes were collected from the STRING database using physical contacts and co-expression only. The network was visualized using the Cytoscape program and is presented in Figure II.3. Further, the NetworkAnalyzer, a Cytoscape plugin, was used to analyse and calculate the following parameters: 1) the average number of neighbours, which indicates the average connectivity of a node in the network; 2) the mean clustering coefficient of the network, which characterizes how nearest neighbouring nodes are connected to each other.

The total number of proteins mapped in the nuclear age-related protein-protein interaction (PPI) network was 265 (nodes) and the total number of connections between them was 1443 (edges). Of note, only 43 of the 308 nuclear age-related genes are not connected to this PPI network. The average number of neighbours for a node in the network is 10.891, and the mean clustering coefficient of the network is 0.283. This value is 10 times larger than the clustering coefficient expected for a sparse random uncorrelated network (0.02) (Newman, 2006; Doncheva *et al.*, 2012). Overall these results clearly indicate that the resulting nuclear age-related PPI network is strongly connected.



**Figure II.3** – Protein-protein interaction (PPI) network of the nuclear age-related genes. Node size according to the degree (number of neighbours) in the network.


The nuclear age-related PPI network was further analysed using the Cytoscape plugin ClusterMaker (GLay) (Figure II.4) that allows the analysis of complex networks in a biological context and the identification of functional relationships. The analysis resulted in the identification of 9 clusters from which the composition of clusters 1 and 2 suggests the formation of enriched functional clusters (Figure II.4).




**Figure II.4** – Nuclear age-related PPI network clusters produced using the Cytoscape plugin clusterMaker (GLay).

Therefore, we proceeded with further analysis of the two main clusters (Figure II.5). The total number of proteins mapped in the cluster 1 network was 85. The average number of neighbours for a node in the network is 10, and the mean clustering coefficient of the network is 0.3483. A total number of proteins mapped in the cluster 2 network was 77. The average number of neighbours for a node in the network is 11.992, and the mean clustering coefficient of the network is 0.423. Overall these results clearly indicate that our nuclear age-related PPI clusters are closely connected and therefore the proteins of these networks are closely functionally associated.

## A. Cluster 1



## B. Cluster 2



**Figure II.5** – Nuclear age-related PPI network cluster 1 (A) and cluster 2 (B) produced using the Cytoscape plugin clusterMaker (GLay). Node size corresponding to node degree.

We performed an analysis of the Biological Processes involved in the age-related genes that comprise the clusters 1 and 2 using Panther Online Resource (Tables II.2 and II.3, respectively). The main biological processes associated with cluster 1 proteins are related to transcription (namely, TAF1, TCF3, TP53 and CREBBP) and transcription regulation by chromatin remodelling/organization (namely, EP300, HDAC1, HDAC 2, HDAC3, HDAC5, HDAC7, SIRT1 and SMARCA4). In cluster 2, the most prominent biological processes are DNA metabolic process and DNA repair (namely, APTX, PCNA, RAD51, BLM, ATM, H2AX and *TP53BP1*). Noticeably, the cluster 2 comprises the lamins (*LMNA*, *LMNB1*) genes which were also previously associated to DNA damage response and consequently to the ageing process (Mahen *et al.*, 2013). In fact, both A- and B-type lamins are required for the recruitment of factors involved in DNA repair, namely 53BP1, BRCA1 and RAD51 (reviewed in Gonzalo, (2014).



**Table II.2.** – Biological processes functional annotation enrichment analysis of the cluster 1 using Panther online resource. Enriched categories are identified as those with Bonferroni adjusted p value <0.05.

| <b>GO Biological Process</b>                                | <b>Nr of genes</b> | <b>Fold enrichment</b> | <b>p-value</b> |
|---|--------------------|------------------------|----------------|
| regulation of transcription from RNA polymerase II promoter | 27                 | 11.18                  | 1.55E-18       |
| transcription from RNA polymerase II promoter               | 29                 | 9.28                   | 5.56E-18       |
| transcription, DNA-dependent                                | 32                 | 7.77                   | 5.97E-18       |
| RNA metabolic process                                       | 32                 | 5.05                   | 1.19E-12       |
| metabolic process   | 58                 | 2.44                   | 3.90E-12       |
| chromatin organization                                      | 14                 | 12.70                  | 1.99E-09       |
| biosynthetic process  | 29                 | 4.11                   | 5.07E-09       |
| negative regulation of apoptotic process                    | 9                  | 22.50                  | 1.18E-07       |
| nucleobase-containing compound metabolic process            | 34                 | 3.01                   | 2.28E-07       |
| nitrogen compound metabolic process                         | 29                 | 2.84                   | 2.32E-05       |
| primary metabolic process                                   | 40                 | 2.08                   | 1.72E-04       |
| response to abiotic stimulus                                | 6                  | 19.29                  | 2.44E-04       |
| intracellular signal transduction                           | 16                 | 3.70                   | 1.39E-03       |
| developmental process                                       | 19                 | 3.13                   | 1.75E-03       |
| cellular process  | 54                 | 1.62                   | 2.25E-03       |
| response to stimulus  | 25                 | 2.31                   | 1.14E-02       |
| JAK-STAT cascade  | 3                  | 43.69                  | 1.60E-02       |
| MAPK cascade  | 8                  | 5.82                   | 1.87E-02       |
| organelle organization                                      | 15                 | 3.06                   | 2.40E-02       |
| regulation of biological process                            | 23                 | 2.31                   | 2.66E-02       |
| biological regulation                                       | 26                 | 2.16                   | 2.75E-02       |
| regulation of cell cycle                                    | 6                  | 7.99                   | 2.94E-02       |

**Table II.3.** – Biological processes functional annotation enrichment analysis of the cluster 2 using Panther online resource. Enriched categories are identified as those with Bonferroni adjusted p value <0.05.

| <b>GO Biological Process</b>                     | <b>Nr of genes</b> | <b>Fold enrichment</b> | <b>p-value</b> |
|--|--------------------|------------------------|----------------|
| DNA metabolic process                            | 40                 | 27.60                  | 1.22E-44       |
| DNA repair                                       | 30                 | 48.46                  | 6.86E-39       |
| response to stress                               | 32                 | 13.22                  | 4.96E-25       |
| nucleobase-containing compound metabolic process | 51                 | 4.92                   | 1.03E-23       |
| DNA recombination                                | 13                 | 67.44                  | 2.74E-17       |
| nitrogen compound metabolic process              | 42                 | 4.49                   | 1.53E-16       |
| primary metabolic process                        | 53                 | 3.01                   | 5.19E-15       |
| metabolic process                                | 58                 | 2.66                   | 6.70E-15       |
| regulation of cell cycle                         | 12                 | 17.40                  | 1.95E-09       |
| response to stimulus                             | 33                 | 3.33                   | 2.19E-08       |
| cell cycle                                       | 18                 | 6.72                   | 3.66E-08       |
| DNA replication                                  | 10                 | 17.18                  | 1.35E-07       |
| organelle organization                           | 21                 | 4.67                   | 5.45E-07       |
| meiosis  | 7                  | 30.46                  | 1.50E-06       |
| cellular process                                 | 56                 | 1.83                   | 1.77E-06       |
| cellular component organization                  | 24                 | 3.30                   | 2.48E-05       |
| chromosome segregation                           | 7                  | 19.67                  | 2.48E-05       |
| phosphate-containing compound metabolic process  | 21                 | 3.55                   | 5.85E-05       |
| cellular component organization or biogenesis    | 24                 | 3.08                   | 8.43E-05       |
| reproduction                                     | 7                  | 7.77                   | 9.05E-03       |
| biosynthetic process                             | 18                 | 2.78                   | 1.38E-02       |

## 2.4. Discussion

Ageing is a multifactorial and complex process, so studying ageing should never be focused in a unique protein, gene or pathway. Network approaches provide a framework for understanding the complexity of biological processes and diseases, looking further than to a simple gene, protein or pathway. More than looking at a specific level, interaction networks analysis allows us to better understand the protein complexes formed, rather than single interactions, enabling us to identify new disease/trait/process players.

In this chapter, the integration of multiple bioinformatic tools allowed the development of an intricate study of the ageing process. Briefly, we assembled a list of age-related genes by combining the data of two public databases. Remarkably, the analysis of the data places the nucleus in the spotlight of the ageing process, given that almost half of the age-related genes correspond to nuclear proteins (308 proteins). Moreover, PPI network construction lead us to the identification of prominent age-related functional clusters related with transcription regulation and chromatin remodelling (Cluster 1), and DNA metabolic process and DNA repair (Cluster 2).

In fact, numerous of the described hallmarks of ageing are correlated with epigenetic alterations that regulate transcription (López-Otín *et al.*, 2013). Changes in the chromatin-transcriptional pathways during ageing have been reported. In physiological ageing models, alterations in transcription and aberrant RNA splicing have been described, which might be due to chromatin structure changes (Zahn and Kim, 2007; Harries *et al.*, 2011). At molecular level, in aged tissues was reported alterations in multiple histone modifications, as is the case of histone acetylation which is a major regulator of transcription by regulating the interactions between DNA and histones (Benayoun *et al.*, 2015). Moreover, alterations in several histones and histone-modifying enzymes occur through lifespan (López-Otín *et al.*, 2013; Zane *et al.*, 2014). Among these are histone deacetylases (HDAC), as is the case of sirtuins (SIRT), that is well established to regulate longevity through their roles in genomic stability, metabolic regulation and chromatin remodelling (Ghosh *et al.*, 2013).

Moreover, using *in vitro* aged cells and aged tissues it was observed cumulative occurrence of DNA damage which might be due to a functional decline of DNA repair systems contributing for the genomic instability that increases with age (reviewed in Chen *et al.*, (2007). Several studies suggest defective DNA repair pathways on the origin of

premature ageing disorders since several of these syndromes are related to defects in DNA repair or in the processing of DNA damage (Brosh and Bohr, 2007; Vijg, 2008; Campisi and Vijg, 2009; Martin, 2011). Although the HGPS is not directly related to mutations in genes involved in DNA damage repair, the mutant lamin A accumulates and sequesters replication and repair factors, namely RAD50, RAD51 and 53BP1 resulting in delayed checkpoint response and defective DNA repair, culminating with an accumulation of DNA damage in HGPS cells (Liu *et al.*, 2005; Krishnan *et al.*, 2011). Of note, lamin A and lamin B1 in our PPI network analysis was found in the cluster 2, a cluster of proteins functionally enriched in DNA repair. Remarkably, both A- and B-type lamins are required for the recruitment of factors involved in DNA repair, namely 53BP1, BRCA1 and RAD51 (reviewed in Gonzalo, (2014)). So, it appears that expression of lamin A mutant proteins is strongly associated with an impairment in the capacity of cells adequately repair DNA damage and keep telomere homeostasis, resulting in genomic instability (Gonzalo, 2014).

All together, our data and previous studies indicate that the nuclear functions are very compromised during the ageing process. Remarkably, the nuclear periphery has been recently pointed out as potential regulator of the ageing phenotype (Serebryanny and Misteli, 2018), and in particular the lamina together with inner nuclear membranes represents a scaffold platform for the genome integrity maintenance. In fact, several alterations in the nuclear transport, chromatin organization and telomere maintenance were already proposed to be involved in the ageing process (Lombard *et al.*, 2005; van Heemst *et al.*, 2007; Kryston *et al.*, 2011; Ogino *et al.*, 2012). However, defects in the NE architecture and in the nuclear envelope proteins in ageing are still poorly studied. It urges the need of studying them further and understand what kind of alterations they could present with ageing. Moreover, the identification of additional proteins involved in the ageing are crucial for the understanding the ageing phenotype.

The NE integrity and its dynamic remodelling are crucial for cellular homeostasis, and so, when perturbed, NE dysfunction occurs. Therefore, revealing the mechanisms underlying NE dysfunction will significantly contribute to our understanding of the precise mechanisms underlying the ageing process.

## Supplementary Data

**Table SII.1** – Age-related genes obtained from the online databases GenAGE and GENEID. Uniprot accession numbers, gene and protein names are listed.

| Uniprot accession | Gene name | Protein name  |
|-------------------|-----------|---|
| P10912            | GHR       | Growth hormone receptor   |
| P01286            | SLIB      | Somatoliberin   |
| P29353            | SHC1      | SHC-transforming protein 1  |
| P28069            | PIT1      | Pituitary-specific positive transcription factor 1                            |
| O75360            | PROP1     | Homeobox protein prophet of Pit-1   |
| P04637            | P53       | Cellular tumor antigen p53  |
| O14746            | TERT      | Telomerase reverse transcriptase  |
| Q13315            | ATM       | Serine-protein kinase ATM   |
| P00749            | UROK      | Urokinase-type plasminogen activator  |
| P18074            | ERCC2     | General transcription and DNA repair factor IIIH helicase subunit XPD         |
| Q13216            | ERCC8     | DNA excision repair protein ERCC-8  |
| Q14191            | WRN       | Werner syndrome ATP-dependent helicase  |
| P02545            | LMNA      | Prelamin-A/C  |
| P08069            | IGF1R     | Insulin-like growth factor 1 receptor   |
| P10599            | THIO      | Thioredoxin   |
| Q9UEF7            | KLOT      | Klotho  |
| Q01094            | E2F1      | Transcription factor E2F1   |
| Q06124            | PTN11     | Tyrosine-protein phosphatase non-receptor type 11                             |
| Q00653            | NFKB2     | Nuclear factor NF-kappa-B p100 subunit  |
| P51692            | STA5B     | Signal transducer and activator of transcription 5B                           |
| P40763            | STAT3     | Signal transducer and activator of transcription 3                            |
| P42229            | STA5A     | Signal transducer and activator of transcription 5A                           |
| Q02297            | NRG1      | Pro-neuregulin-1, membrane-bound isoform                                      |
| O15379            | HDAC3     | Histone deacetylase 3   |
| P01241            | SOMA      | Somatotropin  |
| P16871            | IL7RA     | Interleukin-7 receptor subunit alpha  |
| P05019            | IGF1      | Insulin-like growth factor I  |
| P01344            | IGF2      | Insulin-like growth factor II   |
| P01308            | INS       | Insulin   |
| P01138            | NGF       | Beta-nerve growth factor  |
| P35568            | IRS1      | Insulin receptor substrate 1  |
| P18031            | PTN1      | Tyrosine-protein phosphatase non-receptor type 1                              |
| Q9Y4H2            | IRS2      | Insulin receptor substrate 2  |
| P31749            | AKT1      | RAC-alpha serine/threonine-protein kinase                                     |
| P42338            | PK3CB     | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform |
| P08138            | TNR16     | Tumor necrosis factor receptor superfamily member 16                          |
| P01112            | RASH      | GTPase HRas   |
| P01106            | MYC       | Myc proto-oncogene protein  |
| P00533            | EGFR      | Epidermal growth factor receptor  |
| P04626            | ERBB2     | Receptor tyrosine-protein kinase erbB-2                                       |

|        |       |  |
|--------|-------|--|
| P06213 | INSR  | Insulin receptor   |
| O75376 | NCOR1 | Nuclear receptor corepressor 1   |
| O60934 | NBN   | Nibrin   |
| P17535 | JUND  | Transcription factor jun-D   |
| P60568 | IL2   | Interleukin-2  |
| P01127 | PDGFB | Platelet-derived growth factor subunit B   |
| P01133 | EGF   | Pro-epidermal growth factor  |
| P31785 | IL2RG | Cytokine receptor common subunit gamma   |
| P01100 | FOS   | Proto-oncogene c-Fos   |
| P09619 | PGFRB | Platelet-derived growth factor receptor beta   |
| P19235 | EPOR  | Erythropoietin receptor  |
| P61278 | SMS   | Somatostatin   |
| Q05655 | KPCD  | Protein kinase C delta type  |
| Q07869 | PPARA | Peroxisome proliferator-activated receptor alpha   |
| P07949 | RET   | Proto-oncogene tyrosine-protein kinase receptor Ret  |
| P16885 | PLCG2 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2                                    |
| P50542 | PEX5  | Peroxisomal targeting signal 1 receptor  |
| P15923 | TFE2  | Transcription factor E2-alpha  |
| Q9HCS4 | TF7L1 | Transcription factor 7-like 1  |
| P09874 | PARP1 | Poly [ADP-ribose] polymerase 1   |
| P38398 | BRCA1 | Breast cancer type 1 susceptibility protein  |
| Q13526 | PIN1  | Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1   |
| P60484 | PTEN  | Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN |
| Q92793 | CBP   | CREB-binding protein   |
| Q16665 | HIF1A | Hypoxia-inducible factor 1-alpha   |
| P0CG47 | UBB   | Polyubiquitin-B  |
| P27694 | RFA1  | Replication protein A 70 kDa DNA-binding subunit   |
| P54132 | BLM   | Bloom syndrome protein   |
| P10415 | BCL2  | Apoptosis regulator Bcl-2  |
| P04271 | S100B | Protein S100-B   |
| P55072 | TERA  | Transitional endoplasmic reticulum ATPase  |
| P54098 | DPOG1 | DNA polymerase subunit gamma-1   |
| P17936 | IBP3  | Insulin-like growth factor-binding protein 3   |
| P07900 | HS90A | Heat shock protein HSP 90-alpha  |
| P04150 | GCR   | Glucocorticoid receptor  |
| P18146 | EGR1  | Early growth response protein 1  |
| P15692 | VEGFA | Vascular endothelial growth factor A   |
| P00519 | ABL1  | Tyrosine-protein kinase ABL1   |
| P51587 | BRCA2 | Breast cancer type 2 susceptibility protein  |
| P11388 | TOP2A | DNA topoisomerase 2-alpha  |
| Q02880 | TOP2B | DNA topoisomerase 2-beta   |
| P19838 | NFKB1 | Nuclear factor NF-kappa-B p105 subunit   |
| P11387 | TOP1  | DNA topoisomerase 1  |
| Q06609 | RAD51 | DNA repair protein RAD51 homolog 1   |

|        |       |   |
|--------|-------|---|
| P63279 | UBC9  | SUMO-conjugating enzyme UBC9  |
| P01375 | TNFA  | Tumor necrosis factor   |
| O15530 | PDPK1 | 3-phosphoinositide-dependent protein kinase 1                         |
| P49715 | CEBPA | CCAAT/enhancer-binding protein alpha                                  |
| P17676 | CEBPB | CCAAT/enhancer-binding protein beta                                   |
| P50539 | MXI1  | Max-interacting protein 1   |
| P01137 | TGFB1 | Transforming growth factor beta-1                                     |
| Q03468 | ERCC6 | DNA excision repair protein ERCC-6                                    |
| Q15831 | STK11 | Serine/threonine-protein kinase STK11                                 |
| Q09472 | EP300 | Histone acetyltransferase p300  |
| Q7Z2E3 | APTX  | Aprataxin   |
| P29590 | PML   | Protein PML   |
| P49841 | GSK3B | Glycogen synthase kinase-3 beta                                       |
| P31645 | SC6A4 | Sodium-dependent serotonin transporter                                |
| P42858 | HD    | Huntingtin  |
| P17252 | KPCA  | Protein kinase C alpha type   |
| P32745 | SSR3  | Somatostatin receptor type 3  |
| Q9NRZ9 | HELLS | Lymphoid-specific helicase  |
| P02656 | APOC3 | Apolipoprotein C-III  |
| P13639 | EF2   | Elongation factor 2   |
| P19447 | ERCC3 | General transcription and DNA repair factor IIIH helicase subunit XPB |
| P54274 | TERF1 | Telomeric repeat-binding factor 1                                     |
| P78527 | PRKDC | DNA-dependent protein kinase catalytic subunit                        |
| P04040 | CATA  | Catalase  |
| Q6IB77 | GLYAT | Glycine N-acyltransferase   |
| P28715 | ERCC5 | DNA repair protein complementing XP-G cells                           |
| P10275 | ANDR  | Androgen receptor   |
| Q13888 | TF2H2 | General transcription factor IIH subunit 2                            |
| P13010 | XRCC5 | X-ray repair cross-complementing protein 5                            |
| P12004 | PCNA  | Proliferating cell nuclear antigen                                    |
| P39748 | FEN1  | Flap endonuclease 1   |
| P25445 | TNR6  | Tumor necrosis factor receptor superfamily member 6                   |
| P49327 | FAS   | Fatty acid synthase   |
| Q15554 | TERF2 | Telomeric repeat-binding factor 2                                     |
| P12956 | XRCC6 | X-ray repair cross-complementing protein 6                            |
| P28340 | DPOD1 | DNA polymerase delta catalytic subunit                                |
| Q07812 | BAX   | Apoptosis regulator BAX   |
| P06400 | RB    | Retinoblastoma-associated protein                                     |
| P50402 | EMD   | Emerin  |
| P62993 | GRB2  | Growth factor receptor-bound protein 2                                |
| O43524 | FOXO3 | Forkhead box protein O3   |
| Q12778 | FOXO1 | Forkhead box protein O1   |
| Q00613 | HSF1  | Heat shock factor protein 1   |
| P23025 | XPA   | DNA repair protein complementing XP-A cells                           |
| Q9UJ68 | MSRA  | Mitochondrial peptide methionine sulfoxide reductase                  |

|        |       |   |
|--------|-------|---|
| O94761 | RECQ4 | ATP-dependent DNA helicase Q4                               |
| P04179 | SODM  | Superoxide dismutase [Mn], mitochondrial                    |
| P00441 | SODC  | Superoxide dismutase [Cu-Zn]                                |
| Q08050 | FOXO1 | Forkhead box protein O1                                     |
| Q99807 | COQ7  | 5-demethoxyubiquinone hydroxylase, mitochondrial            |
| O00555 | CAC1A | Voltage-dependent P/Q-type calcium channel subunit alpha-1A |
| P98164 | LRP2  | Low-density lipoprotein receptor-related protein 2          |
| O95831 | AIFM1 | Apoptosis-inducing factor 1, mitochondrial                  |
| P09936 | UCHL1 | Ubiquitin carboxyl-terminal hydrolase isozyme L1            |
| P05067 | APP   | Amyloid-beta A4 protein                                     |
| P02649 | APOE  | Apolipoprotein E  |
| P01023 | A2MG  | Alpha-2-macroglobulin                                       |
| O76070 | SYUG  | Gamma-synuclein   |
| Q06830 | PRDX1 | Peroxiredoxin-1   |
| P27169 | PON1  | Serum paraoxonase/arylesterase 1                            |
| Q04206 | TF65  | Transcription factor p65                                    |
| P05231 | IL6   | Interleukin-6   |
| Q15493 | RGN   | Regucalcin  |
| P48047 | ATPO  | ATP synthase subunit O, mitochondrial                       |
| P43351 | RAD52 | DNA repair protein RAD52 homolog                            |
| O95985 | TOP3B | DNA topoisomerase 3-beta-1                                  |
| P07992 | ERCC1 | DNA excision repair protein ERCC-1                          |
| Q96EB6 | SIRT1 | NAD-dependent protein deacetylase sirtuin-1                 |
| Q13547 | HDAC1 | Histone deacetylase 1                                       |
| P38646 | GRP75 | Stress-70 protein, mitochondrial                            |
| P07203 | GPX1  | Glutathione peroxidase 1                                    |
| P00390 | GSHR  | Glutathione reductase, mitochondrial                        |
| P48637 | GSHB  | Glutathione synthetase                                      |
| O15217 | GSTA4 | Glutathione S-transferase A4                                |
| P09211 | GSTP1 | Glutathione S-transferase P                                 |
| P00395 | COX1  | Cytochrome c oxidase subunit 1                              |
| P10809 | CH60  | 60 kDa heat shock protein, mitochondrial                    |
| P0DMV8 | HS71A | Heat shock 70 kDa protein 1A                                |
| P0DMV9 | HS71B | Heat shock 70 kDa protein 1B                                |
| P22061 | PIMT  | Protein-L-isoaspartate                                      |
| P45983 | MK08  | Mitogen-activated protein kinase 8                          |
| P63104 | 1433Z | 14-3-3 protein zeta/delta                                   |
| Q14289 | FAK2  | Protein-tyrosine kinase 2-beta                              |
| Q05397 | FAK1  | Focal adhesion kinase 1                                     |
| P13232 | IL7   | Interleukin-7   |
| Q16539 | MK14  | Mitogen-activated protein kinase 14                         |
| P11362 | FGFR1 | Fibroblast growth factor receptor 1                         |
| P08047 | SP1   | Transcription factor Sp1                                    |
| Q8N907 | DAND5 | DAN domain family member 5                                  |
| P17948 | VGFR1 | Vascular endothelial growth factor receptor 1               |



|        |       |  |
|--------|-------|--|
| P05412 | JUN   | Transcription factor AP-1  |
| O95243 | MBD4  | Methyl-CpG-binding domain protein 4  |
| Q15648 | MED1  | Mediator of RNA polymerase II transcription subunit 1                            |
| P45984 | MK09  | Mitogen-activated protein kinase 9   |
| P27361 | MK03  | Mitogen-activated protein kinase 3   |
| P09429 | HMGB1 | High mobility group protein B1   |
| P20248 | CCNA2 | Cyclin-A2  |
| P26583 | HMGB2 | High mobility group protein B2   |
| Q99683 | M3K5  | Mitogen-activated protein kinase kinase kinase 5                                 |
| P21675 | TAF1  | Transcription initiation factor TFIID subunit 1                                  |
| P20700 | LMNB1 | Lamin-B1   |
| Q99643 | C560  | Succinate dehydrogenase cytochrome b560 subunit, mitochondrial                   |
| P98177 | FOXO4 | Forkhead box protein O4  |
| Q9UBX0 | HESX1 | Homeobox expressed in ES cells 1   |
| P27986 | P85A  | Phosphatidylinositol 3-kinase regulatory subunit alpha                           |
| Q96G97 | BSCL2 | Seipin   |
| O15120 | PLCB  | 1-acyl-sn-glycerol-3-phosphate acyltransferase beta                              |
| P35226 | BMI1  | Polycomb complex protein BMI-1   |
| P68104 | EF1A1 | Elongation factor 1-alpha 1  |
| P05549 | AP2A  | Transcription factor AP-2-alpha  |
| P23560 | BDNF  | Brain-derived neurotrophic factor  |
| P16220 | CREB1 | Cyclic AMP-responsive element-binding protein 1                                  |
| P15336 | ATF2  | Cyclic AMP-dependent transcription factor ATF-2                                  |
| P20226 | TBP   | TATA-box-binding protein   |
| P27695 | APEX1 | DNA- (apurinic or apyrimidinic site) lyase                                       |
| O60381 | HBP1  | HMG box-containing protein 1   |
| Q8IV16 | HDBP1 | Glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 |
| O60566 | BUB1B | Mitotic checkpoint serine/threonine-protein kinase BUB1 beta                     |
| P35354 | PGH2  | Prostaglandin G/H synthase 2   |
| P11142 | HSP7C | Heat shock cognate 71 kDa protein  |
| Q96ST3 | SIN3A | Paired amphipathic helix protein Sin3a   |
| P06493 | CDK1  | Cyclin-dependent kinase 1  |
| Q14186 | TFDP1 | Transcription factor Dp-1  |
| P35638 | DDIT3 | DNA damage-inducible transcript 3 protein  |
| P09884 | DPOLA | DNA polymerase alpha catalytic subunit   |
| P10636 | TAU   | Microtubule-associated protein tau   |
| P29279 | CTGF  | Connective tissue growth factor  |
| Q92769 | HDAC2 | Histone deacetylase 2  |
| P61244 | MAX   | Protein max  |
| Q05195 | MAD1  | Max dimerization protein 1   |
| Q00987 | MDM2  | E3 ubiquitin-protein ligase Mdm2   |
| P63165 | SUMO1 | Small ubiquitin-related modifier 1   |
| P16104 | H2AX  | Histone H2AX   |
| P09629 | HXB7  | Homeobox protein Hox-B7  |
| P09017 | HXC4  | Homeobox protein Hox-C4  |

|        |       |  |
|--------|-------|--|
| O60674 | JAK2  | Tyrosine-protein kinase JAK2   |
| P03372 | ESR1  | Estrogen receptor  |
| P41159 | LEP   | Leptin   |
| O15243 | OBRG  | Leptin receptor gene-related protein                                 |
| P48357 | LEPR  | Leptin receptor  |
| P25963 | IKBA  | NF-kappa-B inhibitor alpha   |
| P10909 | CLUS  | Clusterin  |
| Q02643 | GHRHR | Growth hormone-releasing hormone receptor                            |
| P35222 | CTNB1 | Catenin beta-1   |
| P49768 | PSN1  | Presenilin-1   |
| Q9NYJ7 | DLL3  | Delta-like protein 3   |
| P42771 | CDN2A | Cyclin-dependent kinase inhibitor 2A                                 |
| Q8N726 | ARF   | Tumor suppressor ARF   |
| P62136 | PP1A  | Serine/threonine-protein phosphatase PP1-alpha catalytic subunit     |
| Q16643 | DREB  | Drebrin  |
| Q13253 | NOGG  | Noggin   |
| P15502 | ELN   | Elastin  |
| P20848 | AIATR | Putative alpha-1-antitrypsin-related protein                         |
| Q13535 | ATR   | Serine/threonine-protein kinase ATR                                  |
| Q9H6X2 | ANTR1 | Anthrax toxin receptor 1   |
| P55916 | UCP3  | Mitochondrial uncoupling protein 3                                   |
| O75844 | FACE1 | CAAX prenyl protease 1 homolog                                       |
| Q9H3D4 | P63   | Tumor protein 63   |
| P55851 | UCP2  | Mitochondrial uncoupling protein 2                                   |
| P06746 | DPOLB | DNA polymerase beta  |
| P48506 | GSH1  | Glutamate--cysteine ligase catalytic subunit                         |
| P48507 | GSH0  | Glutamate--cysteine ligase regulatory subunit                        |
| Q8N6T7 | SIRT6 | NAD-dependent protein deacetylase sirtuin-6                          |
| O43684 | BUB3  | Mitotic checkpoint protein BUB3                                      |
| P78406 | RAE1L | mRNA export factor   |
| P20382 | MCH   | Pro-MCH [Cleaved into: Neuropeptide-glycine-glutamic acid            |
| P40692 | MLH1  | DNA mismatch repair protein Mlh1                                     |
| P49674 | KC1E  | Casein kinase I isoform epsilon                                      |
| Q9UNE7 | CHIP  | E3 ubiquitin-protein ligase CHIP                                     |
| O15297 | PPM1D | Protein phosphatase 1D   |
| O96017 | CHK2  | Serine/threonine-protein kinase Chk2                                 |
| P35558 | PCKGC | Phosphoenolpyruvate carboxykinase, cytosolic [GTP]                   |
| Q07960 | RHG01 | Rho GTPase-activating protein 1                                      |
| P60953 | CDC42 | Cell division control protein 42 homolog                             |
| O00327 | BMAL1 | Aryl hydrocarbon receptor nuclear translocator-like protein 1        |
| O15516 | CLOCK | Circadian locomotor output cycles protein kaput                      |
| Q14526 | HIC1  | Hypermethylated in cancer 1 protein                                  |
| Q13219 | PAPP1 | Pappalysin-1   |
| O95622 | ADCY5 | Adenylate cyclase type 5   |
| Q9UBK2 | PRGC1 | Peroxisome proliferator-activated receptor gamma coactivator 1-alpha |

|        |        |  |
|--------|--------|--|
| P36969 | GPX4   | Phospholipid hydroperoxide glutathione peroxidase                              |
| P25874 | UCP1   | Mitochondrial brown fat uncoupling protein 1                                   |
| Q9GZV9 | FGF23  | Fibroblast growth factor 23  |
| Q12805 | FBLN3  | EGF-containing fibulin-like extracellular matrix protein 1                     |
| Q92889 | XPF    | DNA repair endonuclease XPF  |
| P11597 | CETP   | Cholesteryl ester transfer protein   |
| P37231 | PPARG  | Peroxisome proliferator-activated receptor gamma                               |
| P30556 | AGTR1  | Type-1 angiotensin II receptor   |
| Q8N5K1 | CISD2  | CDGSH iron-sulfur domain-containing protein 2                                  |
| O43324 | MCA3   | Eukaryotic translation elongation factor 1 epsilon-1                           |
| Q12929 | EPS8   | Epidermal growth factor receptor kinase substrate 8                            |
| P22001 | KCNA3  | Potassium voltage-gated channel subfamily A member 3                           |
| Q9NRC8 | SIR7   | NAD-dependent protein deacetylase sirtuin-7                                    |
| Q9BZW2 | S13A1  | Solute carrier family 13 member 1  |
| O14508 | SOCS2  | Suppressor of cytokine signaling 2   |
| P29144 | TPP2   | Tripeptidyl-peptidase 2  |
| Q12888 | TP53B  | TP53-binding protein 1   |
| Q9NTG7 | SIR3   | NAD-dependent protein deacetylase sirtuin-3, mitochondrial                     |
| Q9Y618 | NCOR2  | Nuclear receptor corepressor 2   |
| O94901 | SUN1   | SUN domain-containing protein 1  |
| Q16611 | BAK    | Bcl-2 homologous antagonist/killer   |
| P18065 | IBP2   | Insulin-like growth factor-binding protein 2                                   |
| P32322 | P5CR1  | Pyrroline-5-carboxylate reductase 1, mitochondrial                             |
| O15350 | P73    | Tumor protein p73  |
| P21554 | CNR1   | Cannabinoid receptor 1   |
| Q16236 | NF2L2  | Nuclear factor erythroid 2-related factor 2                                    |
| P38936 | CDN1A  | Cyclin-dependent kinase inhibitor 1  |
| P16234 | PGFRA  | Platelet-derived growth factor receptor alpha                                  |
| P42336 | PK3CA  | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform |
| P02745 | C1QA   | Complement C1q subcomponent subunit A  |
| P42772 | CDN2B  | Cyclin-dependent kinase 4 inhibitor B  |
| Q9GZV4 | IF5A2  | Eukaryotic translation initiation factor 5A-2                                  |
| P03971 | MIS    | Muellerian-inhibiting factor   |
| P14174 | MIF    | Macrophage migration inhibitory factor   |
| O75907 | DGAT1  | Diacylglycerol O-acyltransferase 1   |
| P04732 | MT1E   | Metallothionein-1E   |
| Q9NSA1 | FGF21  | Fibroblast growth factor 21  |
| O43464 | HTRA2  | Serine protease HTRA2, mitochondrial   |
| P49840 | GSK3A  | Glycogen synthase kinase-3 alpha   |
| P36639 | 8ODP   | 7,8-dihydro-8-oxoguanine triphosphatase  |
| O14920 | IKKB   | Inhibitor of nuclear factor kappa-B kinase subunit beta                        |
| Q13501 | SQSTM1 | Sequestosome-1   |
| P50613 | CDK7   | Cyclin-dependent kinase 7  |
| P28799 | GRN    | Granulins  |
| P05121 | PAI1   | Plasminogen activator inhibitor 1  |

|        |       |  |
|--------|-------|--|
| Q9H040 | SPRTN | SprT-like domain-containing protein Spartan                                    |
| Q6R327 | RICTR | Rapamycin-insensitive companion of mTOR  |
| Q16619 | CTF1  | Cardiotrophin-1  |
| Q12931 | TRAP1 | Heat shock protein 75 kDa, mitochondrial                                       |
| Q58FF3 | ENPLL | Putative endoplasmin-like protein  |
| Q8NER1 | TRPV1 | Transient receptor potential cation channel subfamily V member 1               |
| Q14494 | NF2L1 | Endoplasmic reticulum membrane sensor NFE2L1                                   |
| P01574 | IFNB  | Interferon beta  |
| O95390 | GDF11 | Growth/differentiation factor 11   |
| Q13131 | AAPK1 | 5'-AMP-activated protein kinase catalytic subunit alpha-1                      |
| P00813 | ADA   | Adenosine deaminase  |
| P48736 | PK3CG | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform |
| O00443 | P3C2A | Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha   |
| Q96BI3 | APH1A | Gamma-secretase subunit APH-1A   |
| Q8WW43 | APH1B | Gamma-secretase subunit APH-1B   |
| P06576 | ATPB  | ATP synthase subunit beta, mitochondrial                                       |
| Q9HD33 | RM47  | 39S ribosomal protein L47, mitochondrial                                       |
| P13861 | KAP2  | cAMP-dependent protein kinase type II-alpha regulatory subunit                 |
| P31323 | KAP3  | cAMP-dependent protein kinase type II-beta regulatory subunit                  |
| Q14457 | BECN1 | Beclin-1   |
| O43683 | BUB1  | Mitotic checkpoint serine/threonine-protein kinase BUB1                        |
| P10606 | COX5B | Cytochrome c oxidase subunit 5B, mitochondrial                                 |
| Q9UK39 | NOCT  | Nocturnin  |
| Q9UQ13 | SHOC2 | Leucine-rich repeat protein SHOC-2   |
| P17987 | TCPA  | T-complex protein 1 subunit alpha  |
| Q13972 | RGRF1 | Ras-specific guanine nucleotide-releasing factor 1                             |
| O14827 | RGRF2 | Ras-specific guanine nucleotide-releasing factor 2                             |
| Q07889 | SOS1  | Son of sevenless homolog 1   |
| Q99741 | CDC6  | Cell division control protein 6 homolog  |
| Q13415 | ORC1  | Origin recognition complex subunit 1   |
| Q9Y619 | ORNT1 | Mitochondrial ornithine transporter 1  |
| O00311 | CDC7  | Cell division cycle 7-related protein kinase                                   |
| P42574 | CASP3 | Caspase-3  |
| P55210 | CASP7 | Caspase-7  |
| P55212 | CASP6 | Caspase-6  |
| P42575 | CASP2 | Caspase-2  |
| Q14790 | CASP8 | Caspase-8  |
| P61964 | WDR5  | WD repeat-containing protein 5   |
| O60907 | TBL1X | F-box-like/WD repeat-containing protein TBL1X                                  |
| Q8NCM8 | DYHC2 | Cytoplasmic dynein 2 heavy chain 1   |
| P21333 | FLNA  | Filamin-A  |
| O75390 | CISY  | Citrate synthase, mitochondrial  |
| Q9Y4R8 | TELO2 | Telomere length regulation protein TEL2 homolog                                |
| Q9NZJ6 | COQ3  | Ubiquinone biosynthesis O-methyltransferase, mitochondrial                     |
| P20674 | COX5A | Cytochrome c oxidase subunit 5A, mitochondrial                                 |

|        |       |   |
|--------|-------|---|
| P08574 | CY1   | Cytochrome c1, heme protein, mitochondrial                  |
| O60266 | ADCY3 | Adenylate cyclase type 3                                    |
| P17568 | NDUB7 | NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7 |
| Q9HBG6 | IF122 | Intraflagellar transport protein 122 homolog                |
| P48380 | RFX3  | Transcription factor RFX3                                   |
| Q33E94 | RFX4  | Transcription factor RFX4                                   |
| P48382 | RFX5  | DNA-binding protein RFX5                                    |
| Q13705 | AVR2B | Activin receptor type-2B                                    |
| P37173 | TGFR2 | TGF-beta receptor type-2                                    |
| P36897 | TGFR1 | TGF-beta receptor type-1                                    |
| Q13188 | STK3  | Serine/threonine-protein kinase 3                           |
| Q13043 | STK4  | Serine/threonine-protein kinase 4                           |
| P10632 | CP2C8 | Cytochrome P450 2C8   |
| P08684 | CP3A4 | Cytochrome P450 3A4   |
| P11712 | CP2C9 | Cytochrome P450 2C9   |
| Q9NR63 | CP26B | Cytochrome P450 26B1  |
| P04798 | CP1A1 | Cytochrome P450 1A1   |
| P11509 | CP2A6 | Cytochrome P450 2A6   |
| O43174 | CP26A | Cytochrome P450 26A1  |
| Q9NQZ3 | DAZ1  | Deleted in azoospermia protein 1                            |
| P51530 | DNA2  | DNA replication ATP-dependent helicase/nuclease DNA2        |
| P49917 | DNLI4 | DNA ligase 4  |
| Q7Z6J0 | SH3R1 | E3 ubiquitin-protein ligase SH3RF1                          |
| Q15822 | ACHA2 | Neuronal acetylcholine receptor subunit alpha-2             |
| P17787 | ACHB2 | Neuronal acetylcholine receptor subunit beta-2              |
| P13637 | AT1A3 | Sodium/potassium-transporting ATPase subunit alpha-3        |
| Q13976 | KGP1  | cGMP-dependent protein kinase 1                             |
| Q8N8Q8 | COX18 | Cytochrome c oxidase assembly protein COX18, mitochondrial  |
| O00213 | APBB1 | Amyloid-beta A4 precursor protein-binding family B member 1 |
| Q99729 | ROAA  | Heterogeneous nuclear ribonucleoprotein A/B                 |
| P50616 | TOB1  | Protein Tob1  |
| P62324 | BTG1  | Protein BTG1  |
| P14324 | FPPS  | Farnesyl pyrophosphate synthase                             |
| P42345 | MTOR  | Serine/threonine-protein kinase mTOR                        |
| Q9Y478 | AAKB1 | 5'-AMP-activated protein kinase subunit beta-1              |
| O43741 | AAKB2 | 5'-AMP-activated protein kinase subunit beta-2              |
| P20594 | ANPRB | Atrial natriuretic peptide receptor 2                       |
| P16066 | ANPRA | Atrial natriuretic peptide receptor 1                       |
| P51841 | GUC2F | Retinal guanylyl cyclase 2                                  |
| P05090 | APOD  | Apolipoprotein D  |
| P46531 | NOTC1 | Neurogenic locus notch homolog protein 1                    |
| Q99466 | NOTC4 | Neurogenic locus notch homolog protein 4                    |
| P63096 | GNAI1 | Guanine nucleotide-binding protein G                        |
| P09471 | GNAO  | Guanine nucleotide-binding protein G                        |
| P19087 | GNAT2 | Guanine nucleotide-binding protein G                        |

|        |       |   |
|--------|-------|---|
| P21695 | GPDA  | Glycerol-3-phosphate dehydrogenase [NAD                     |
| P46091 | GPR1  | G-protein coupled receptor 1                                |
| Q13952 | NFYC  | Nuclear transcription factor Y subunit gamma                |
| Q9NRG0 | CHRC1 | Chromatin accessibility complex protein 1                   |
| O14733 | MP2K7 | Dual specificity mitogen-activated protein kinase kinase 7  |
| P17066 | HSP76 | Heat shock 70 kDa protein 6                                 |
| Q9Y230 | RUVB2 | RuvB-like 2   |
| O75351 | VPS4B | Vacuolar protein sorting-associated protein 4B              |
| P04792 | HSPB1 | Heat shock protein beta-1                                   |
| O14618 | CCS   | Copper chaperone for superoxide dismutase                   |
| P08294 | SODE  | Extracellular superoxide dismutase [Cu-Zn]                  |
| Q99757 | THIOM | Thioredoxin, mitochondrial                                  |
| O43396 | TXNL1 | Thioredoxin-like protein 1                                  |
| P52789 | HXK2  | Hexokinase-2  |
| P48735 | IDHP  | Isocitrate dehydrogenase [NADP], mitochondrial              |
| P50213 | IDH3A | Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial |
| Q13183 | S13A2 | Solute carrier family 13 member 2                           |
| P14616 | INSRR | Insulin receptor-related protein                            |
| P47985 | UCRI  | Cytochrome b-c1 complex subunit Rieske, mitochondrial       |
| O43808 | PM34  | Peroxisomal membrane protein PMP34                          |
| Q9H2D1 | MFTC  | Mitochondrial folate transporter/carrier                    |
| P27544 | CERS1 | Ceramide synthase 1   |
| P22749 | GNLY  | Granulysin  |
| P15090 | FABP4 | Fatty acid-binding protein, adipocyte                       |
| P05413 | FABPH | Fatty acid-binding protein, heart                           |
| P02689 | MYP2  | Myelin P2 protein   |
| P01116 | RASK  | GTPase KRas   |
| P01111 | RASN  | GTPase NRas   |
| Q8IXJ6 | SIR2  | NAD-dependent protein deacetylase sirtuin-2                 |
| Q9Y6E7 | SIR4  | NAD-dependent protein lipoamidase sirtuin-4, mitochondrial  |
| Q9NXA8 | SIR5  | NAD-dependent protein deacylase sirtuin-5, mitochondrial    |
| Q15031 | SYLM  | Probable leucine--tRNA ligase, mitochondrial                |
| P09012 | SNRPA | U1 small nuclear ribonucleoprotein A                        |
| P08579 | RU2B  | U2 small nuclear ribonucleoprotein B"                       |
| Q6ZRY4 | RBPS2 | RNA-binding protein with multiple splicing 2                |
| Q9Y6E0 | STK24 | Serine/threonine-protein kinase 24                          |
| Q9NQU5 | PAK6  | Serine/threonine-protein kinase PAK 6                       |
| Q99798 | ACON  | Aconitate hydratase, mitochondrial                          |
| Q9UBU8 | MO4L1 | Mortality factor 4-like protein 1                           |
| P11021 | BIP   | Endoplasmic reticulum chaperone BiP                         |
| Q8TB72 | PUM2  | Pumilio homolog 2   |
| Q14671 | PUM1  | Pumilio homolog 1   |
| O15440 | MRP5  | Multidrug resistance-associated protein 5                   |
| Q96J65 | MRP9  | Multidrug resistance-associated protein 9                   |
| Q96J66 | ABCCB | ATP-binding cassette sub-family C member 11                 |

|        |       |  |
|--------|-------|--|
| P48960 | CD97  | CD97 antigen   |
| P55157 | MTP   | Microsomal triglyceride transfer protein large subunit                           |
| P14314 | GLU2B | Glucosidase 2 subunit beta   |
| P19793 | RXRA  | Retinoic acid receptor RXR-alpha   |
| P28702 | RXRB  | Retinoic acid receptor RXR-beta  |
| P41235 | HNF4A | Hepatocyte nuclear factor 4-alpha  |
| P30419 | NMT1  | Glycylpeptide N-tetradecanoyltransferase 1                                       |
| O60551 | NMT2  | Glycylpeptide N-tetradecanoyltransferase 2                                       |
| P40261 | NNMT  | Nicotinamide N-methyltransferase   |
| Q6XQN6 | PNCB  | Nicotinate phosphoribosyltransferase   |
| P01303 | NPY   | Pro-neuropeptide Y   |
| O00115 | DNS2A | Deoxyribonuclease-2-alpha  |
| Q8WZ79 | DNS2B | Deoxyribonuclease-2-beta   |
| O75489 | NDUS3 | NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial             |
| Q96LB3 | IFT74 | Intraflagellar transport protein 74 homolog                                      |
| Q9Y496 | KIF3A | Kinesin-like protein KIF3A   |
| O15066 | KIF3B | Kinesin-like protein KIF3B   |
| O14782 | KIF3C | Kinesin-like protein KIF3C   |
| O95239 | KIF4A | Chromosome-associated kinesin KIF4A  |
| Q2VIQ3 | KIF4B | Chromosome-associated kinesin KIF4B  |
| Q12840 | KIF5A | Kinesin heavy chain isoform 5A   |
| O15294 | OGT1  | UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit |
| Q9Y5Q9 | TF3C3 | General transcription factor 3C polypeptide 3                                    |
| Q9Y366 | IFT52 | Intraflagellar transport protein 52 homolog                                      |
| O14753 | OVOL1 | Putative transcription factor Ovo-like 1   |
| Q9BRP0 | OVOL2 | Transcription factor Ovo-like 2  |
| O00110 | OVOL3 | Putative transcription factor ovo-like protein 3                                 |
| O60260 | PRKN  | E3 ubiquitin-protein ligase parkin   |
| Q3L8U1 | CHD9  | Chromodomain-helicase-DNA-binding protein 9                                      |
| Q9HCK8 | CHD8  | Chromodomain-helicase-DNA-binding protein 8                                      |
| Q07343 | PDE4B | cAMP-specific 3',5'-cyclic phosphodiesterase 4B                                  |
| O76083 | PDE9A | High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A                    |
| Q08499 | PDE4D | cAMP-specific 3',5'-cyclic phosphodiesterase 4D                                  |
| Q9Y243 | AKT3  | RAC-gamma serine/threonine-protein kinase  |
| Q02156 | KPCE  | Protein kinase C epsilon type  |
| P31751 | AKT2  | RAC-beta serine/threonine-protein kinase   |
| P05771 | KPCB  | Protein kinase C beta type   |
| Q9NZ42 | PEN2  | Gamma-secretase subunit PEN-2  |
| Q8N697 | S15A4 | Solute carrier family 15 member 4  |
| P46059 | S15A1 | Solute carrier family 15 member 1  |
| Q16348 | S15A2 | Solute carrier family 15 member 2  |
| Q9H611 | PIF1  | ATP-dependent DNA helicase PIF1  |
| P35232 | PHB   | Prohibitin   |
| P27105 | STOM  | Erythrocyte band 7 integral membrane protein                                     |
| Q99623 | PHB2  | Prohibitin-2   |

|        |       |   |
|--------|-------|---|
| Q13393 | PLD1  | Phospholipase D1  |
| Q8TE04 | PANK1 | Pantothenate kinase 1   |
| Q9BZ23 | PANK2 | Pantothenate kinase 2, mitochondrial  |
| P49810 | PSN2  | Presenilin-2  |
| Q15397 | PUM3  | Pumilio homolog 3   |
| Q15274 | NADC  | Nicotinate-nucleotide pyrophosphorylase   |
| Q8WWV3 | RT4I1 | Reticulon-4-interacting protein 1, mitochondrial  |
| O60671 | RAD1  | Cell cycle checkpoint protein RAD1  |
| Q5T890 | ER6L2 | DNA excision repair protein ERCC-6-like 2   |
| Q9Y620 | RA54B | DNA repair and recombination protein RAD54B   |
| P51532 | SMCA4 | Transcription activator BRG1  |
| P51531 | SMCA2 | Probable global transcription activator SNF2L2  |
| O60264 | SMCA5 | SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5 |
| P28370 | SMCA1 | Probable global transcription activator SNF2L1  |
| Q14565 | DMC1  | Meiotic recombination protein DMC1/LIM15 homolog  |
| Q8IV36 | HID1  | Protein HID1  |
| Q9UKC9 | FBXL2 | F-box/LRR-repeat protein 2  |
| Q99638 | RAD9A | Cell cycle checkpoint control protein RAD9A   |
| P46100 | ATRX  | Transcriptional regulator ATRX  |
| P62070 | RRAS2 | Ras-related protein R-Ras2  |
| Q96NR8 | RDH12 | Retinol dehydrogenase 12  |
| Q8TC12 | RDH11 | Retinol dehydrogenase 11  |
| Q92781 | RDH1  | 11-cis retinol dehydrogenase  |
| O75452 | RDH16 | Retinol dehydrogenase 16  |
| Q8IZV5 | RDH10 | Retinol dehydrogenase 10  |
| Q9NYR8 | RDH8  | Retinol dehydrogenase 8   |
| Q969S3 | ZN622 | Zinc finger protein 622   |
| Q5UIP0 | RIF1  | Telomere-associated protein RIF1  |
| Q9Y581 | INSL6 | Insulin-like peptide INSL6  |
| Q8WUI4 | HDAC7 | Histone deacetylase 7   |
| Q9UKV0 | HDAC9 | Histone deacetylase 9   |
| Q9UQL6 | HDAC5 | Histone deacetylase 5   |
| P62899 | RL31  | 60S ribosomal protein L31   |
| Q02878 | RL6   | 60S ribosomal protein L6  |
| P62834 | RAP1A | Ras-related protein Rap-1A  |
| P61224 | RAP1B | Ras-related protein Rap-1b  |
| P61225 | RAP2B | Ras-related protein Rap-2b  |
| O14948 | TFEC  | Transcription factor EC   |
| P19532 | TFE3  | Transcription factor E3   |
| P54107 | CRIS1 | Cysteine-rich secretory protein 1   |
| P16562 | CRIS2 | Cysteine-rich secretory protein 2   |
| P54108 | CRIS3 | Cysteine-rich secretory protein 3   |
| P48060 | GLIP1 | Glioma pathogenesis-related protein 1   |
| Q01995 | TAGL  | Transgelin  |



|        |       |   |
|--------|-------|---|
| P51911 | CNN1  | Calponin-1  |
| P37802 | TAGL2 | Transgelin-2  |
| Q9UI15 | TAGL3 | Transgelin-3  |
| O00141 | SGK1  | Serine/threonine-protein kinase Sgk1                      |
| Q96BR1 | SGK3  | Serine/threonine-protein kinase Sgk3                      |
| Q9HBY8 | SGK2  | Serine/threonine-protein kinase Sgk2                      |
| P46063 | RECQ1 | ATP-dependent DNA helicase Q1                             |
| O94762 | RECQ5 | ATP-dependent DNA helicase Q5                             |
| Q9NPE6 | SPAG4 | Sperm-associated antigen 4 protein                        |
| P31948 | STIP1 | Stress-induced-phosphoprotein 1                           |
| O15264 | MK13  | Mitogen-activated protein kinase 13                       |
| P28482 | MK01  | Mitogen-activated protein kinase 1                        |
| P53778 | MK12  | Mitogen-activated protein kinase 12                       |
| Q15759 | MK11  | Mitogen-activated protein kinase 11                       |
| P37840 | SYUA  | Alpha-synuclein   |
| P54646 | AAPK2 | 5'-AMP-activated protein kinase catalytic subunit alpha-2 |
| Q9UGJ0 | AAKG2 | 5'-AMP-activated protein kinase subunit gamma-2           |
| P54619 | AAKG1 | 5'-AMP-activated protein kinase subunit gamma-1           |
| Q9UGI9 | AAKG3 | 5'-AMP-activated protein kinase subunit gamma-3           |
| P50416 | CPT1A | Carnitine O-palmitoyltransferase 1, liver isoform         |
| Q92523 | CPT1B | Carnitine O-palmitoyltransferase 1, muscle isoform        |
| O95198 | KLHL2 | Kelch-like protein 2                                      |
| Q9Y573 | IPP   | Actin-binding protein IPP                                 |
| Q9BTW9 | TBCD  | Tubulin-specific chaperone D                              |
| P29992 | GNA11 | Guanine nucleotide-binding protein subunit alpha-11       |
| P50148 | GNAQ  | Guanine nucleotide-binding protein G                      |
| P30679 | GNA15 | Guanine nucleotide-binding protein subunit alpha-15       |
| O95467 | GNAS3 | Neuroendocrine secretory protein 55                       |
| P63092 | GNAS2 | Guanine nucleotide-binding protein G                      |
| P84996 | ALEX  | Protein ALEX  |
| Q5JWF2 | GNAS1 | Guanine nucleotide-binding protein G                      |
| Q9NQ55 | SSF1  | Suppressor of SWI4 1 homolog                              |
| P53701 | CCHL  | Cytochrome c-type heme lyase                              |
| Q9NQW8 | CNGB3 | Cyclic nucleotide-gated cation channel beta-3             |
| P29973 | CNGA1 | cGMP-gated cation channel alpha-1                         |
| Q14028 | CNGB1 | Cyclic nucleotide-gated cation channel beta-1             |
| P07333 | CSF1R | Macrophage colony-stimulating factor 1 receptor           |
| Q04912 | RON   | Macrophage-stimulating protein receptor                   |
| P35916 | VGFR3 | Vascular endothelial growth factor receptor 3             |
| P29320 | EPHA3 | Ephrin type-A receptor 3                                  |
| P50607 | TUB   | Tubby protein homolog                                     |
| Q9UBI4 | STML1 | Stomatin-like protein 1                                   |
| Q9HCH5 | SYTL2 | Synaptotagmin-like protein 2                              |
| Q9UPW8 | UN13A | Protein unc-13 homolog A                                  |
| O14795 | UN13B | Protein unc-13 homolog B                                  |

|        |       |   |
|--------|-------|---|
| Q8NB66 | UN13C | Protein unc-13 homolog C  |
| Q70J99 | UN13D | Protein unc-13 homolog D  |
| O95267 | GRP1  | RAS guanyl-releasing protein 1  |
| Q00975 | CAC1B | Voltage-dependent N-type calcium channel subunit alpha-1B                     |
| Q13936 | CAC1C | Voltage-dependent L-type calcium channel subunit alpha-1C                     |
| Q01668 | CAC1D | Voltage-dependent L-type calcium channel subunit alpha-1D                     |
| Q15878 | CAC1E | Voltage-dependent R-type calcium channel subunit alpha-1E                     |
| O60840 | CAC1F | Voltage-dependent L-type calcium channel subunit alpha-1F                     |
| Q9UJZ1 | STML2 | Stomatin-like protein 2, mitochondrial  |
| O14595 | CTDS2 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 2   |
| Q99259 | DCE1  | Glutamate decarboxylase 1   |
| Q05329 | DCE2  | Glutamate decarboxylase 2   |
| Q9Y600 | CSAD  | Cysteine sulfinic acid decarboxylase  |
| P20711 | DDC   | Aromatic-L-amino-acid decarboxylase   |
| P19113 | DCHS  | Histidine decarboxylase   |
| Q9UB19 | HDC   | Headcase protein homolog  |
| O15056 | SYNJ2 | Synaptojanin-2  |
| O43426 | SYNJ1 | Synaptojanin-1  |
| P11230 | ACHB  | Acetylcholine receptor subunit beta   |
| Q05901 | ACHB3 | Neuronal acetylcholine receptor subunit beta-3                                |
| P30926 | ACHB4 | Neuronal acetylcholine receptor subunit beta-4                                |
| P78337 | PITX1 | Pituitary homeobox 1  |
| O75364 | PITX3 | Pituitary homeobox 3  |
| Q99697 | PITX2 | Pituitary homeobox 2  |
| P23759 | PAX7  | Paired box protein Pax-7  |
| Q15699 | ALX1  | ALX homeobox protein 1  |
| O14813 | PHX2A | Paired mesoderm homeobox protein 2A   |
| Q9ULU8 | CAPS1 | Calcium-dependent secretion activator 1                                       |
| Q16623 | STX1A | Syntaxin-1A   |
| P61266 | STX1B | Syntaxin-1B   |
| Q13277 | STX3  | Syntaxin-3  |
| P32856 | STX2  | Syntaxin-2  |
| O75558 | STX11 | Syntaxin-11   |
| O15400 | STX7  | Syntaxin-7  |
| Q93050 | VPP1  | V-type proton ATPase 116 kDa subunit a isoform 1                              |
| Q13488 | VPP3  | V-type proton ATPase 116 kDa subunit a isoform 3                              |
| A6NJT0 | UNC4  | Homeobox protein unc-4 homolog  |
| O60902 | SHOX2 | Short stature homeobox protein 2  |
| O75569 | PRKRA | Interferon-inducible double-stranded RNA-dependent protein kinase activator A |
| Q9Y2V3 | RX    | Retinal homeobox protein Rx   |
| P40425 | PBX2  | Pre-B-cell leukemia transcription factor 2                                    |
| Q86WB7 | UN93A | Protein unc-93 homolog A  |
| Q9H598 | VIAAT | Vesicular inhibitory amino acid transporter                                   |
| P18505 | GBRB1 | Gamma-aminobutyric acid receptor subunit beta-1                               |
| P47870 | GBRB2 | Gamma-aminobutyric acid receptor subunit beta-2                               |

|        |       |  |
|--------|-------|--|
| P28472 | GBRB3 | Gamma-aminobutyric acid receptor subunit beta-3                |
| P24046 | GBRR1 | Gamma-aminobutyric acid receptor subunit rho-1                 |
| P23415 | GLRA1 | Glycine receptor subunit alpha-1                               |
| O00591 | GBRP  | Gamma-aminobutyric acid receptor subunit pi                    |
| Q9Y623 | MYH4  | Myosin-4   |
| P11055 | MYH3  | Myosin-3   |
| P12883 | MYH7  | Myosin-7   |
| P13535 | MYH8  | Myosin-8   |
| Q9UKX3 | MYH13 | Myosin-13  |
| O00634 | NET3  | Netrin-3   |
| Q9Y6N6 | LAMC3 | Laminin subunit gamma-3  |
| P11047 | LAMC1 | Laminin subunit gamma-1  |
| P55268 | LAMB2 | Laminin subunit beta-2   |
| P25391 | LAMA1 | Laminin subunit alpha-1  |
| O95631 | NET1  | Netrin-1   |
| Q99689 | FEZ1  | Fasciculation and elongation protein zeta-1                    |
| Q9Y250 | LZTS1 | Leucine zipper putative tumor suppressor 1                     |
| Q9UHY8 | FEZ2  | Fasciculation and elongation protein zeta-2                    |
| O75083 | WDR1  | WD repeat-containing protein 1                                 |
| O14727 | APAF  | Apoptotic protease-activating factor 1                         |
| O43172 | PRP4  | U4/U6 small nuclear ribonucleoprotein Prp4                     |
| Q9P2D8 | UNC79 | Protein unc-79 homolog   |
| Q8N2C7 | UNC80 | Protein unc-80 homolog   |
| P18283 | GPX2  | Glutathione peroxidase 2                                       |
| P22352 | GPX3  | Glutathione peroxidase 3                                       |
| Q96SL4 | GPX7  | Glutathione peroxidase 7                                       |
| Q9UI12 | VATH  | V-type proton ATPase subunit H                                 |
| Q8N8U9 | BMPER | BMP-binding endothelial regulator protein                      |
| Q9Y6R7 | FCGBP | IgGfC-binding protein  |
| O75443 | TECTA | Alpha-tectorin   |
| Q96KJ9 | COX42 | Cytochrome c oxidase subunit 4 isoform 2, mitochondrial        |
| P13073 | COX41 | Cytochrome c oxidase subunit 4 isoform 1, mitochondrial        |
| Q99643 | C560  | Succinate dehydrogenase cytochrome b560 subunit, mitochondrial |
| Q06830 | PRDX1 | Peroxisredoxin-1   |
| P47985 | UCRI  | Cytochrome b-c1 complex subunit Rieske, mitochondrial          |
| Q96RD7 | PANX1 | Pannexin-1   |
| Q96H78 | S2544 | Solute carrier family 25 member 44                             |
| O14558 | HSPB6 | Heat shock protein beta-6                                      |
| P02795 | MT2   | Metallothionein-2  |
| P29353 | SHC1  | SHC-transforming protein 1                                     |



## **CHAPTER III**


### **Characterization of the nuclear envelope protein alterations during ageing in mice models**



### 3.1. Introduction

Ageing is a very complex process to study about. As previously stated, studying ageing in humans poses various difficulties like ethical problems, long lifespan, uncontrollable environment impacts, among others. Hence, diverse animal models have been used to study the ageing process and biology. One of the most used ageing animal model is mice. Mice are very similar genetically and physiologically to humans and over the years, they have been used in many research areas. Mice offers advantages like being possible to raise them until full term life in less than 3 years, controlling their growing environment, registering sudden changes (Vanhooren and Libert, 2013).

Mice life cycle is quite different from humans and mice mature a lot faster than humans. Since they are born and until they complete 1 month old, their maturation rate is 150 times faster than in humans. Between their 1 to 6 months old, they mature 45 times faster than a human. After they complete 6 months, they mature 25 times faster than a human being. In terms of translating their ages to “human age” equivalents, there has been reported that a 3 to 6 months old mouse is considered a mature adult mouse, corresponding to 20 to 30 years old human (Figure III.1). A 10 to 14 months old mouse is considered a middle-aged mouse, corresponding to a 38 to 47 years old human (Figure III.1). An 18 to 24 months old mouse is considered old, which corresponds to a 56 to 69 years old human. After the 24 months old, 50% of the mice die (Figure III.1). Their maximum lifespan goes up to 36 months (Figure III.1) (The Jackson Laboratories booklet, 2017).



**Figure III.1** - Life phase equivalencies between mice and human. Taken from (The Jackson Laboratory booklet, 2017).

Given all the ethical constraints to work with humans, the animal models represent a very powerful and attractive model for the study of human physiology and pathology. In our case it was chosen to study the ageing process, particularly to characterize the nuclear envelope proteins alterations during ageing.

## 3.2. Materials and Methodology

### 3.2.1. Animals

C57BL/6 female mice with 6, 18 and 24 months old were obtained from Charles River Laboratory and housed at iBiMED animal facility according the Directive 2010/63/EU recommendations. The procedures were approved and supervised by the Animal welfare body of the Department of Medical Sciences of the University of Aveiro (CEDCM-BEA). Upon arrival the animals were kept one week in quarantine and then were sacrificed by cervical stretching followed by decapitation, and their organs collected, immediately frozen in liquid nitrogen and stored at  $-80^{\circ}\text{C}$ . During all the procedure efforts were made to minimize the number of animals used and their suffering.

In this study, the tissues used were liver and kidney from 4 different mice with 3 specific ages (6,18 and 24 months). Image III.2 summarizes the tissues collected at the different ages.



**Figure III.2** – Illustrative scheme of the tissues (liver and kidney) collected of four different mice at different ages of 6, 18 and 24 months old.



### 3.2.2. Protein extraction

The collected tissues were ground to powder using liquid nitrogen in a mortar and stored for later use at  $-80^{\circ}\text{C}$ . For protein extraction 10 volumes of ELB buffer (0.05M HEPES, 0.25M NaCl, 1mM DTT, 1mM NaF, 2mM EDTA, 1mM EGTA, 1mM  $\text{Na}_3\text{VO}_4$  and 0.5% Triton X-100, containing protease inhibitors) was added. The tissues were sonicated twice, for about 15 seconds/pulses. Then, the lysates were centrifuged for 15 min at  $4^{\circ}\text{C}$  and the supernatant was kept at  $-30^{\circ}\text{C}$ . The resulting lysates were then subjected to a cold acetone protein precipitation protocol. Briefly, it was added 9 parts of cold acetone ( $-20^{\circ}\text{C}$ ) to each part of the sample. The samples were centrifuged at 14,000g for 2h at  $4^{\circ}\text{C}$ . The supernatant was discarded, and the pellets were resuspended in boiling 1% SDS. The samples were boiled for 10 min at  $95^{\circ}\text{C}$ , sonicated twice during 15 seconds/pulses and stored at  $-30^{\circ}\text{C}$ .

### 3.2.3. Protein Quantification

The *Thermo Scientific™ Pierce™ BCA Protein Assay Kit* was used to determine the protein concentration of the samples. This kit is a colorimetric assay based on a combination of the reduction of  $\text{Cu}^{2+}$  to  $\text{Cu}^{+}$  by protein in a basic medium with an extremely accurate colorimetric detection of the cuprous cation ( $\text{Cu}^{+}$ ) by bicinchoninic acid (BCA). The first complex formed is a light blue one that is formed due to the chelation of copper with protein in a basic setting. Then, BCA reacts with the reduced cuprous cation formed previously. This is called the colour development reaction. The result of the chelation of two molecules of BCA with one cuprous ion is an intense purple-coloured reaction product. The complex formed (BCA/copper complex) is soluble in water and displays a linear absorbance at 562nm that increased with the increasing concentration of protein that is compared to a protein standard. The working range of this kit is 20-2000 $\mu\text{g}/\text{ml}$ .

Firstly, standards A, B, C, D, E, F, G, H and I were prepared in duplicate according to the manufacturer's instructions (see the appendix). The standards were prepared in autoclaved  $\text{dH}_2\text{O}$ . Then, 10 $\mu\text{l}$  of each standard were pipetted in duplicated to a 96-well plate. After that, the samples were prepared in a microtube (1 $\mu\text{l}$  of the original sample plus 24 $\mu\text{l}$  of autoclaved  $\text{dH}_2\text{O}$ ). Then, 10 $\mu\text{l}$  of each sample was pipetted in duplicated to the 96-well plate. At that point, the working solution was prepared being the proportion

of the reagent A to B, 50A: 1B, and 100µl of the working solution were pipetted in each well (samples + standards). After that, the plate was incubated at 37°C for 30 min. The absorbance at 562nm was read in a microplate reader (e.g. Infinite® 200 PRO from Tecan). The results were analysed having into account the dilution factor and by comparison with the standard curve.

#### **3.2.4. SDS-Polyacrylamide Gel Electrophoresis**

SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) is a very used method for protein separation by electrophoresis. It uses a discontinuous polyacrylamide gel as a support medium and SDS to denature the proteins. When SDS is dissolved, it has a net negative charge as it is an anionic detergent. The complex structures presented by proteins are destroyed by the negative charges on SDS. The higher molecular weight of the protein, the higher the amount of SDS bonded to a polypeptide chain. The negative charges of SDS are very attracted to an anode in an electric field. Larger molecules cannot migrate as fast as the smaller ones as they are restrained by polyacrylamide gels (Caprette, 2012). Samples were separated in 5-20% gradient SDS-PAGE gels in order to obtain a wider separation range and distinguish better some protein isoforms with close molecular weights. The gradient resolving gels were prepared (see composition in the appendix) and mixed in the Hoefer® GS50 Gradient Maker and allowed to polymerize at room temperature (RT). Then, the 3.5% stacking gel was prepared and loaded on the top of gradient gels. The combs were inserted, and the gels were left to polymerize at RT. Prior to loading, the samples were prepared by the addition of 4x Loading buffer (LB), boiled for 10 min and spinned down. The combs were removed, and the samples were carefully loaded into the wells. Molecular weight protein markers (Precision Plus Protein™ Dual Colour Standards; Bio Rad) were also loaded in the gels. The gels were subjected to electrophoresis in a Hoefer® electrophoresis system at 90mA for approximately 3h.

#### **3.2.5. Immunoblotting**

When the electrophoresis was completed, proteins were transferred from the gel to a nitrocellulose membrane (0.2 µm pore size; Amersham™ Protran®) at 200mA for 18h in a Hoefer™ TE42 Transfer Tank Blotting Unit. After transfer, the membranes were hydrated with 1x TBS-T (see appendix for composition) for 5 min at RT with gentle

agitation. Ponceau S staining was used as a loading control and the membrane scanned in Molecular Imager GS-800 Calibrated Densitometer (Bio-Rad). Membranes were washed in 1x TBS-T until the bands coloured with Ponceau S staining disappeared.

In order to reduce the background and unspecific signals, the blocking solution (5% BSA in 1x TBS-T) was incubated for 22h (4h at RT and overnight at 4°C with agitation). After that, the primary antibodies were incubated for 2-4h at RT and also overnight at 4°C (both with gentle agitation). The antibodies used were: LAP1 Antibody RL13, lamin A/C Antibody (346), lamin B1 Antibody (B-10), emerin Antibody (H-7), Syne-2 Antibody (C-1), SUN1 antibody (see table III.1 for further details). All the primary antibodies were diluted in 3% BSA in 1x TBS-T.

**Table III.1** – Primary antibodies used in order to detect the proteins analysed by immunoblotting.

| <b>Antibody</b>                           | <b>Antibody Company</b>       | <b>Antibody type</b> | <b>Target</b> | <b>Dilution</b> |
|---|-------------------------------|----------------------|---------------|-----------------|
| <b>Lamin A/C Antibody (346) sc-7293</b>   | Santa Cruz Biotechnology      | Mouse, monoclonal    | Lamin A/C     | 1:500           |
| <b>Lamin B1 Antibody (B-10) sc-374015</b> | Santa Cruz Biotechnology      | Mouse, monoclonal    | Lamin B1      | 1:500           |
| <b>Emerin Antibody (H-7) sc-393247</b>    | Santa Cruz Biotechnology      | Mouse, monoclonal    | Emerin        | 1:500           |
| <b>LAP1 Antibody RL13 MA1-074</b>         | Thermo Fisher Scientific      | Mouse, monoclonal    | LAP1          | 1:1000          |
| <b>SUN1 antibody</b>                      | Kindly provided by Ya-Hui Chi | Rabbit, polyclonal   | SUN1          | 1:2000          |
| <b>Syne-2 Antibody (C-1) sc-365097</b>    | Santa Cruz Biotechnology      | Mouse, monoclonal    | Nesprin-2     | 1:500           |

Anti-mouse or anti-rabbit horseradish peroxidase (HRP)-linked secondary antibodies (GE Healthcare) were used and diluted in 3% milk in 1x TBS-T. The secondary antibodies were incubated for 2h at RT. Between the primary and the secondary antibodies, the membranes were washed 4 times for 5 min with agitation. The washes were also performed after removing the secondary antibodies. The membranes were incubated with Luminata Crescendo™ Western HRP Substrate (Millipore) for 5 min

before image acquisition in the ChemiDoc™ Touch Imaging System (Bio-Rad). Luminata Crescendo™ Western HRP Substrate (Millipore) is a chemiluminescent reagent used to detect immobilized specific antigens conjugated directly or indirectly with HRP-labelled antibodies.

### **3.2.6. Data Analysis and Statistics**


Quantitative analyses of immunoblots was performed using Image Lab™ Software (Bio-Rad Laboratories; Version 6.00 Build 25). All data were corrected relative to loading control (Ponceau S) and were expressed as mean  $\pm$  SEM (standard error). Statistical significance analysis was conducted using GraphPad Prism 6 software and data were analysed using one-way ANOVA followed by the Dunnett's multi-comparisons test, for comparison of data with control values.

### **3.3. Results**

Several studies have pointed protein sequestration at the nuclear envelope periphery as a potential regulatory mechanism of the ageing phenotype. Here, the protein levels of six relevant nuclear envelope proteins were evaluated across mice lifespan in liver and kidney. Therefore, liver and kidney protein extracts from mice with 6, 18 and 24 months (4 animals for each time point) were obtained and further analysed by SDS-PAGE followed by immunoblotting using the specific antibodies against NE proteins. The NE proteins analysed were lamin A/C, lamin B1, emerin, LAP1, SUN1, and nesprin-2. The results are presented in Figure III.3A-E and Figure III.4A-F, referent to mice liver and mice kidney, respectively.

Regarding liver tissue, the first proteins analysed were the nuclear lamina proteins, particularly lamin A/C and lamin B1. The lamins protein levels are presented in figure III.3A and III.3B and we observe a significant increase in lamin A/C protein levels at 18 months old (p-value 0,001; 3.98 fold change) and a tendency to increase at 24 months old (2.35 fold change) in comparison with the 6 months old mice. Moreover, lamin B1 protein levels (Figure III.3B) also increases significantly at 18 months old (p-value 0.0164; 2.41 fold change) and also presents a tendency to increase at 24 months old (1.15 fold change) when compared with the 6 months old. The inner nuclear membrane proteins (INM) analysed were emerin and LAP1. The emerin protein levels are presented

in Figure III.3C, and revealed a significant increase comparing the 6 to 18 months old (p-value=0,0175; 4.72 fold change). The same pattern was observed when comparing the 6 months samples to the 24 months old ones (2.24 fold change). The levels of LAP1 total protein (Figure III.3D) increase significantly between 6 and 18 months old (p-value=0.0287; 2.70 fold change), and also between 6 and 24 months old animals (p-value= 0.0059; 2.91 fold change). Finally, the nesprin-2 protein levels are present in Figure III.3E, seems to increase with age, presenting a tendency to increase at 18 months (6.49 fold change) and being significantly increased in 24 months mice (p-value= 0,0145; 18.59 fold change) when compared with 6 months old mice.




**Figure III.3-** Protein levels of specific nuclear envelope proteins during ageing in mice liver. Analysis of nuclear lamina protein levels [lamin A/C (A) and lamin B1 (B)], the INM protein levels [emerin (C), and LAP1 (D)] and the ONM protein levels [nesprin-2 (E)] by immunoblotting. Three different ages were analysed (6, 18 and 24 months old). Ponceau S staining was used as a loading control. The quantitative data are presented as mean  $\pm$  SEM of the 4 independent animals. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$ . Statistical symbols: (\*) for comparisons to control (6 months) by using one-way ANOVA followed by the Dunnett's test. (A.U.=Arbitrary Units).

Concerning nuclear lamina protein levels in the kidney tissue, the results are presented in Figure III.4A. We observe a significant increase in lamin A/C protein levels in 18 months old (p-value =0.0187; 9.23 fold change) and a tendency to increase at 24 months old (7.63 fold change) in comparison with the 6 months old mice. Moreover, lamin B1 protein levels (Figure III.4B) also presents a significant increase at 18 (p-value 0.0003; 2.51 fold change). At 24 months old, a tendency to decrease is noticed (0.80 fold change) when compared with the 6 months old samples.


Concerning the INM proteins, the results of emerin protein levels are shown in Figure III.4C, and revealed a significant increase comparing the 6 to 18 months old mice (p-value=0.011; 63.41 fold change). The same significant pattern was observed when comparing the 6 month samples to the 24 months old (p-value 0.0056; 63.42 fold change). The LAP1 total protein levels (Figure III.4D) also increase significantly between 6 and 18 months old (p-value 0.0057; 5.36 fold change), and also presents a significant increase between 6 and 24 months old animals (p-value 0.0456; 3.26 fold change) although not so pronounced.

Regarding the LINC complex proteins, the SUN1 protein levels (Figure III.4E) present a tendency to increase between 6 and 18 months old (1.23 fold increase) and also when comparing the 6 months samples to the 24 months old ones (1.18 fold change). As indicated in Figure III.4F, nesprin-2 protein levels increase significantly between 6 and 18 months (p-value=0.0059; 37.44 fold change), and also when comparing 6 to 24 months mice (p-value= 0.003; 35.99 fold change).


### A. Lamin A/C protein levels in kidney




### B. Lamin B1 protein levels in kidney




### C. Emerin protein levels in kidney




### D. LAP1 protein levels in kidney



### E. SUN1 protein levels in kidney



### F. Nesprin-2 protein levels in kidney



**Figure III.4** - Protein levels of specific nuclear envelope proteins during ageing in mice kidney. Analysis of nuclear lamina protein levels [lamin A/C (A) and lamin B1 (B)], the INM protein levels [emerin (C), LAP1 (D), and SUN1 (E)] and the ONM protein levels [(nesprin-2 (F)) by immunoblotting. Three different ages were analysed (6, 18 and 24 months old). Ponceau S staining was used as a loading control. The quantitative data are presented as mean  $\pm$  SEM of the 4 independent animals. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$ . Statistical symbols: (\*) for comparisons to control (6 months) by using one-way ANOVA followed by the Dunnett's test. (A.U.=Arbitrary Units).



### 3.4. Discussion

Ageing is a highly complex process and can be described as a continued loss of physiological integrity that leads to altered function and a higher susceptibility to death. Many important diseases arise due to this impairment and deterioration of organism physiology, like cancer, diabetes, cardiovascular and neurodegenerative disorders (López-Otín et al., 2013). Nevertheless, there are some aspects that cannot be recapitulated in mice (Blackburn *et al.*, 2015). It is important to keep in mind that a crossover between genetics and environmental factors has a tremendous impact on the degree and rate of ageing in same species-individuals and in the variances among species (Rando, 2013).

Interestingly, defects or alterations in the nuclear proteins have been associated to various premature ageing disorders. It leads to the main idea that the nuclear lamina together with associated INM can effectively be central regulators of the ageing phenotype (Serebryannyy and Misteli, 2018). Mutations in *LMNA* outcome in disorders linked with skeletal balance, muscle, heart, vascular tissue, and premature ageing (Barascu et al., 2012b).

The results presented in this chapter indicated that lamin A/C, lamin B1, emerin, LAP1, and nesprin-2 protein levels increase in both tissues during ageing. Emerin levels increase in both tissues, but it increases more significantly in the kidney tissue. The same happens with nesprin-2. SUN1 seems to increase with age in kidney, but intriguingly it is not detected in liver. Both of these results might be attributed to a tissue-specific expression. Of note, the results presented are referent to four different mice that have individual-specific differences between them.

LAP1 protein is still poorly studied and there are no reports in the literature about its possible effect in the ageing process. Nevertheless, LAP1 was one of first proteins to be associated with lamins (Foisner and Gerace, 1993) and this association between LAP1 and lamins seems to be crucial for the preservation of the nuclear envelope architecture and to the lamins attachment to the nuclear envelope during the interphase (Foisner and Gerace, 1993; Rebelo *et al.*, 2015; Santos *et al.*, 2015). Since LAP1 is closely associated with lamins, it is not surprising that after so many reports of lamin A/C being involved in the ageing process, that LAP1 is also important/involved in this process.

Previous results from Petrini *et al.* (2017) have shown that in young human iPSCs (early passages) nesprin-2 is faintly detected. However, after passaging iPSCs for about

one year (aged iPSCs) the nesprin-2 expression is uniformly increased through the nucleus which are in line with our results. Nesprins have been associated with many diseases like myopathies, neurological disorders, cancer, hearing loss and arthrogyrosis. Nesprin-1 and -2 are linked with EDMD and EDMD-like phenotypes since it binds to emerin which is crucial for its proper localization. Lamin A/C mutations affect the LINC complex, consequently altering nesprin-2 localization (Cartwright and Karakesisoglou, 2014; Petrini *et al.*, 2017).

Several studies indicated that an accumulation of prelamin A or progerin has been associated with the normal ageing phenotype (Scaffidi and Misteli, 2006; Ragnauth *et al.*, 2010; Sieprath *et al.*, 2015). The expression of altered isoforms of lamin A has been widely mentioned in the literature in human physiological ageing models (Cao *et al.*, 2011; Lattanzi *et al.*, 2014; McClintock *et al.*, 2007; Olive *et al.*, 2010; Ragnauth *et al.*, 2010; Rodriguez *et al.*, 2009; Scaffidi and Misteli, 2006). Augmented levels of wild-type lamin A have been described to be associated with a shorter lifespan and nuclear aberrancies that result in apoptosis and senescence in human dermal fibroblasts, common features of HGPS phenotype. Over-expressing ZMPSTE24, a metalloproteinase in charge of removing the farnesylated carboxyl terminal region of lamin A, rescues the normal phenotype (Candelario *et al.*, 2008).

The vast majority of the literature correlates an accentuated loss of lamin B with age (Freund *et al.*, 2012; Chen *et al.*, 2015; Lukášová *et al.*, 2017). However, this is not consensual. Interestingly, some studies indicate that overexpression of lamin B1 in wild-type human fibroblasts is enough to induce senescence without the induction of DNA damage. Different studies showed that if lamin B1 level is altered, a nuclear shape alteration is observed (Barascu *et al.*, 2012b). Some studies in drosophila point to the evidence that an overexpression of lamin B1 leads to nuclear shape alterations (Padiath *et al.*, 2007; Taimen *et al.*, 2009; Barascu *et al.*, 2012). These nuclear shape alterations possibly result in a change in lamina organization, driving to senescence (Barascu *et al.*, 2012b). Cellular senescence is a hallmark of ageing (López-Otín *et al.*, 2013) and can be defined as the moment the cells stop cell division and growth permanently suffering chromatin and secretome alterations (Kuilman *et al.*, 2010). Other hallmarks that involve DNA damage, telomere shortening, and oxidative stress contribute to this senescence process (Collado *et al.*, 2007; Van Deursen, 2014). Furthermore, when mutations in lamin A and nesprins occur, emerin can be mislocated. In human aged-iPSCs, emerin was found

overexpressed although it was mislocated (Zhang *et al.*, 2007; Ho *et al.*, 2013; Petrini *et al.*, 2017). It seems clear that emerin might play a role in the ageing phenotype.


SUN1 is part of the LINC complex. Lamin A/C interacts with the LINC complex proteins mediating the interaction between the actin cytoskeleton and the nucleus that results in movement in the cell (Meinke *et al.*, 2011). SUN1 was found over-accumulated in human progeric laminopathies. Deleting SUN1 in *Lmna*-deficient mice proved to ameliorate cellular and organs disorders of premature ageing in mice and knocking-out SUN1 corrected the nuclear aberrancies and the senescence tendencies of HGPS skin fibroblasts. Ageing is a result of inappropriate location of accumulated proteins. Correcting the over-accumulated proteins like SUN1, should be considered when working on possible treatments (Chen *et al.*, 2012; Chi *et al.*, 2012).

Over the years, some studies referenced the possibility of INM proteins accumulate with age as in the HGPS. NPC is clustered, emerin is mislocated and overexpressed, LAP2 is diminished and SUN1 and nesprin-2 are increased. What leads some of these proteins to be mislocated and overaccumulated is still not understood, but some speculate that INM proteins might occupy non-random territories in the INM and perhaps migrate to certain locations in the INM to play different functions. Lamin A might be controlling their movement (Chi *et al.*, 2012).


The results presented and discussed in this chapter, places the nuclear envelope proteins in the spotlight in the ageing process. Most of them seem to accumulate with age. Most of what we know so far about the possible involvement of the nuclear envelope proteins in the ageing process comes from evidences observed in premature ageing disorders like progerias and other ageing models different from mice. The results presented here are particularly important because it evaluates the nuclear envelope proteins alterations in physiological ageing. In order to further confirm these results, more animals should be used, and more tissues should be analysed. Moreover, it would be worthy to investigate whether this also happens in humans and it would be interesting to look at the protein localization since various studies mention protein mislocalization. Therefore, in the next chapter of this thesis, we will address some of these issues.

## Supplementary Data


### A. Ponceau Liver 1




### B. Ponceau Liver 2




### C. Ponceau Kidney 1



### D. Ponceau Kidney 2



### E. Ponceau Kidney 3



**Figure SIII.1** – Ponceau S scans used to normalize the mice samples. Regarding the liver tissue, LAP1 and nesprin-2 were immunoblotted in membrane liver 1 (A) and emerin, lamin A/C and lamin B1 were immunoblotted in membrane liver 2 (B). Concerning the kidney tissue, emerin and SUN1 were immunoblotted in membrane kidney 1 (C), LAP1 and nesprin-2 were immunoblotted in membrane kidney 2 (D), and lamin A/C and lamin B1 were immunoblotted in membrane kidney 3 (E).

## **CHAPTER IV**


### **Characterization of the nuclear envelope protein alterations during ageing in human models**



## 4.1.Introduction

Physiological ageing is a multifaceted process that is impacted by genetic and environmental factors that lead to a decline in organismal fitness that can lead to numerous diseases, such as dementia, cancer, among others. Therefore, it urges to understand the underlying mechanisms of the ageing process (Ludovico *et al.*, 2012).

Human fibroblasts have been widely used as an excellent ageing model. They are long-lived cells that are impacted by various exogenous influences that can promote extrinsic ageing. It is believed that fibroblasts can provide an overview of the ageing process going on the organism. Fibroblasts aged *in vivo* and *in vitro* recapitulate most of the hallmarks of ageing postulated by López-Ótin *et al.* (2013). Aged fibroblasts *in vitro* present the following hallmarks of ageing: genomic instability, telomere attrition, epigenetic alterations, mitochondrial dysfunction, cellular senescence, altered intercellular communication, and loss of proteostasis (figure IV.1). The other hallmarks have either not been tested yet or are not observable. Not all of these hallmarks mentioned to be observed in fibroblasts aged *in vitro* are observable in fibroblasts normally aged *in vivo* (Tigges *et al.*, 2014).



**Figure IV.1** – Schematic representation of the ageing, confirmed *in vitro* by using aged fibroblasts as model.

## 4.2. Materials and Methods

### 4.2.1. Samples

Fibroblasts from biopsies from donors with a range of ages: 24 years old (AG09319, Coriell Institute), 25 years old AG09429, Coriell Institute), 46 years old (AG02258, Coriell Institute), 69 years old (3027122310VA, Axol Bioscience) and 80 years old (3027033110VA, Axol Bioscience) were obtained. All the donors were female, Caucasian, and apparently healthy (Figure IV.2).



**Figure IV.2** – Categorization of the fibroblasts samples across lifespan. Biopsies were performed on healthy Caucasian women with ages between 24 yo (years old) to 80 yo. Image adapted from (<http://www.longlonglife.org/en/transhumanism-longevity/aging/biological-causes-aging-lifespan-limitation/> ).

### 4.2.2. Cell Culture

Fibroblasts were cultured in DMEM (Dulbecco's Modified Eagle Medium, high glucose) (Gibco™) supplemented with 15% FBS (Fetal Bovine Serum, Origin South America) (Gibco™). All the washes performed were made using Dulbecco's 1X PBS (Phosphate buffered Saline), without  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  (BioConcept Ltd. Amimed®). Fibroblasts were subcultured whenever 85-90% confluence was reached. It was incubated 0.05% Trypsin-EDTA (Gibco™) for 5 min to separate the cells from the cell flask whenever subculture was needed. Cell cultures were maintained at 37°C under 5%  $\text{CO}_2$ .

Fibroblasts were maintained until passage number 10 (10-13) was reached. At passage 10, cells were harvested for western blotting and flow cytometry and prepared for immunocytochemistry analysis (see below).



### 4.2.3. Flow Cytometry

In order to evaluate the phenotype and robustness of our human ageing model, parameters like apoptosis and necrosis were assessed using flow cytometry.

#### 4.2.3.1. Annexin V/Propidium Iodide Staining

The two main mechanisms of cell death are apoptosis and necrosis. Apoptosis happens almost naturally in order to eliminate aberrant cells and keep the homeostasis. Necrosis results from environmental perturbations with uncontrolled release of inflammatory cellular components (Fink and Cookson, 2005). The flipping of phosphatidylserine of the plasma membrane from the inside surface to the outside surface is characteristic of an early apoptosis. Annexin V bind specifically in presence of  $\text{Ca}^{2+}$  ions to negatively charged phospholipids like phosphatidylserine (Reutelingsperger and van Heerde, 1997). APC conjugated annexin V can be used as a fluorescence probe to label apoptotic cells. Propidium iodide (PI) can also be used in conjunction with annexin-V-APC detection to detect necrotic cells. Viable cells (with proper membrane integrity) are not permeable to PI. Overall, this flow cytometric method allows us to distinguish between viable, apoptotic and necrotic cells.

Briefly, fibroblasts of all ages were trypsinized and centrifuged at 1000rpm for 3 min. The supernatant was removed, and  $0.5 \times 10^6$  cells were resuspended in 500  $\mu\text{l}$  of binding buffer (1x PBS with  $\text{Ca}^{2+}$ ). Another centrifugation at 1000rpm for 3min was performed. The supernatant was discarded, and the cells were resuspended in 70  $\mu\text{l}$  of binding buffer. It was added 4  $\mu\text{l}$  of annexin V-APC (31490016, ImmunoTools®) to the cell suspension and incubated for 15 min at RT in the dark. The cell suspension was immediately analysed in BD Accuri™ C6 (BD Biosciences®). Further, it was added 10  $\mu\text{l}$  of PI (10  $\mu\text{g}/\text{ml}$ ) to the cell suspension and the analysis was performed again. Proper negative and positive controls were also analysed. The negative control corresponds to cells without annexin V-APC or PI. The positive control was performed with cells that were incubated for 20 min at 50°C and properly stained with annexin V-APC and PI. The data were analysed using BD Accuri™ C6 Software (BD Biosciences®).

#### 4.2.4. Antibodies

The following primary antibodies were used: Trimethyl Histone H3, lamin A/C, lamin B1, emerin, LAP1, SUN1, Nup133, and Nup93 (see table IV.1 for further details).

**Table IV.1** – Primary antibodies used in order to detect the multiple proteins. WB, Western Blotting; ICC, immunocytochemistry.

| <b>Antibody</b>                                 | <b>Antibody company</b>       | <b>Antibody type</b> | <b>Target</b> | <b>Dilution</b>            |
|---|-------------------------------|----------------------|---------------|----------------------------|
| <b>Trimethyl Histone H3 (6F12-H4) sc-130356</b> | Santa Cruz Biotechnology      | Mouse, monoclonal    | H3K9me3       | WB: 1:500                  |
| <b>Lamin A/C Antibody (E-1) sc-376248</b>       | Santa Cruz Biotechnology      | Mouse, monoclonal    | Lamin A/C     | WB: 1:500<br>ICC: 1:250    |
| <b>Lamin B1 Antibody (H-90) sc-20682</b>        | Santa Cruz Biotechnology      | Rabbit, polyclonal   | Lamin B1      | ICC: 1:50                  |
| <b>Emerin Antibody (H-12) sc-25284</b>          | Santa Cruz Biotechnology      | Mouse, monoclonal    | Emerin        | WB 1:3000<br>ICC: 1:750    |
| <b>LAP1 Antibody</b>                            | Kindly provided by Dr. Dauer  | Rabbit, polyclonal   | LAP1          | WB: 1:20000<br>ICC: 1:4000 |
| <b>SUN1 antibody</b>                            | Kindly provided by Ya-Hui Chi | Rabbit, polyclonal   | SUN1          | WB: 1:2000<br>ICC: 1:500   |
| <b>Nup133 Antibody (E-6) sc-376763</b>          | Santa Cruz Biotechnology      | Mouse, monoclonal    | NUP133        | WB 1:500                   |
| <b>Nup93 Antibody (F-2) sc-374400</b>           | Santa Cruz Biotechnology      | Mouse, monoclonal    | NUP93         | WB 1:500                   |

The secondary antibodies used in Western Blotting (WB) were HRP-conjugated (GE Healthcare). The secondary antibodies used in immunocytochemistry were Invitrogen Alexa Fluor 488 dye from Thermo Fisher Scientific (mouse or rabbit, accordingly).

#### 4.2.5. Western Blotting

##### 4.2.5.1. Protein Extraction

Fibroblasts at PN10-PN13 were lysed using 1% SDS (300µl per confluent T75 cell flask), and the cell lysates boiled at 95°C for 10 min and then sonicated for 15 seconds.

#### **4.2.5.2.Preparation of Soluble and Insoluble Protein Fractions from Fibroblasts**

Cells were collected in 300µl of extraction buffer (50mM Tris-HCl pH 7.5, 1% Triton X-100 and Protease Inhibitors – Roche protease inhibitor cocktail and PMSF). The cells were incubated in the buffer for 20 min on ice. Then, protein was quantified as described in 3.2.3. section. Homogenates with 150µg and a final volume of 100µL were prepared and centrifuged at 20000xg for 15 min at 4°C. The supernatant was collected to another microtube and corresponds to the soluble fraction. To the supernatants was added 25µl of 4x Loading Buffer (LB) and then were boiled at 95°C for 10min. The pellet is considered the insoluble fraction and was solubilized in 125µl 1x LB and boiled at 95°C for 10 min. Total extracts with 75µg were also prepared.

#### **4.2.5.3. Protein quantification**

The *Thermo Scientific™ Pierce™ BCA Protein Assay Kit* was used to determine the protein concentration of the samples, following the same protocol mentioned in the previous chapter (see 3.2.3 section).

#### **4.2.5.4.Sample preparation by SDS-PAGE**

Prior to loading, samples with 75µg of total protein were prepared by the addition of ¼ volume of 4x LB, boiled at 95°C for 10 min and spun down.

#### **4.2.5.5.Gradient SDS Polyacrylamide Gel Electrophoresis**

Gradient SDS Polyacrylamide Gel Electrophoresis was performed as described in the previous chapter (see 3.2.4. section).

#### **4.2.5.6.Immunoblotting**

The transfer to membranes were performed as described in the materials and methods of 3.2.5 section. The overall protocol is very similar, apart from the fact that blocking time was 2-4h using 5% BSA in 1x TBS-T. The primary antibodies were incubated 2h at RT plus overnight at 4°C (both with gentle agitation). The primary

antibodies used are the ones described in 4.2.4 section (also see table IV.1 for further details).

#### **4.2.6. Immunocytochemistry**

Fibroblasts of the donors at passage 10 (PN10-PN12) were grown in 6-well plates (Corning) with coverslips. Then, cells were washed once with 1x PBS and 4% paraformaldehyde (PFA) was added for 20 min in a ventilated hood to each well of the plate (cell fixation). Cells were washed three times with 1x PBS. Then the cells were permeabilized using 0.2% Triton-X in 1x PBS for 10 min. Cells were then washed with 1x PBS. After that, cells were incubated with a blocking solution (3% BSA in 1x PBS) for 1h to avoid unspecific binding, and the primary antibodies were incubated for 2h at RT. Further, cells were washed with 1x PBS and the adequate fluorescence secondary antibodies were incubated for 1h in the dark. A final wash was performed with 1x PBS. Coverslips were mounted on a microscope slide with VECTASHIELD® Mounting Media with 4',6-diamidino-2-phenolyde (DAPI) (Vector Laboratories) and observed in an epifluorescence microscopy Zeiss AxioImager Z1 (Zeiss) motorized microscope equipped with a Plan-ApoCHROMAT 63x/1.40 oil objective lens. Photographs were taken with a digital AxioCam HR3 (Soft Imaging System).

### **4.3. Results**


#### **4.3.1. Characterization of our human ageing model**

Three well established ageing markers were used to validate our human cellular model. Essentially the histone 3 K9 trimethylation (H3K9me3) proteins levels were determined, as well as the percentage of apoptosis and necrosis using annexin V and PI staining.

##### **4.3.1.1. Histone H3 K9 trimethylation (H3K9me3) protein levels**

Fibroblasts of the donors at passage 10 (PN10-PN12) were subjected to SDS-PAGE and immunoblotting analysis and the H3K9me3 protein levels were evaluated (Figure IV.3). The results revealed a decrease of the H3K9me3 protein levels during ageing. In fact, when comparing the fibroblasts from the aged group (46, 69 and 80 yo)


to the young group (24 and 25 yo) it was possible to observe a decrease (0.66 fold change) in H3K9me3 (Figure IV.3).



**Figure IV.3.** – H3K9me3 protein levels evaluated by immunoblotting in human fibroblasts from five different patients analysed separated or grouped into 2 groups: young (24, and 25yo) and aged (46, 69 and 89yo). Ponceau S staining was used to access gel loading. The quantitative data are presented as mean  $\pm$  SEM of 2 independent experiments (A.U.=Arbitrary Units; YO = Years Old)

#### 4.3.1.2. Annexin V/Propidium Iodide staining using flow cytometry

Fibroblasts of the donors at passage 10 (PN10-PN12) were collected, stained with annexin V-APC and PI, followed by flow cytometry analysis. The results are presented in figure IV.4. The percentage of cells annexin V positive/PI negative was of about 0.1% at 24 yo; 1.4% at 46 yo; 0.8% at 69 yo, and 2.1% at 80 yo. The percentage of cells Annexin V positive/PI positive is 4.2% at 24 yo; 8.2% at 46yo; 4.3% at 69 yo, and 7.0% at 80 yo. Briefly, the results revealed a tendency to increase both Annexin V positive/PI negative and Annexin V positive/PI positive cells during ageing.



**Figure IV.4.** – Percentage of fibroblasts annexin V positive/PI negative stained (black bars) and annexin V positive/PI positive stained (grey bars) of four different donors (24, 46, 69 and 80 yo). Proper negative and positive controls were used. No statistical analysis was performed since only one experiment was performed (YO = Years Old; PI – Propidium Iodide).


#### 4.3.2. Evaluation of Nuclear Envelope Proteins during ageing

Quite a few studies have pointed protein sequestration at the nuclear envelope periphery as a potential regulatory mechanism of the ageing phenotype. Here, the protein levels of six relevant nuclear envelope proteins were evaluated across human lifespan using samples of human fibroblasts. Therefore, lysates of human fibroblasts from donors with 24, 25, 46, 69, and 80 years old at passage number 10 were analysed by SDS-PAGE and immunoblotting.

The proteins analysed were lamin A/C, emerin, LAP1, SUN1, NUP133, and NUP93. The results are presented in Figures IV5-7.


Regarding nuclear lamina protein levels, in Figure IV.5A., we observe a small tendency of lamin A/C protein levels to increase in the aged group (1.04 fold change) when comparing to the young one. In Figure IV.5B it is also possible to observe a drastic reduction of the soluble lamin A/C protein levels (0.05 fold change). The insoluble fraction seems to increase with age (1.20 fold change) when comparing the aged to the young group.

### Lamin A/C protein levels in human fibroblasts



**Figure IV.5** – Lamin A/C protein levels during ageing in human fibroblasts. A – Lamin A/C protein levels were evaluated in total extracts from donors with 24, 25, 46, 69, and 80 yo, analysed separated or grouped into two groups: young (24 and 25yo) and aged (46, 69, and 80yo). Ponceau S staining was used as loading control. The quantitative data are presented as mean  $\pm$  SEM of 3 independent experiments by comparison between the young and aged group by using t-student's test. B - Lamin A/C protein levels were evaluated in detergent soluble and insoluble fractions from a young donor (24 yo) and an aged donor (69 yo).  $\beta$ -tubulin was used to access the total protein loading. No statistical analysis was performed as the data results from only one experiment (A.U.=Arbitrary Units; YO = Years Old).


Regarding the inner nuclear membrane proteins, emerin protein levels do not seem to change significantly with age (0.95 fold change) (Figure IV.6A). On the other hand, as presented in Figure IV.6B, the SUN1 protein levels present a significant increase between the young and aged group (p-value 0.0112; 1.26 fold change). The LAP1 protein levels (Figure IV.6C) do not seem to change significantly between the aged and the young group (0.99 fold change). Nevertheless, LAP1 isoforms levels were analysed separately and in fact it was possible to observe a significant increase in LAP1B protein levels with age (p-value 0.0189; 1.52 fold change). LAP1C seems to present a small decrease (0.89 fold change) when comparing the aged group to the young group (Figure IV.6C).



**Figure IV.6** – The inner nuclear membrane proteins levels during ageing in human fibroblasts. Analysis of emerin (A), SUN1 (B), and LAP1 protein levels (C) by immunoblotting in human fibroblasts lysates from five different patients were analysed separated and grouped in 2 groups: young (24 and 25 yo) and aged (46, 69 and 80 yo). Ponceau S staining was used to assess gel loading. The quantitative data are presented as mean  $\pm$  SEM of 3 independent experiments by comparison of the young and aged group by using t-student’s test. Statistical significance symbol represents \*  $p < 0.05$ . (A.U.=Arbitrary Units; YO = Years Old)

Concerning, the nuclear pore complex proteins, as indicated in Figure IV.7A, the NUP133 protein levels decrease significantly when comparing the young to the aged group ( $p < 0.0001$ ; 0.65 fold change). NUP93 protein levels (Figure IV.7B) also decrease significantly when comparing the young to the aged group ( $p < 0.0001$ ; 0.63 fold change).






**Figure IV.7** – Nuclear Pore Complex Proteins levels during ageing in human fibroblasts. Analysis of NUP133 (A) and NUP93 protein levels (B) by immunoblotting in human fibroblasts lysates from five different patients analysed separated or grouped into 2 groups: young (24 and 25 yo) and aged (46, 69 and 80 yo). Ponceau S staining was used to access gel loading. The quantitative data is presented as mean  $\pm$  SEM of 3 independent experiments by comparison of the young and aged group by using t-student’s test. Statistical significance symbol represent \*\*\*\* $p < 0.0001$ . (A.U.=Arbitrary Units; YO = Years Old)

#### 4.2.3. Nuclear Envelope Proteins localization during ageing

In order to investigate the localization of the nuclear envelope proteins during ageing, immunocytochemistry was performed. Briefly, human fibroblasts from representative ages (24, 46, 69 and 80 years old) at passage number 10 were labelled with lamin A/C (Figure IV.8), lamin B1 (Figure IV.9), emerin (Figure IV.10), LAP1 (Figure IV.11), and SUN1 (Figure IV.12). Additionally, the lamin A/C protein localization of the 24 yo sample was also analysed at passage number 20 (Figure IV.13).


The overall signal of lamin A/C seems to be increasing with age, whether the nucleoplasmic signal is significantly depleted (reduced) with age (p-value 0.0072 comparing 24 to 46 yo; 0.0058 comparing 24 to 69 yo; and 0.0001 comparing 24 to 80 yo). Lamin A/C dependent-nuclear abnormalities are significantly increased with age (p-value  $< 0.0001$  comparing 24 to 46 yo; 0.0018 comparing 24 to 69 yo; and 0.0009 comparing 24 to 80yo) (Fig. IV.8).



**Figure IV.8.** – Subcellular distribution of lamin A/C in fibroblasts from donors' samples with 24 (A), 46 (B), 69 (C) and 80 yo (D). Lamin A/C was detected using an anti-mouse Alexa-488 conjugated secondary antibody (green). Nucleic acids were stained using DAPI (blue). Lamin A/C dependent-nuclear abnormalities and depletions of nucleoplasmic lamin A/C are also

observed in subnuclear structures (arrows). The quantitative data are presented as mean  $\pm$  SEM and was obtained by analysing at least 30 cells per condition from three independent experiments. Statistical significance symbols: \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$  for comparisons to control (24 yo) by using one-way ANOVA followed by the Dunnett's test. (A.U.=Arbitrary Units).


Remarkably, the depletion of lamin A/C at nucleoplasm is even more pronounced at PN20 fibroblasts when comparing with the observed at PN10 ( $p$ -value 0.0006). Moreover, lamin A/C dependent-nuclear abnormalities increases about 50% at PN20 ( $p$ -value 0.0002) when comparing with PN10 fibroblasts (Figure IV.9).



**Figure IV.9.** – Subcellular distribution of lamin A/C in fibroblasts from donors' samples with 24 yo at PN10 and at PN20. Lamin A/C was detected using an anti-mouse Alexa-488 conjugated secondary antibody (green). Nucleic acids were stained using DAPI (blue). Lamin A/C

abnormalities and depletions of nucleoplasmic lamin A/C are observed in subnuclear structures (arrows). The quantitative data are presented as mean  $\pm$  SEM and was obtained by analysing at least 30 cells per condition from three independent experiments. Statistical significance symbols: \*\*\*  $p < 0.001$  for comparisons to control (24YO PN10) by using t-student's test. (A.U.=Arbitrary Units; PN = Passage Number)


Subcellular localization of lamin B1 in human fibroblasts revealed, as expected, a localization at the inner surface of the nuclear envelope. Moreover, lamin B1 staining seems to decrease with age in human fibroblasts (Figure IV.10), although no fluorescence intensity quantification was performed.



**Figure IV.10.** – Subcellular distribution of Lamin B1 in fibroblasts from donors' samples with 24 (A), 46 (B), 69 (C) and 80 yo (D). Lamin B1 was detected using an anti-rabbit Alexa-488 conjugated secondary antibody (green). Nucleic acids were stained using DAPI (blue).

Regarding emerin distribution in human fibroblasts, it was detected in the nuclear envelope at all ages analysed (Figure IV.11). In addition, it was possible to observe the


presence of emerin nuclear speckles, which are significantly increased in the aged human fibroblasts (p-value <0.0001; 1.39 fold change) (Fig. IV.10).



**Figure IV.11** – Subcellular distribution of emerin in fibroblasts from donors' samples with 24 (A), 46 (B), 69 (C) and 80 yo (D). Emerin was detected using an anti-mouse Alexa-488 conjugated

secondary antibody (green). Nucleic acids were stained using DAPI (blue). Emerin nuclear speckles are observed (arrows). The quantitative data are presented as mean  $\pm$  SEM and was obtained by analysing at least 30 cells per condition from three independent experiments. Statistical significance symbols: \*\*\*\*  $p < 0.0001$  for comparisons of the young group (24 yo) to the aged group (46, 69 and 80 yo) by using t-student's test (A.U.=Arbitrary Units).


SUN1 also reveals a nuclear envelope staining in human fibroblasts at all ages (Figure IV.12). By performing a qualitative analysis of the images acquired it was possible to observe an increase in the SUN1 protein staining with age (Figure IV.12) which in fact, are in accordance with the immunoblotting data.



**Figure IV.12** – Subcellular distribution of SUN1 in fibroblasts from donors’ samples with 24 (A), 69 (B) and 80 yo (C). SUN1 was detected using an anti-rabbit Alexa-488 conjugated secondary antibody (green). Nucleic acids were stained using DAPI (blue).

Lastly, LAP1 subcellular localization was also investigated in human fibroblasts, and a nuclear envelope staining is observed (Figure IV.13). Noticeably, it seems that LAP1 is being recruited to the invaginations and abnormalities that occur during ageing (Figure IV.13 arrows) and further studies should be performed in order to pursue this feature.





**Figure IV.13** – Subcellular distribution of LAP1 in fibroblasts from donors' samples with 24 (A), 46 (B), 69 (C) and 80yo (D). LAP1 was detected using an anti-rabbit Alexa-488 conjugated

secondary antibody (green). Nucleic acids were stained using DAPI (blue). Arrows point to LAPI staining in nuclear abnormalities.

#### **4.4. Discussion**

The underlying mechanisms of ageing have been studied in diverse cellular and animal models. Fibroblasts cultures derived from patients and healthy donors have been employed in studies from diverse research areas. Moreover, fibroblasts have been used to study ageing at a cellular level. Nevertheless, it is important to highlight that any results obtained in any model should be interpreted with caution when trying to translate to human ageing (Schneider, 1979; Ludovico *et al.*, 2012). Selecting samples of a normal human population to investigate ageing is a complex mission. Trying to find aged individuals without serious conditions and, whether we should even choose to do so, can be tricky. It is almost impossible to distinguish between the normal alterations from the pathological ones that come with ageing. Therefore, there is no ideal population to study ageing (Schneider, 1979).


Over the years, studies have pointed to the nuclear periphery as a possible intervenient in the ageing phenotype. In fact, lamins, nesprin-2, emerin and some nucleopore complex proteins have already been described to be altered mainly in premature ageing disorders (Scaffidi and Misteli, 2006, 2008; Barascu *et al.*, 2012; Lattanzi *et al.*, 2014; Lukášová *et al.*, 2017; Petrini *et al.*, 2017; Serebryanny and Misteli, 2018).

In the work here presented, we started by performing a characterization of our ageing model. Our results evidenced a decrease of the H3K9me3 protein levels (Figure IV.3). In fact, levels of H3K9me3 has been well described as decreased with age in the literature (Villeponteau, 1997; Tsurumi and Li, 2012; Zhang *et al.*, 2015; Maleszewska *et al.*, 2016). H3K9me3 is able to recruit heterochromatin protein-1 (HP1), which is thought to be involved in heterochromatin formation. The model of heterochromatin loss for cell ageing is based on the assumption that over the years the heterochromatin domains are shortened. This shortening affects the gene expression at the periphery of the heterochromatin domains since the transcription factors become more accessible. This could lead to many small but important alterations in gene expression patterns with ageing (Villeponteau, 1997). Moreover, we analysed fibroblasts for the Annexin V/Propidium Iodide staining by flow cytometry. Annexin V is capable of distinguish early apoptotic cells from the viable ones. Propidium iodide only stains necrotic cells. Viable cells should

not be stained by any of these two compounds. Our results suggest that early apoptotic cells and necrotic cells are increasing with age (Figure IV.4). Whether apoptosis is increased with ageing is still debatable in the literature. Nevertheless, studies point to a higher level of apoptosis in diverse aged cell types and organs. In these cases, apoptosis is seen as a protective tool of the organism in order to fight the increase and spread of abnormal cells. Consequently, an increase of the apoptosis rate can be seen as marker of an overall decline in fitness of the cell, organ and organism (Muradian and Schachtschabel, 2001; Lu *et al.*, 2012). Higher rates of apoptosis and necrosis have also been reported in older donors fibroblasts samples compared with the young donors fibroblast samples (Dekker *et al.*, 2009). Altogether, our results strongly suggest that our human ageing model is adequate and accurate.

Of notice, the 46 yo fibroblasts sample is quite different from the rest ages, presenting a higher apoptotic and necrotic rate than the older samples, and in general comprises a different phenotype both in immunoblotting and immunocytochemistry. This fact might be explained by environmental influences and/or any other underlying problem not reported. This case enlightens the urge of increasing the number of samples in order to further characterize the observed alterations with more confidence.

A short recapitulation of the main results obtained for the protein levels and localization of the nuclear envelope proteins evaluated in this work are presented in Figure IV.14.



**Figure IV.14** – Schematic summary of the main results obtained by immunoblotting and immunocytochemistry analysis of lamin A/C, lamin B1, emerin, SUN1, LAP1, NUP133, and NUP93 in human fibroblasts.

Our results reveal a small tendency of lamin A/C to accumulate with age both *in vivo* and *in vitro* (evaluated by increasing passage number; Figures IV.8 and Figure IV.9). Moreover, we could observe a number of lamin A/C-dependent nuclear abnormalities which increase with age. There is also a depletion of the nucleoplasmic lamin A/C, corroborating the strong diminution of the lamin A/C protein levels observed in the aged fibroblasts soluble fraction. Increased levels of wild-type lamin A have been previously reported to be associated with a shorter lifespan and nuclear aberrancies that result in apoptosis and senescence, common features of the HGPS phenotype. Over-expression of the ZMPSTE24, the metalloproteinase in charge of removing the farnesylated carboxyl terminal region of lamin A, rescues the normal phenotype (Candelario *et al.*, 2008).

Furthermore, high *LMNA* mRNA levels are expressed in aged iPSCs (induced pluripotent stem cells), showing a thicker nuclear lamina and nuclear abnormalities like blebs, doughnut-shaped nuclei and folded nuclear envelope (Petrini *et al.*, 2017). Scaffidi and Misteli. (2006), describe a depletion on the nucleoplasmic lamin A/C and consequent accumulation at the nuclear rim, as well as irregularities of the NE in wild-type aged fibroblasts, which is in accordance with our results. The nucleoplasmic lamin A/C has been correlated with functions like chromatin organization and gene expression. Therefore, the depletion of nucleoplasmic lamin A/C can exacerbate the ageing phenotype (Serebryanny and Misteli, 2018). An accumulation of mutant or normal lamin A can impact mitosis, producing DNA damage, premature senescence and an overall problematic nuclear architecture that can be attributed to the ageing process.

Moreover, immunolocalization studies suggest that lamin B1 is decreasing with age in human fibroblasts which is in line with the vast majority of the literature that correlate a loss of lamin B1 with increased cellular senescence. The decrease of lamin B1 have been reported in primary human and murine cell strains, WI-38 cells, E145K cells, HGPS patient derived fibroblasts, as well as fibroblasts and keratinocytes undergoing replicative senescence (Taimen *et al.*, 2009; Shimi *et al.*, 2011; Freund *et al.*, 2012; Dreesen *et al.*, 2013a, 2013b).

Concerning emerin, the protein levels do not seem to increase with age in human fibroblasts. However, a significant increase of emerin nuclear speckles is noticed when comparing the young group to the aged one. Emerin has been reported to be increased and mislocated in aged-iPSCs when mutations in nesprins and lamin A occur (Zhang *et al.*, 2007; Ho *et al.*, 2013; Petrini *et al.*, 2017). Nuclear emerin with a granular brighter speckles appearance is reported to be seen in fibroblasts, differently to what happens in sections of skin or cardiac muscle where emerin is generally localized at the nuclear periphery (Morris *et al.*, 2002). Whether or not this is important to the ageing process is still not clear and should be explored in the future.

SUN1 protein levels are significantly increased in human fibroblasts and it also seems to be increasing with age in our immunocytochemistry analysis, although no fluorescence intensity quantification was performed. As previously stated, SUN1 was found to be increased in progerias (Chen *et al.*, 2012). In studies where SUN1 was deleted in *Lmna*-deficient mice, the overall cellular and organs premature disorders ameliorated, correcting nuclear aberrancies and diminishing their course of senescence in HGPS skin

fibroblasts (Chen *et al.*, 2012). Taking all into account, there should be a crescent interest in targeting SUN1 to slow down the ageing phenotype.

Our results suggest that LAP1 protein levels do not change with age. However, LAP1B isoform was found to be significantly increased with age in human fibroblasts. Furthermore, LAP1 staining seems to be more intense in nuclear abnormalities sites. LAP1 is still poorly studied and not much is known about its precise physiological function. However, it is known that LAP1 binds to lamins and chromatin contributing to the maintenance of the nuclear architecture. Since lamin A/C-dependent abnormalities have been observed, and LAP1 binds to lamins, it is not surprising that LAP1 might be also localized in the abnormality's sites. Studies report that rat LAP1A and LAP1B bind directly to lamin A/C *in vitro* but not rat LAP1C (Foisner and Gerace, 1993). Human LAP1C is similar to rat LAP1C (Santos *et al.*, 2014), and in fact, both LAP1C are easily solubilized from lamina in a Triton X-100 low salt concentrations buffer (Foisner and Gerace, 1993; Santos *et al.*, 2014). In our work, total lamin A/C seems to increase with age and so does LAP1B. Therefore, we speculate that there might exist a functional relationship between lamin A/C and LAP1B during ageing, impacting nuclear architecture.

Regarding the nuclear pore complex protein, our results show that both NUP133 and NUP93 protein levels decreases significantly with age. NUP133 is part of membrane-apposed coat NUPs. The membrane-apposed coat NUPs form a Nup107–160 complex, which comprehends the largest NPC subunit in size and complexity, which is necessary in the first stages of NPC assembly (Nofrini *et al.*, 2016). Specific NPC nuclear transport events impacts ageing (Lord *et al.*, 2015). A defective NPC will alter the balance and localization of the nuclear envelope proteins. The adapter NUPs form the NUP93 complex, the second largest NPC structural unit that play a key role in delimiting the NE sub-compartments, creating a blockade that avoids the movement of membrane proteins from ONM to the INM (Solmaz *et al.*, 2011). The loss of NE integrity leads to a gradual decrease in nucleocytoplasmic transport, to selective loss and degradation of NE components that culminates in rupture inducing aberrant molecules transport between the nucleus and cytoplasm (Robijns *et al.*, 2018). In fact, previous studies indicated that the long-lived NPC structure deteriorates with time, thereby increasing the nuclear permeability across lifespan. In particular, some studies have observed that Nup93 were lost in old and permeable nuclei (D'Angelo *et al.*, 2009). Interestingly, Nup93 has previously been functionally associated with NPC permeability barrier (Galy *et al.*, 2003)

which explains the correlation between the age-related loss of this nucleoporin and the increased nuclear permeability observed (D'Angelo et al., 2009).

Noticeably, some literature mention that some of the differences in the protein levels and/or mislocalization during ageing are only observed in extensively passaged fibroblasts (Cao et al., 2011), which is not the case of our fibroblasts that were at passage number 10. Therefore, we hypothesised that at passage number 20 (or later), a number of other or more prominent changes might be observed.

To sum up, the work here presented puts the nuclear envelope proteins in the spotlight in the ageing process. Some of our results are pioneering in physiological ageing, since most of the studies available out there are based on premature ageing models, and can be the foundation for future studies regarding the nuclear envelope dysfunction and its contribution to the ageing process






## **CHAPTER V**

### **General discussion and concluding remarks**



Ageing is a multi-factorial process that urge to be studied profoundly if we ever want to unpuzzle this complex process. The nuclear periphery has caught the attention of some researchers in the last few years, especially due to the fact of some progeroid/premature ageing syndromes being due to defects in nuclear envelope proteins. Remarkably, the PPI network analysis of the age-associated genes available in the public databases places nuclear proteins and their associated functions in the spotlight of the ageing process (Chapter 2). Moreover, our results using the mice as ageing model suggest that lamin A/C, lamin B1, emerin, LAP1, nesprin-2, and SUN1 protein levels increases during ageing (chapter 3). In human fibroblasts from healthy individuals passage-matched, lamin A/C, LA1PB and SUN1 protein levels seems to increase with age, whereas lamin B1, NUP133 and NUP93 protein levels seems decrease with age. In addition, concomitantly with increasing levels of lamin A/C, the significant increase of lamin A/C dependent abnormalities and depletion of nucleoplasmic lamin A/C were observed with age (chapter 4). A short recapitulation and comparison of the main results obtained from both ageing models (mice and humans) is presented in Figure V.1.



**Figure V.1** – Schematic summary of the main results obtained with both ageing models studied in this work (mouse model left, and human fibroblast model right). ↑ indicates the increase and ↓ indicates decrease of each protein level. The subcellular localization of some proteins are also indicated.

Comparing the results obtained from the two models, it becomes clear that lamin A/C, emerin, LAP1 and SUN1 seem to be altered during the ageing process. Lamin A/C seems to increase with age in both models. Concomitantly, lamin A/C-dependent nuclear abnormalities increase with age and the nucleoplasmic fraction (soluble fraction) of lamin A/C decreases with age. These results are in agreement with previous studies that have shown an increase of lamin A with ageing (Candelario *et al.*, 2008) and an increase of depleted nucleoplasmic lamin A/C in human fibroblasts (Scaffidi and Misteli, 2006). In

our hands, emerin is mislocalized in human aged fibroblasts and seems to be increasing with age in mice. In a previous study performed in iPSCs aged *in vitro*, emerin seems to be increasing and it is mislocalized around the nuclei (Petrini *et al.*, 2017). We do not observe this kind of mislocalization, but human fibroblasts had previously been reported to have a different emerin localization (Morris *et al.*, 2002). LAP1 increases with ageing in mice and LAP1B increases in human aged fibroblasts. This is the first time to our knowledge that any efforts were made to characterize LAP1 alterations during ageing. SUN1 is also increased in both of our ageing models which is in line with what we already knew from mice studies (deletion of SUN1 in *Lmna*-deficient mice ameliorates their nuclear aberrancies and improves their overall fitness) and from HGPS fibroblasts (SUN1 is increased in progerias) (Chen *et al.*, 2012; Chi *et al.*, 2012). NUP133 is decreased with ageing in human fibroblasts. No previous studies related NUP133 with ageing, but other nucleoporins had already been linked with a leaky nuclear pore complex during the ageing process (D'Angelo *et al.*, 2009) as it is the case of NUP93 which is also decreased with age in our human fibroblasts. Nesprin-2 is increased with age in our mice model. This result is corroborated by the study performed in aged human iPSCs that reported an increase of nesprin-2 protein levels with age (Petrini *et al.*, 2017).

Regarding the lamin B1, the results in mice depicted an increase of protein levels with age at 18 months and then decrease with 24 months, whereas in human fibroblasts cellular model it seems to decrease. Barascu *et al.*, (2012) reported that in premature ageing syndrome Ataxia Telangiectasia (A-T), higher levels of ROS synthesis and defective nuclear shape results in higher levels of lamin B1. Overexpression of lamin B1 results in nuclear architecture defects leading to a state of premature senescence in normal cells. The higher expression of lamin B1 seems to be due to ROS synthesis. Pro-oxidant stimulation in normal cells enhanced lamin B1 protein levels. Although, anti-oxidant treatment of A-T cells led to decreased lamin B1 protein levels. Therefore, it seems that ROS-dependent higher lamin B1 expression is connected with p38 MAP kinase that is associated with senescence, pointing to a new ATM-independent stress-sensing that results in a senescence. On the other hand, other studies performed in fibroblasts derived from an atypical progeria patient that quickly became senescence show a strong loss of lamin B1 protein levels (Taimen *et al.*, 2009). Moreover, other work reports a diminution of lamin B1 protein levels in either replicative or oncogene-induced senescence fibroblasts (Shimi and Goldman, 2014). Silencing lamin B1 with siRNA resulted in lower proliferation rates and enhanced cellular senescence. The silencing of lamin B1 was

linked with higher p53 expression and cells entered in a state of senescence dependent of the activity of p53 and Rb. Silencing lamin B1 was linked with a p53-dependent decrease in the mitochondrial ROS synthesis (Shimi and Goldman, 2014). This might seem conflicting results and conclusions, but there is a possibility of the both results being plausible. Lamin B1 seems to be a signalling hub and its response could be different according to what senescence pathway is activated (ROS-induced premature senescence, Replicative-induced senescence and Oncogene-induced senescence) (Hutchison, 2012).

The integrative results of this thesis are particularly important since are one of the only results available out there performed that explores the nuclear envelope proteins in physiological ageing. Nevertheless, more samples should be used.

To sum up, the nuclear envelope proteins are definitely affected by the ageing phenotype and further studies should be performed in order to uncover their role in this complex process. Perhaps in the future, the knowledge acquired about the nuclear envelope proteins role in the ageing process can be put into use to design therapeutics targeting the nuclear dysfunction.

Therefore, we propose the following future perspectives:

- Complement this study by increasing the number of mice samples and human fibroblasts;
- Evaluate the mRNA levels of the NE proteins during ageing, in mice tissues and human fibroblast samples;
- Characterize the nuclear envelope alterations reported in this study in extensively passaged fibroblasts.



## **Bibliographic references**





- Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., and Walter, P. (2008). *Molecular Biology of Cell* (Garland Science, Taylor & Francis Group, LLC.).
- Ashburner, M., Ball, C.A., Blake, J.A., Botstein, D., Butler, H., Cherry, J.M., Davis, A.P., Dolinski, K., Dwight, S.S., Eppig, J.T., et al. (2000). Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. *Nat. Genet.* *25*, 25–29.
- Aunan, J.R., Watson, M.M., Hagland, H.R., and Søreide, K. (2016). Molecular and biological hallmarks of ageing. *BJS* *103*, e29–e46.
- Balistreri, C.R., Madonna, R., Melino, G., and Caruso, C. (2016). The emerging role of Notch pathway in ageing: Focus on the related mechanisms in age-related diseases. *Ageing Res. Rev.* *29*, 50–65.
- Barascu, A., Chalony, C. Le, Genet, D., Imam, N., Lopez, B., and Bertrand, P. (2012a). Oxidative stress induces an ATM-independent senescence pathway through p38 MAPK-mediated lamin B1 accumulation. *31*, 1080–1094.
- Barascu, A., Le Chalony, C., Pennarun, G., Genet, D., Zaarour, N., and Bertrand, P. (2012b). Oxidative stress alters nuclear shape through lamins dysregulation. *Nucleus* *3*, 411–417.
- Barzilai, N., and Ferrucci, L. (2012). Insulin resistance and aging: A cause or a protective response? *Journals Gerontol. - Ser. A Biol. Sci. Med. Sci.* *67*, 1329–1331.
- Benayoun, B.A., Pollina, E.A., and Brunet, A. (2015). Epigenetic regulation of ageing: Linking environmental inputs to genomic stability. *Nat. Rev. Mol. Cell Biol.*
- Bengtsson, L., and Wilson, K.L. (2004). Multiple and surprising new functions for emerin, a nuclear membrane protein. *Curr. Opin. Cell Biol.* *16*, 73–79.
- Berk, J.M., Tifft, K.E., and Wilson, K.L. (2013). The nuclear envelope LEM-domain protein emerin. *Nucleus* *4*, 298–314.
- Blackburn, E.H., Epel, E.S., and Lin, J. (2015). Human telomere biology: A contributory and interactive factor in aging, disease risks, and protection. *Science (80-. )*. *350*, 1193–1198.
- Blagosklonny, M. V (2008). Aging: ROS or TOR. *Cell Cycle* *7*, 3344–3354.
- Borggreffe, T., Lauth, M., Zwijsen, A., Huylebroeck, D., Oswald, F., and Giaimo, B.D. (2016). The Notch intracellular domain integrates signals from Wnt, Hedgehog, TGF $\beta$ /BMP and hypoxia pathways. *Biochim. Biophys. Acta - Mol. Cell Res.* *1863*, 303–313.
- Brady, G.F., Kwan, R., Bragazzi Cunha, G., Elenbaas, J.S., and Omary, M.B. (2018). Lamins and Lamin-Associated Proteins in Gastrointestinal Health and Disease. *Gastroenterology* *154*, 1–18.
- Bray, S.J. (2016). Notch signalling in context. *Nat. Rev. Mol. Cell Biol.* *17*, 722–735.
- Brosh, R.M., and Bohr, V.A. (2007). Human premature aging, DNA repair and RecQ helicases. *Nucleic Acids Res.*
- Brown, R.S.H., Zhao, C., Chase, A.R., Wang, J., and Schlieker, C. (2014). The mechanism of Torsin ATPase activation. *Proc. Natl. Acad. Sci. U. S. A.* *111*, E4822–E4831.

- Burke, B., and Ellenberg, J. (2002). Remodelling the walls of the nucleus. *Nat. Rev. Mol. Cell Biol.* 3, 487–497.
- Burtner, C.R., and Kennedy, B.K. (2010). Progeria syndromes and ageing: What is the connection? *Nat. Rev. Mol. Cell Biol.* 11, 567–578.
- Campisi, J., and Vijg, J. (2009). Does damage to DNA and other macromolecules play a role in aging? If so, how? In *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, p.
- Candelario, J., Sudhakar, S., Navarro, S., Reddy, S., and Comai, L. (2008). Perturbation of wild-type lamin A metabolism results in a progeroid phenotype. *Aging Cell* 7, 355–367.
- Cao, K., Blair, C.D., Faddah, D.A., Kieckhafer, J.E., Olive, M., Erdos, M.R., Nabel, E.G., and Collins, F.S. (2011). Progerin and telomere dysfunction collaborate to trigger cellular senescence in normal human fibroblasts. *J. Clin. Invest.* 121, 2833–2844.
- Caprette, D.R. (2012). Introduction to SDS-PAGE. <https://www.ruf.rice.edu/~bioslabs/studies/sds-page/gellab2.html>
- Capri, M., Yani, S.L., Chattat, R., Fortuna, D., Bucci, L., Lanzarini, C., Morsiani, C., Catena, F., Ansaloni, L., Adversi, M., et al. (2014). Pre-operative, high-IL-6 blood level is a risk factor of post-operative delirium onset in old patients. *Front. Endocrinol. (Lausanne)*. 5, 6.
- Carlquist, J.F., Knight, S., Cawthon, R.M., Le, V.T., Jared Bunch, T., Horne, B.D., Rollo, J.S., Huntinghouse, J.A., Brent Muhlestein, J., and Anderson, J.L. (2016). Shortened telomere length is associated with paroxysmal atrial fibrillation among cardiovascular patients enrolled in the Intermountain Heart Collaborative Study. *Hear. Rhythm* 13, 21–27.
- Carrero, D., Soria-Valles, C., and López-Otín, C. (2016). Hallmarks of progeroid syndromes: lessons from mice and reprogrammed cells. *Dis. Model. & Mech.* 9, 719 LP-735.
- Cartwright, S., and Karakesisoglou, I. (2014). Nesprins in health and disease. *Semin. Cell Dev. Biol.* 29, 169–179.
- Chautard, E., Thierry-Mieg, N., and Ricard-Blum, S. (2010). Interaction networks as a tool to investigate the mechanisms of aging. *Biogerontology* 11, 463–473.
- Chen, C.-Y., Chi, Y.-H., Mutalif, R.A., Starost, M.F., Myers, T.G., Anderson, S.A., Stewart, C.L., and Jeang, K.-T. (2012). Accumulation of the Inner Nuclear Envelope Protein Sun1 Is Pathogenic in Progeric and Dystrophic Laminopathies. *Cell* 149, 565–577.
- Chen, H., Zheng, X., and Zheng, Y. (2015). Lamin-B in systemic inflammation, tissue homeostasis, and aging. *Nucleus* 6, 183–186.
- Chen, J.H., Hales, C.N., and Ozanne, S.E. (2007). DNA damage, cellular senescence and organismal ageing: Causal or correlative? *Nucleic Acids Res.*
- Chi, Y., Chen, C., and Jeang, K.-T. (2012). Reversal of laminopathies: the curious case of SUN1. *Nucleus* 3, 418–421.
- Choe, K.N., and Moldovan, G.L. (2017). Forging Ahead through Darkness: PCNA, Still the

Principal Conductor at the Replication Fork. *Mol. Cell* 65, 380–392.

Chojnowski, A., Ong, P.F., Wong, E.S.M., Lim, J.S.Y., Mutalif, R.A., Navasankari, R., Dutta, B., Yang, H., Liow, Y.Y., Sze, S.K., et al. (2015). Progerin reduces LAP2 $\alpha$ -telomere association in hutchinson-gilford progeria. *Elife* 4, 1–21.

Clark, A.R., Lubsen, N.H., and Slingsby, C. (2012). SHSP in the eye lens: Crystallin mutations, cataract and proteostasis. *Int. J. Biochem. Cell Biol.* 44, 1687–1697.

Cobb, A.M., Murray, T. V., Warren, D.T., Liu, Y., and Shanahan, C.M. (2016). Disruption of PCNA-lamins A/C interactions by prelamin A induces DNA replication fork stalling. *Nucleus* 7, 498–511.

Collado, M., Blasco, M.A., and Serrano, M. (2007). Cellular Senescence in Cancer and Aging. *Cell* 130, 223–233.

Conneely, K.N., Capell, B.C., Erdos, M.R., Sebastiani, P., Solovieff, N., Swift, A.J., Baldwin, C.T., Budagov, T., Barzilai, N., Atzmon, G., et al. (2012). Human longevity and common variations in the LMNA gene: A meta-analysis. *Aging Cell* 11, 475–481.

D'Angelo, M. a, and Hetzer, M.W. (2006). The role of the nuclear envelope in cellular organization. *Cell. Mol. Life Sci.* 63, 316–332.

D'Angelo, M., Raices, M., Panowski, S., and Hetzer, M. (2009). Age dependent deterioration of nuclear pore complexes causes a loss of nuclear integrity in post mitotic cells. *Cell* 136, 284–295.

D'Aquila, P.D., Rose, G., Bellizzi, D., Passarino, G., D'Aquila, P., Rose, G., Bellizzi, D., and Passarino, G. (2013). Epigenetics and aging. *Maturitas* 74, 130–136.

Dechat, T., Pflieger, K., Sengupta, K., Shimi, T., Shumaker, D.K., Solimando, L., and Goldman, R.D. (2008). Nuclear Lamins, Major Factors in the Structural Organization and Function of the Nucleus and Chromatin. *Genes Dev* 22, 832–853.

DeGrasse, J.A., DuBois, K.N., Devos, D., Siegel, T.N., Sali, A., Field, M.C., Rout, M.P., and Chait, B.T. (2009). Evidence for a Shared Nuclear Pore Complex Architecture That Is Conserved from the Last Common Eukaryotic Ancestor. *Mol. Cell. Proteomics* 8, 2119–2130.

Dekker, P., Maier, A.B., Van Heemst, D., De Koning-Treurniet, C., Blom, J., Dirks, R.W., Tanke, H.J., and Westendorp, R.G.J. (2009). Stress-induced responses of human skin fibroblasts in vitro reflect human longevity. *Aging Cell* 8, 595–603.

Delbarre, E., Tramier, M., Coppey-Moisan, M., Gaillard, C., Courvalin, J.C., and Buendia, B. (2006). The truncated prelamin A in Hutchinson-Gilford progeria syndrome alters segregation of A-type and B-type lamin homopolymers. *Hum. Mol. Genet.* 15, 1113–1122.

Van Deursen, J.M. (2014). The role of senescent cells in ageing. *Nature* 509, 439–446.

Dittmer, T.A., and Misteli, T. (2011). The lamin protein family. *Genome Biol.* 12, 222.

Doncheva, N.T., Assenov, Y., Domingues, F.S., and Albrecht, M. (2012). Topological analysis and interactive visualization of biological networks and protein structures. *Nat. Protoc.* 7, 670.

Dreesen, O., and Stewart, C.L. (2011). Accelerated aging syndromes, are they relevant to normal

human aging? *Aging* (Albany, NY). *3*, 889–895.

Dreesen, O., Chojnowski, A., Ong, P.F., Zhao, T.Y., Common, J.E., Lunny, D., Lane, E.B., Lee, S.J., Vardy, L.A., Stewart, C.L., et al. (2013a). Lamin B1 fluctuations have differential effects on cellular proliferation and senescence. *J. Cell Biol.* *200*, 605–617.

Dreesen, O., Ong, P.F., Chojnowski, A., and Colman, A. (2013b). The contrasting roles of lamin B1 in cellular aging and human disease. *Nucleus* *4*, 283–290.

Durieux, J., Wolff, S., and Dillin, A. (2011). The cell-non-autonomous nature of electron transport chain-mediated longevity. *Cell* *144*, 79–91.

Eckersley-Maslin, M.A., Bergmann, J.H., Lazar, Z., and Spector, D.L. (2013). Lamin A/C is expressed in pluripotent mouse embryonic stem cells. *Nucleus* *4*, 53–60.

Eisenstein, M. (2014). Remove, reuse, recycle. *Nature* *514*, 5–7.

Fairley, E.A., Kendrick-Jones, J., and Ellis, J.A. (1999). The Emery-Dreifuss muscular dystrophy phenotype arises from aberrant targeting and binding of emerin at the inner nuclear membrane. *J. Cell Sci.* *112*, 2571 LP-2582.

Fernández-Álvarez, A., and Cooper, J.P. (2017). Chromosomes Orchestrate Their Own Liberation: Nuclear Envelope Disassembly. *Trends Cell Biol.* *27*, 255–265.

Fink, S.L., and Cookson, B.T. (2005). Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. *Infect. Immun.* *73*, 1907–1916.

Foisner, R. (2003). Cell Cycle Dynamics of the Nuclear Envelope. *Sci. World J.* *3*, 1–20.

Foisner, R., and Gerace, L. (1993). Integral membrane proteins of the nuclear envelope interact with lamins and chromosomes, and binding is modulated by mitotic phosphorylation. *Cell* *73*, 1267–1279.

Franceschi, C., and Campisi, J. (2014). Chronic inflammation (Inflammaging) and its potential contribution to age-associated diseases. *Journals Gerontol. - Ser. A Biol. Sci. Med. Sci.* *69*, S4–S9.

Freund, A., Laberge, R.-M., Demaria, M., and Campisi, J. (2012). Lamin B1 loss is a senescence-associated biomarker. *Mol. Biol. Cell* *23*, 2066–2075.

Friedberg, E.C. (2003). DNA damage and repair. *Nature* *421*, 436.

Fu, X., Liang, C., Li, F., Wang, L., Wu, X., Lu, A., Xiao, G., and Zhang, G. (2018). The Rules and Functions of Nucleocytoplasmic Shuttling Proteins. *Int. J. Mol. Sci.* *19*, 1445.

Galy, V., Mattaj, I.W., and Askjaer, P. (2003). *Caenorhabditis elegans* Nucleoporins Nup93 and Nup205 Determine the Limit of Nuclear Pore Complex Size Exclusion In Vivo. *Mol. Biol. Cell* *14*, 5104–5115.

Gama-Carvalho, M., and Carmo-Fonseca, M. (2001). The rules and roles of nucleocytoplasmic shuttling proteins. *FEBS Lett.* *498*, 157–163.

Gems, D., and Partridge, L. (2013). Genetics of Longevity in Model Organisms: Debates and Paradigm Shifts. *Annu. Rev. Physiol.* *75*, 621–644.

- Gesson, K., Vidak, S., and Foisner, R. (2014). Lamina-associated polypeptide (LAP)2 $\alpha$  and nucleoplasmic lamins in adult stem cell regulation and disease(). *Semin. Cell Dev. Biol.* 29, 116–124.
- Ghosh, S., Liu, B., and Zhou, Z. (2013). Resveratrol activates SIRT1 in a Lamin A-dependent manner. *Cell Cycle* 12, 872–876.
- Glick, D., Barth, S., and Macleod, K.F. (2010). Autophagy: cellular and molecular mechanisms. *J. Pathol.* 221, 3–12.
- González-Aguilera, C., Palladino, F., and Askjaer, P. (2014). *C. elegans* epigenetic regulation in development and aging. *Brief. Funct. Genomics* 13, 223–234.
- Gonzalo, S. (2014). DNA damage and lamins. *Adv. Exp. Med. Biol.* 773, 377–399.
- Gruenbaum, Y., and Medalia, O. (2015). Lamins: The structure and protein complexes. *Curr. Opin. Cell Biol.* 32, 7–12.
- Harman, D. (2009). Origin and evolution of the free radical theory of aging: A brief personal history, 1954-2009. *Biogerontology* 10, 773–781.
- Harries, L.W., Hernandez, D., Henley, W., Wood, A.R., Holly, A.C., Bradley-Smith, R.M., Yaghootkar, H., Dutta, A., Murray, A., Frayling, T.M., et al. (2011). Human aging is characterized by focused changes in gene expression and deregulation of alternative splicing. *Aging Cell*.
- van Heemst, D., den Reijer, P.M., and Westendorp, R.G.J. (2007). Ageing or cancer: A review: On the role of caretakers and gatekeepers. *Eur. J. Cancer* 43, 2144–2152.
- Hekimi, S., Lapointe, J., and Wen, Y. (2011). Taking a “good” look at free radicals in the aging process. *Trends Cell Biol.* 21, 569–576.
- Hetzer, M.W. (2010). The Nuclear Envelope. *Cold Spring Harb. Perspect. Biol.* 2, a000539.
- Heydari, A.R., Unnikrishnan, A., Lucente, L.V., and Richardson, A. (2007). Caloric restriction and genomic stability. *Nucleic Acids Res.* 35, 7485–7496.
- Hilton, B.A., Liu, J., Cartwright, B.M., Liu, Y., Breitman, M., Wang, Y., Jones, R., Tang, H., Rusinol, A., Musich, P.R., et al. (2017). Progerin sequestration of PCNA promotes replication fork collapse and mislocalization of XPA in laminopathy-related progeroid syndromes. *FASEB J.* 31, 3882–3893.
- Ho, C.Y., Jaalouk, D.E., Vartiainen, M.K., and Lammerding, J. (2013). Lamin A/C and emerin regulate MKL1-SRF activity by modulating actin dynamics. *Nature* 497, 507–511.
- Hoeijmakers, J.H.J. (2009). DNA damage, aging, and cancer. *N. Engl. J. Med.* 361, 1475–1485.
- Hoelz, A., Debler, E.W., and Blobel, G. (2011). The Structure of the Nuclear Pore Complex. *Annu. Rev. Biochem.* 80, 613–643.
- Horn, H.F. (2014). Chapter Six - LINC Complex Proteins in Development and Disease. In *Mouse Models of The Nuclear Envelopathies and Related Diseases*, C.L.B.T.-C.T. in D.B. Stewart, ed. (Academic Press), pp. 287–321.
- Huang, D.W., Sherman, B.T., and Lempicki, R.A. (2008). Systematic and integrative analysis of

large gene lists using DAVID bioinformatics resources. *Nat. Protoc.* *4*, 44.

Huang, D.W., Sherman, B.T., and Lempicki, R.A. (2009). Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res.* *37*, 1–13.

Hunt, S.C., Kimura, M., Hopkins, P.N., Carr, J.J., Heiss, G., Province, M.A., and Aviv, A. (2015). Leukocyte telomere length and coronary artery calcium. *Am. J. Cardiol.* *116*, 214–218.

Hutchison, C.J. (2012). B-type lamins and their elusive roles in metazoan cell proliferation and senescence. *EMBO J.* *31*, 1058–1059.

Jahed, Z., Fadavi, D., Vu, U.T., Asgari, E., Luxton, G.W.G., and Mofrad, M.R.K. (2018). Molecular Insights into the Mechanisms of SUN1 Oligomerization in the Nuclear Envelope. *Biophys. J.* *114*, 1190–1203.

Kabachinski, G., and Schwartz, T.U. (2015). The nuclear pore complex – structure and function at a glance. *J. Cell Sci.* *128*, 423 LP-429.

Kaerberlein, M., Jegalian, B., and McVey, M. (2002). AGEID: a database of aging genes and interventions. *Mech. Ageing Dev.* *123*, 1115–1119.

Katta, S.S., Smoyer, C.J., and Jaspersen, S.L. (2014). Destination: inner nuclear membrane. *Trends Cell Biol.* *24*, 221–229.

Kishi, S. (2014). The Zebrafish Models to Explore Genetic and Epigenetic Impacts on Evolutionary Developmental Origins of Aging. *Transl Res* *163*, 123–125.

Koch, A.J., and Holaska, J.M. (2014). Emerin in health and disease. *Semin. Cell Dev. Biol.* *29*, 95–106.

Koga, H., Kaushik, S., and Cuervo, A.M. (2011). Protein homeostasis and aging: The importance of exquisite quality control. *Ageing Res. Rev.* *10*, 205–215.

Krishnan, V., Chow, M.Z.Y., Wang, Z., Zhang, L., Liu, B., Liu, X., and Zhou, Z. (2011). Histone H4 lysine 16 hypoacetylation is associated with defective DNA repair and premature senescence in Zmpste24-deficient mice. *Proc. Natl. Acad. Sci.*

Kryston, T.B., Georgiev, A.B., Pissis, P., and Georgakilas, A.G. (2011). Role of oxidative stress and DNA damage in human carcinogenesis. *Mutat. Res.* *711*, 193–201.

Kubben, N., and Misteli, T. (2017). Shared molecular and cellular mechanisms of premature ageing and ageing-associated diseases. *Nat. Rev. Mol. Cell Biol.* *18*, 595–609.

Kubben, N., Zhang, W., Wang, L., Voss, T.C., Yang, J., Qu, J., Liu, G.H., and Misteli, T. (2016). Repression of the antioxidant NRF2 pathway in premature aging. *Cell* *165*, 1361–1374.

Kuilman, T., Michaloglou, C., Mooi, W.J., and Peeper, D.S. (2010). The essence of senescence. *Genes Dev.* *24*, 2463–2479.

Kuszel, L., Trzeciak, T., Richter, M., and Czarny-Ratajczak, M. (2015). Osteoarthritis and telomere shortening. *J. Appl. Genet.* *56*, 169–176.

Labbadia, J., and Morimoto, R.I. (2015). The Biology of Proteostasis in Aging and Disease. *Annu. Rev. Biochem.* *84*, 435–464.

- Lattanzi, G., Ortolani, M., Columbaro, M., Prencipe, S., Mattioli, E., Lanzarini, C., Maraldi, N.M., Cenni, V., Garagnani, P., Salvioli, S., et al. (2014). Lamins are rapamycin targets that impact human longevity: a study in centenarians. *J. Cell Sci.* *127*, 147–157.
- Lee, C., and Longo, V.D. (2011). Fasting vs dietary restriction in cellular protection and cancer treatment: From model organisms to patients. *Oncogene* *30*, 3305–3316.
- Lee, Y.L., and Burke, B. (2017). LINC complexes and nuclear positioning. *Semin. Cell Dev. Biol.*
- Lee, S.J., Jung, Y.S., Yoon, M.H., Kang, S.M., Oh, A.Y., Lee, J.H., Jun, S.Y., Woo, T.G., Chun, H.Y., Kim, S.K., et al. (2016). Interruption of progerin-lamin A/C binding ameliorates Hutchinson-Gilford progeria syndrome phenotype. *J. Clin. Invest.* *126*, 3879–3893.
- de Leeuw, R., Gruenbaum, Y., and Medalia, O. (2018). Nuclear Lamins: Thin Filaments with Major Functions. *Trends Cell Biol.* *28*, 34–45.
- Li, P., Stumpf, M., Müller, R., Eichinger, L., Glöckner, G., and Noegel, A.A. (2017). The function of the inner nuclear envelope protein SUN1 in mRNA export is regulated by phosphorylation. *Sci. Rep.* *7*, 9157.
- Lin, F., Blake, D.L., Callebaut, I., Skerjanc, I.S., Holmer, L., McBurney, M.W., Paulin-Levasseur, M., and Worman, H.J. (2000). MAN1, an Inner Nuclear Membrane Protein That Shares the LEM Domain with Lamina-associated Polypeptide 2 and Emerin. *J. Biol. Chem.* *275*, 4840–4847.
- Liu, B., Wang, J., Chan, K.M., Tjia, W.M., Deng, W., Guan, X., Huang, J.D., Li, K.M., Chau, P.Y., Chen, D.J., et al. (2005). Genomic instability in laminopathy-based premature aging. *Nat. Med.*
- Liu, G.-H., Li, M., Qu, J., and Belmonte, J.C.I. (2012). Gating neural development and aging via nuclear pores. *Cell Res.* *22*, 1212–1214.
- Lombard, D.B., Chua, K.F., Mostoslavsky, R., Franco, S., Gostissa, M., and Alt, F.W. (2005). DNA repair, genome stability, and aging. *Cell* *120*, 497–512.
- López-Otín, C., Blasco, M.A., Partridge, L., Serrano, M., and Kroemer, G. (2013). The Hallmarks of Aging. *Cell* *153*, 1194–1217.
- Lord, C.J., and Ashworth, A. (2012). The DNA damage response and cancer therapy. *Nature* *481*, 287.
- Lord, C.L., Timney, B.L., Rout, M.P., and Wentz, S.R. (2015). Altering nuclear pore complex function impacts longevity and mitochondrial function in *S. cerevisiae*. *J. Cell Biol.* *208*, 729–744.
- Lu, B., Chen, H., and Lu, H. (2012). The relationship between apoptosis and aging. *Adv. Biosci. Biotechnol.* *3*, 705–711.
- Ludérus, M.E.E., Van Steensel, B., Chong, L., Sibon, O.C.M., Cremers, F.F.M., and De Lange, T. (1996). Structure, subnuclear distribution, and nuclear matrix association of the mammalian telomeric complex. *J. Cell Biol.* *135*, 867–881.
- Ludovico, P., Osiewacz, H.D., Costa, V., and Burhans, W.C. (2012). Cellular models of aging.

Oxid. Med. Cell. Longev. 2012, 1–4.

Lukášová, E., Kovarčík, A., Bacíková, A., Falk, M., and Kozubek, S. (2017). Loss of lamin B receptor is necessary to induce cellular senescence. *Biochem. J.* 474, 281–300.

Ma, Q. (2013). Role of Nrfe in Oxidative Stress and Toxicity. *Annu Rev Pharmacol Toxicol* 53, 401–426.

Madeo, F., Zimmermann, A., Maiuri, M.C., and Kroemer, G. (2015). Essential role for autophagy in life span extension. *J. Clin. Invest.* 125, 85–93.

de Magalhães, J.P. (2004). From cells to ageing: A review of models and mechanisms of cellular senescence and their impact on human ageing. *Exp. Cell Res.* 300, 1–10.

de Magalhães, J.P., and Toussaint, O. (2004). GenAge: a genomic and proteomic network map of human ageing. *FEBS Lett.* 571, 243–247.

de Magalhães, J.P., Curado, J., and Church, G.M. (2009). Meta-analysis of age-related gene expression profiles identifies common signatures of aging. *Bioinformatics* 25, 875–881.

De Magistris, P., and Antonin, W. (2018). The Dynamic Nature of the Nuclear Envelope. *J. Cell Biol.* 108, 277–297.

Mahen, R., Hattori, H., Lee, M., Sharma, P., Jeyasekharan, A.D., and Venkitaraman, A.R. (2013). A-Type Lamins Maintain the Positional Stability of DNA Damage Repair Foci in Mammalian Nuclei. *PLoS One*.

Maleszewska, M., Mawer, J.S.P., and Tessarz, P. (2016). Histone Modifications in Ageing and Lifespan Regulation. *Curr. Mol. Biol. Reports* 2, 26–35.

Martin, G.M. (2011). The biology of aging: 1985-2010 and beyond. *FASEB J.*

McClintock, D., Ratner, D., Lokuge, M., Owens, D.M., Gordon, L.B., Collins, F.S., and Djabali, K. (2007). The mutant form of Lamin A that causes Hutchinson-Gilford progeria is a biomarker of cellular aging in human skin. *PLoS One* 2.

Meinke, P., Nguyen, T.D., and Wehnert, M.S. (2011). The LINC complex and human disease. *Biochem. Soc. Trans.* 39, 1693–1697.

Mi, H., Muruganujan, A., Casagrande, J.T., and Thomas, P.D. (2013). Large-scale gene function analysis with the PANTHER classification system. *Nat. Protoc.* 8, 1551.

Mi, H., Huang, X., Muruganujan, A., Tang, H., Mills, C., Kang, D., and Thomas, P.D. (2017). PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements. *Nucleic Acids Res.* 45, D183–D189.

Michan, S. (2014). Calorie restriction and NAD<sup>+</sup>/sirtuin counteract the hallmarks of aging. *Front. Biosci.* 19, 1300–1319.

Mitchell, S.J., Scheibye-Knudsen, M., Longo, D.L., and de Cabo, R. (2015). Animal Models of Aging Research: Implications for Human Aging and Age-Related Diseases. *Annu. Rev. Anim. Biosci.* 3, 283–303.

Morris, G.E., Manilal, S., Holt, I., Tunnah, D., Clements, L., Wilkinson, F.L., Sewry, C.A., and



- Nguyen, M. thi (2002). The Distribution of Emerin and Lamins in X-Linked Emery-Dreifuss Muscular Dystrophy. In *Nuclear Envelope Dynamics in Embryos and Somatic Cells*, P. Collas, ed. (Springer US), pp. 143–151.
- Moskalev, A.A., Shaposhnikov, M. V, Plyusnina, E.N., Zhavoronkov, A., Budovsky, A., Yanai, H., and Fraifeld, V.E. (2013). The role of DNA damage and repair in aging through the prism of Koch-like criteria. *Ageing Res. Rev.* *12*, 661–684.
- Muradian, K., and Schachtschabel, D.O. (2001). The role of apoptosis in aging and age-related disease: Update. *Z. Gerontol. Geriatr.* *34*, 441–446.
- Nelson, G., Wordsworth, J., Wang, C., Jurk, D., Lawless, C., Martin-Ruiz, C., and von Zglinicki, T. (2012). A senescent cell bystander effect: senescence-induced senescence. *Aging Cell* *11*, 345–349.
- Newman, M.E.J. (2006). Modularity and community structure in networks. *Proc. Natl. Acad. Sci. U. S. A.* *103*, 8577–8582.
- Newport, J.W., and Forbes, D.J. (1987). The Nucleus: Structure, Function, and Dynamics. *Annu. Rev. Biochem.* *56*, 535–565.
- Nikolakaki, E., Mylonis, I., and Giannakouros, T. (2017). Lamin B Receptor: Interplay between Structure, Function and Localization. *Cells* *6*, 28.
- Nofrini, V., Di Giacomo, D., and Mecucci, C. (2016). Nucleoporin genes in human diseases. *Eur. J. Hum. Genet.* *24*, 1388–1395.
- Ogino, S., Chan, A.T., Fuchs, C.S., and Giovannucci, E. (2012). Molecular Pathologic Epidemiology of Colorectal Neoplasia: An Emerging Transdisciplinary and Interdisciplinary Field. *60*, 397–411.
- Olive, M., Harten, I., Mitchell, R., Beers, J., Djabali, K., Cao, K., Erdos, M.R., Blair, C., Funke, B., Smoot, L., et al. (2010). Cardiovascular Pathology in Hutchinson-Gilford Progeria: Correlation with the Vascular Pathology of Aging. *Arterioscler. Thromb. Vasc. Biol.* *30*, 2301–2309.
- Olovnikov, A.M. (1996). Telomeres, telomerase, and aging: Origin of the theory. *Exp. Gerontol.* *31*, 443–448.
- Padiath, Q.S., Saigoh, K., Schiffmann, R., Asahara, H., Yamada, T., Fu, Y., Koeppen, A., Hogan, K., and Pta, L.J. (2007). Lamin B1 duplications cause autosomal dominant leukodystrophy. *38*.
- Pascual-Garcia, P., and Capelson, M. (2014). Nuclear pores as versatile platforms for gene regulation. *Curr. Opin. Genet. Dev.* *25*, 110–117.
- Patel, S.S., Belmont, B.J., Sante, J.M., and Rexach, M.F. (2007). Natively Unfolded Nucleoporins Gate Protein Diffusion across the Nuclear Pore Complex. *Cell* *129*, 83–96.
- Pemberton, L.F., and Paschal, B.M. (2005). Mechanisms of receptor-mediated nuclear import and nuclear export. *Traffic* *6*, 187–198.
- Pesce, V., Cormio, A., Fracasso, F., Vecchiet, J., Felzani, G., Lezza, A.M.S., Cantatore, P., and

Gadaleta, M.N. (2001). Age-related mitochondrial genotypic and phenotypic alterations in human skeletal muscle. *Free Radic. Biol. Med.* *30*, 1223–1233.

Petrini, S., Borghi, R., D’Oria, V., Restaldi, F., Moreno, S., Novelli, A., Bertini, E., and Compagnucci, C. (2017). Aged induced pluripotent stem cell (iPSCs) as a new cellular model for studying premature aging. *Aging (Albany. NY)*. *9*, 1453–1469.

Pitt, J.N., and Kaerberlein, M. (2015). Why Is Aging Conserved and What Can We Do about It? *PLOS Biol.* *13*, e1002131.

Pollex, R., and Hegele, R. (2004). Hutchinson–Gilford progeria syndrome. *Clin. Genet.* *66*, 375–381.

Postberg, J., Lipps, H.J., and Cremer, T. (2010). Evolutionary origin of the cell nucleus and its functional architecture. *Essays Biochem.* *48*, 1–24.

Puckelwartz, M.J. (2017). The Missing LINC for Genetic Cardiovascular Disease? *Circ. Cardiovasc. Genet.* *10*, e001793.

Ragnauth, C.D., Warren, D.T., Liu, Y., McNair, R., Tajsic, T., Figg, N., Shroff, R., Skepper, J., and Shanahan, C.M. (2010). Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. *Circulation* *121*, 2200–2210.

Rando, T.A. (2013). The Ins and Outs of Aging and Longevity. *Annu. Rev. Physiol.* *75*, 617–619.

Razafsky, D., and Hodzic, D. (2009). Bringing KASH under the SUN: the many faces of nucleocytoplasmic connections. *J. Cell Biol.* *186*, 461–472.

Rebelo, S., Edgar, F., and Odete, A.B. (2015). Genetic mutations strengthen functional association of LAP1 with DYT1 dystonia and muscular dystrophy. *Mutat. Res. Mutat. Res.* *2–7*.

Reddy, S., and Comai, L. (2016). Recent advances in understanding the role of lamins in health and disease. *F1000Research* *5*, 2536.

Reutelingsperger, C.P., and van Heerde, W.L. (1997). Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. *Cell. Mol. Life Sci.* *53*, 527–532.

Riera, C.E., and Dillin, A. (2015). Tipping the metabolic scales towards increased longevity in mammals. *Nat. Cell Biol.* *17*, 196–203.

Robijns, J., Houthaeve, G., Braeckmans, K., and De Vos, W.H. (2018). Chapter Five - Loss of Nuclear Envelope Integrity in Aging and Disease. *L.B.T.-I.R. of C. and M.B. Galluzzi*, ed. (Academic Press), pp. 205–222.

Rodriguez, S., Coppedè, F., Sagelius, H., and Eriksson, M. (2009). Increased expression of the Hutchinson–Gilford progeria syndrome truncated lamin A transcript during cell aging. *Eur. J. Hum. Genet.* *17*, 928–937.

Rothballer, A., and Kutay, U. (2013). Poring over pores: Nuclear pore complex insertion into the nuclear envelope. *Trends Biochem. Sci.* *38*, 292–301.

Samson, C., Celli, F., Hendriks, K., Zinke, M., Essawy, N., Herrada, I., Arteni, A.-A., François-

Xavier, T., Alpha-Bazin, B., Armengaud, J., et al. (2017). Emerin self-assembly mechanism: role of the LEM domain. *FEBS J.* 284, 338–352.

Santos, M., Domingues, S.C., Costa, P., Muller, T., Galozzi, S., Marcus, K., da Cruz e Silva, E.F., da Cruz e Silva, O.A., and Rebelo, S. (2014). Identification of a Novel Human LAP1 Isoform That Is Regulated by Protein Phosphorylation. *PLoS One* 9, e113732.

Santos, M., Costa, P., Martins, F., da Cruz e Silva, E., da Cruz e Silva, O.A.B., and Rebelo, S. (2015). LAP1 is a crucial protein for the maintenance of the nuclear envelope structure and cell cycle progression. *Mol Cell Biochem. Springer* 399, 143–153.

Scaffidi, P., and Misteli, T. (2006a). Lamin A-Dependent Nuclear Defects in Human Aging. *Science* (80-. ). 312, 1059–1063.

Scaffidi, P., and Misteli, T. (2006b). Good news in the nuclear envelope: Loss of lamin A might be a gain. *J. Clin. Invest.* 116, 632–634.

Scaffidi, P., and Misteli, T. (2008). Lamin A-dependent misregulation of adult stem cells associated with accelerated ageing. *Nat. Cell Biol.* 10, 452–459.

Schirmer, E.C., and Foisner, R. (2007). Proteins that associate with lamins: Many faces, many functions. *Exp. Cell Res.* 313, 2167–2179.

Schneider, E.L. (1979). Aging and Cultured Human Skin in Fibroblasts. *J. Invest. Dermatol.* 73, 15–18.

Schreiber, K.H., and Kennedy, B.K. (2013). When Lamins Go Bad: Nuclear Structure and Disease. *Cell* 152, 1365–1375.

Schumacher, B., Garinis, G.A., and Hoeijmakers, J.H.J. (2008). Age to survive: DNA damage and aging. *Trends Genet.* 24, 77–85.

Schütz, W., Alsheimer, M., Öllinger, R., and Benavente, R. (2005). Nuclear envelope remodeling during mouse spermiogenesis: Postmeiotic expression and redistribution of germline lamin B3. *Exp. Cell Res.* 307, 285–291.

Senior, A., and Gerace, L. (1988). Integral membrane proteins specific to the inner nuclear membrane and associated with the nuclear lamina. *J. Cell Biol.* 107, 2029–2036.

Serebryanny, L., and Misteli, T. (2018). Protein sequestration at the nuclear periphery as a potential regulatory mechanism in premature aging. *J. Cell Biol.* 217, 21–38.

Sergio, G. (2008). Exploring the complex relations between inflammation and aging (inflamm-aging): anti-inflamm-aging remodelling of inflamm- aging, from robustness to frailty. *Inflamm. Res.* 57, 558–563.

Serrano, J.B., da Cruz e Silva, O.A.B., and Rebelo, S. (2016). Lamina associated polypeptide 1 (LAP1) interactome and its functional features. *Membranes (Basel).* 6, 1–19.

Serrano, J.B., Martins, F., Sousa, J.C., Pereira, C.D., van Pelt, A.M.M., Rebelo, S., and da Cruz e Silva, O.A.B. (2017). Descriptive Analysis of LAP1 Distribution and That of Associated Proteins throughout Spermatogenesis. *Membranes (Basel).* 7, 22.

- Shimi, T., and Goldman, R.D. (2014). Nuclear Lamins and Oxidative Stress in Cell Proliferation and Longevity. *Adv. Exp. Med. Biol.* 773, 415–430.
- Shimi, T., Butin-israeli, V., Adam, S. a, Hamanaka, R.B., Goldman, A.E., Lucas, C. a, Shumaker, D.K., Kosak, S.T., Chandel, N.S., and Goldman, R.D. (2011). The role of nuclear lamin B1 in cell proliferation and senescence The role of nuclear lamin B1 in cell proliferation and senescence. *Genes Dev.* 25, 2579–2593.
- Shin, J.-Y., Méndez-López, I., Wang, Y., Hays, A.P., Tanji, K., Lefkowitz, J.H., Schulze, P.C., Worman, H.J., and Dauer, W.T. (2013). Lamina-associated Polypeptide-1 Interacts with the Muscular Dystrophy Protein Emerin and is Essential for Skeletal Muscle Maintenance. *Dev. Cell* 26, 591–603.
- Shin, J., Dauer, W.T., and Worman, H.J. (2014). Lamina-associated polypeptide 1: Protein interactions and tissue-selective functions. *Semin. Cell Dev. Biol.* 1–5.
- Sieprath, T., Corne, T.D.J., Nooteboom, M., Grootaert, C., Rajkovic, A., Buyschaert, B., Robijns, J., Broers, J.L. V, Ramaekers, F.C.S., Koopman, W.J.H., et al. (2015). Sustained accumulation of prelamin A and depletion of lamin A / C both cause oxidative stress and mitochondrial dysfunction but induce different cell fates. *Nucleus* 6, 236–246.
- Sinclair, D.A. (2002). Paradigms and pitfalls of yeast longevity research. *Mech. Ageing Dev.* 123, 857–867.
- Solmaz, S.R., Chauhan, R., Blobel, G., and Melčák, I. (2011). Molecular Architecture of the Transport Channel of the Nuclear Pore Complex. *Cell* 147, 590–602.
- Sosa, B.A., Kutay, U., and Schwartz, T.U. (2013). Structural Insights into LINC Complexes. 23, 285–291.
- Sosa, B.A., Demircioglu, F.E., Chen, J.Z., Ingram, J., Ploegh, H.L., and Schwartz, T.U. (2014). How lamina-associated polypeptide 1 (LAP1) activates Torsin. 1, 1–13.
- Stewart, C.L., Roux, K.J., and Burke, B. (2007). Blurring the boundary: The nuclear envelope extends its reach. *Science* (80-. ). 318, 1408–1412.
- Szarc Vel Szic, K., Declerck, K., Vidaković, M., and Vanden Berghe, W. (2015). From inflammaging to healthy aging by dietary lifestyle choices: Is epigenetics the key to personalized nutrition? *Clin. Epigenetics* 7.
- Szklarczyk, D., Morris, J.H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M., Santos, A., Doncheva, N.T., Roth, A., Bork, P., et al. (2017). The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. *Nucleic Acids Res.* 45, D362–D368.
- Tacutu, R., Thornton, D., Johnson, E., Budovsky, A., Barardo, D., Craig, T., Diana, E., Lehmann, G., Toren, D., Wang, J., et al. (2018). Human Ageing Genomic Resources: new and updated databases. *Nucleic Acids Res.* 46, D1083–D1090.
- Taimen, P., Pflieger, K., Shimi, T., Möller, D., Ben-Harush, K., Erdos, M.R., Adam, S.A.,

Herrmann, H., Medalia, O., Collins, F.S., et al. (2009). A progeria mutation reveals functions for lamin A in nuclear assembly, architecture, and chromosome organization. *Proc. Natl. Acad. Sci. U. S. A.* *106*, 20788–20793.

Takeuchi, H., and Runger, T.M. (2013). Longwave UV light induces the aging-associated progerin. *J. Invest. Dermatol.* *133*, 1857–1862.

Tanno, M., Ogihara, M., and Taguchi, T. (1996). Age-related changes in proliferating cell nuclear antigen levels. *Mech. Ageing Dev.* *92*, 53–66.

The Gene Ontology Consortium (2017). Expansion of the Gene Ontology knowledgebase and resources. *Nucleic Acids Res.* *45*, D331–D338.

The Jackson Laboratory, B. (2017). Aged C57BL/6J Mice for research studies: considerations, applications, and best practices.

Thomas, P.D., Kejariwal, A., Guo, N., Mi, H., Campbell, M.J., Muruganujan, A., and Lazareva-Ulitsky, B. (2006). Applications for protein sequence–function evolution data: mRNA/protein expression analysis and coding SNP scoring tools. *Nucleic Acids Res.* *34*, W645–W650.

Tigges, J., Krutmann, J., Fritsche, E., Haendeler, J., Schaal, H., Fischer, J.W., Kalfalah, F., Reinke, H., Reifenberger, G., Stuhler, K., et al. (2014). The hallmarks of fibroblast ageing. *Mech. Ageing Dev.* *138*, 26–44.

Tsai, P.-L., Zhao, C., Turner, E., and Schlieker, C. (2016). The Lamin B receptor is essential for cholesterol synthesis and perturbed by disease-causing mutations. *Elife* *5*, e16011.

Tsurumi, A., and Li, W.X. (2012). Global heterochromatin loss: a unifying theory of aging? *Epigenetics* *7*, 680–688.

Ungricht, R., and Kutay, U. (2017). Mechanisms and functions of nuclear envelope remodelling. *Nat. Rev. Mol. Cell Biol.* *18*, 229–245.

Vanhooren, V., and Libert, C. (2013). The mouse as a model organism in aging research: Usefulness, pitfalls and possibilities. *Ageing Res. Rev.* *12*, 8–21.

Varani, J. (2010). Fibroblast aging: Intrinsic and extrinsic factors. *Drug Discov. Today Ther. Strateg.* *7*, 65–70.

Varela, I., Cadi˜anos, J., Pendas, A.M., Gutierrez-Fernandez, A., Folgueras, A.R., Sanchez, L.M., Zhou, Z., Rodriguez, F.J., Stewart, C.L., Vega, J.A., et al. (2005). Accelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation. *Nature* *437*, 564–568.

Van De Ven, M., Andressoo, J.O., Holcomb, V.B., Von Lindern, M., Jong, W.M.C., De Zeeuw, C.I., Suh, Y., Hasty, P., Hoeijmakers, J.H.J., Van Der Horst, G.T.J., et al. (2006). Adaptive stress response in segmental progeria resembles long-lived dwarfism and calorie restriction in mice. *PLoS Genet.* *2*, 2013–2025.

Vidak, S., Kubben, N., Dechat, T., and Foisner, R. (2015). Proliferation of progeria cells is enhanced by lamina-associated polypeptide 2alpha (LAP2alpha) through expression of extracellular matrix proteins. *Genes Dev* *29*, 2022–2036.

- Vijg, J. (2008). The role of DNA damage and repair in aging: New approaches to an old problem. *Mech. Ageing Dev.*
- Villeponteau, B. (1997). The heterochromatin loss model of aging. *Exp. Gerontol.* 32, 383–394.
- Waldera-Lupa, D.M., Kalfalah, F., Florea, A.-M., Sass, S., Kruse, F., Rieder, V., Tigges, J., Fritsche, E., Krutmann, J., Busch, H., et al. (2014). Proteome-wide analysis reveals an age-associated cellular phenotype of in situ aged human fibroblasts. *Aging (Albany, NY)*. 6, 856–872.
- Walther, D.M., and Mann, M. (2011). Accurate quantification of more than 4000 mouse tissue proteins reveals minimal proteome changes during aging. *Mol. Cell. Proteomics* 10, M110.004523-M110.004523.
- Watson, M.L. (1955). The Nuclear Envelope: Its Structure and Relation to Cytoplasmic Membranes. *J. Biophys. Biochem. Cytol.* 1, 257–270.
- Wente, S.R., and Rout, M.P. (2010). The nuclear pore complex and nuclear transport. *Cold Spring Harb. Perspect. Biol.* 2, 1–19.
- Wilkinson, F.L., Holaska, J.M., Zhang, Z., Sharma, A., Manilal, S., Holt, I., Stamm, S., Wilson, K.L., and Morris, G.E. (2003). Emerin interacts in vitro with the splicing-associated factor, YT521-B. *Eur. J. Biochem.* 270, 2459–2466.
- Wilson, K.L., Holaska, J.M., Oca, R.M. De, Tiffit, K., Zastrow, M., Segura-Totten, M., Mansharamani, M., and Bengtsson, L. (2008). Nuclear Membrane Protein Emerin: Roles in Gene Regulation, Actin Dynamics and Human Disease. *Nucl. Organ. Dev. Dis.*
- Wood, A.M., Danielsen, J.M.R., Lucas, C.A., Rice, E.L., Scalzo, D., Shimi, T., Goldman, R.D., Smith, E.D., Le Beau, M.M., and Kosak, S.T. (2014). TRF2 and lamin A/C interact to facilitate the functional organization of chromosome ends. *Nat. Commun.* 5, 1–9.
- Xu, S., and Powers, M.A. (2013). In vivo analysis of human nucleoporin repeat domain interactions. *Mol. Biol. Cell* 24, 1222–1231.
- Yang, H.J., Iwamoto, M., Hiraoka, Y., and Haraguchi, T. (2017). Function of nuclear membrane proteins in shaping the nuclear envelope integrity during closed mitosis. *J. Biochem.* 161, 471–477.
- Zahn, J.M., and Kim, S.K. (2007). Systems biology of aging in four species. *Curr. Opin. Biotechnol.*
- Zane, L., Sharma, V., and Misteli, T. (2014). Common features of chromatin in aging and cancer: Cause or coincidence? *Trends Cell Biol.* 24, 686–694.
- Zhang, H., Davies, K.J.A., and Forman, H.J. (2015a). Oxidative stress response and Nrf2 signaling in aging. *Free Radic. Biol. Med.* 88, 314–336.
- Zhang, Q., Bethmann, C., Worth, N.F., Davies, J.D., Wasner, C., Feuer, A., Ragnauth, C.D., Yi, Q., Mellad, J.A., Warren, D.T., et al. (2007). Nesprin-1 and -2 are involved in the pathogenesis of Emery – Dreifuss muscular dystrophy and are critical for nuclear envelope integrity. *16*, 2816–2833.

Zhang, W., Li, J., Suzuki, K., Qu, J., Wang, P., Zhou, J., Liu, X., Ren, R., Xu, X., Ocampo, A., et al. (2015b). Aging stem cells. A Werner syndrome stem cell model unveils heterochromatin alterations as a driver of human aging. *Science* 348, 1160–1163.

Zhu, R., Antoku, S., and Gundersen, G.G. (2017). Centrifugal Displacement of Nuclei Reveals Multiple LINC Complex Mechanisms for Homeostatic Nuclear Positioning. *Curr. Biol.* 27, 3097–3110.e5.





## **Appendix**



## ELB Lysis buffer

Samples

### Stock ELB (Vf≈10 ml)

Triton X-100 100% 50 µl  
 HEPES pH 7 1M 500 µl  
 NaCl 5M 500 µl  
 H<sub>2</sub>O 8,95 ml

### Complete ELB (Vf≈5ml)

ELB stock 4,645 ml  
 DTT 1M 5 µl  
 NaF 1M 5µl  
 EDTA 0.5M 20µl  
 EGTA 100.0mM 50µl  
 Na<sub>3</sub>VO<sub>4</sub> 100.0mM 50µl

When working with samples, distribute 955µl of complete ELB in each microtube and store it like that. After, at the time you will use it, complete it with 20µl of cComplete™, EDTA-free Protease Inhibitor Cocktail Roche and 25µl of PMSF Protease Inhibitor.

---

## SDS-PAGE (1D)

29:1 Acrylamide:Bis Acrylamide Ratio (3.3% cross-linker concentration)

- Gradient gel

Lower Gel (Gel with 1.5mm):

| <b>½ system</b>       |                |                 | <b>1 system</b>       |                |                 |
|-----------------------|----------------|-----------------|-----------------------|----------------|-----------------|
|                       | <b>LG (5%)</b> | <b>LG (20%)</b> |                       | <b>LG (5%)</b> | <b>LG (20%)</b> |
| <b>H<sub>2</sub>O</b> | 9.29ml         | 3.67ml          | <b>H<sub>2</sub>O</b> | 18.59ml        | 7.34ml          |
| <b>LGB</b>            | 3.75ml         | 3.75ml          | <b>LGB</b>            | 7.5ml          | 7.5ml           |
| <b>Acrylamide</b>     | 1.875ml        | 7.5ml           | <b>Acrylamide</b>     | 3.75ml         | 15ml            |
| <b>APS</b>            | 75µl           | 75µl            | <b>APS</b>            | 150µl          | 150µl           |
| <b>TEMED</b>          | 7.5µl          | 7.5µl           | <b>TEMED</b>          | 15µl           | 15µl            |

| <b>3.5% Upper Gel (gel with 1.5mm)</b> |          |          |
|--|----------|----------|
|  | ½ system | 1 system |
| <b>H<sub>2</sub>O</b>                  | 6.92ml   | 13.83ml  |
| <b>Acrylamide</b>                      | 0.88ml   | 1.75ml   |
| <b>UGB</b>                             | 2ml      | 4ml      |
| <b>SDS 10%</b>                         | 100µl    | 200µl    |
| <b>APS 10%</b>                         | 100µl    | 200µl    |
| <b>TEMED</b>                           | 10µl     | 20µl     |

### **10% APS (ammonium persulfate)**

0.1g em 1ml de dH<sub>2</sub>O autoclaved

Note: Always prepare it fresh before using it.

### **LGB (Lower Gel Buffer)**

V=0.5L

Tris 90.825g

SDS 2g

Note: It is necessary to heat. Adjust pH 8.9. Keep at 4°C.

### **UGB (Upper Gel Buffer)**

Vf=0.5L

Tris 37.845g

Note: Adjust pH 8.9. Keep at 4°C.

### **10% SDS (sodium dodecylsulfate)**

Dissolve 10g of SDS in 100ml H<sub>2</sub>O.

### **Tris-Gly 10x Stock**

30.3g TRIS (250mM)

144.1g Glycine (1.92M)

Make up to 1L with dH<sub>2</sub>O

Do not adjust pH 8.3

### **LB 4X**

| <b>LB 4x (Loading Buffer 4x)</b> | <b>Vf=10ml</b> |
|----------------------------------|----------------|
| Tris 1M                          | 2,5ml          |
| SDS                              | 0,8g           |
| Glycerol                         | 4ml            |
| 2-Mercaptoethanol                | 2ml            |
| Bromophenol blue                 | 0.001g         |

### **Stock Tris 1M**

Dissolve 30.3g Tris in 250ml of dH<sub>2</sub>O. Adjust pH 6.8. Store at 4°C.

### **TBS 10X**

|             | <b>Vf=1L</b> |
|-------------|--------------|
| <b>Tris</b> | 12.11g       |
| <b>NaCl</b> | 87.66g       |

Adjust pH 8,0. Store at 4°C.

### **TBST 10x**

|                 | <b>Vf=1L</b> |
|-----------------|--------------|
| <b>Tris</b>     | 12.11g       |
| <b>NaCl</b>     | 87.66g       |
| <b>Tween 20</b> | 5ml          |

Adjust pH 8,0. Store at 4°C.

### **Running Buffer (1L)**

800ml dH<sub>2</sub>O

100ml Tris-Gly 10x Stock

10ml SDS 10%

Make up to 1L with dH<sub>2</sub>O

### **Transfer Solution (1L)**

100ml Tris-Gly 10x Stock

700ml dH<sub>2</sub>O

200ml methanol

### Stripping Solution

|             |          |
|-------------|----------|
|             | Vf=500ml |
| <b>Tris</b> | 3.76g    |
| <b>SDS</b>  | 10g      |

**Note:** It is necessary to heat the solution. Adjust pH to 6.7. Store at RT. Immediately before usage, add 175 $\mu$ l of 2-Mercaptoethanol for each 25ml of solution.

### Dilution scheme for Standard Teste Tube Protocol and Microplate Procedure (Working range 20-2,000 $\mu$ g/mL)

| Vial     | Volume of Diluent ( $\mu$ L) | Volume and Source of BSA ( $\mu$ L) | Final BSA Concentration ( $\mu$ g/mL) |
|----------|------------------------------|-------------------------------------|---------------------------------------|
| <b>A</b> | 0                            | 300 of Stock                        | 2000                                  |
| <b>B</b> | 125                          | 375 of Stock                        | 1500                                  |
| <b>C</b> | 325                          | 325 of Stock                        | 1000                                  |
| <b>D</b> | 175                          | 175 of vial B dilution              | 750                                   |
| <b>E</b> | 325                          | 325 of vial C dilution              | 500                                   |
| <b>F</b> | 325                          | 325 of vial E dilution              | 250                                   |
| <b>G</b> | 325                          | 325 of vial F dilution              | 125                                   |
| <b>H</b> | 400                          | 100 of vial G dilution              | 25                                    |
| <b>I</b> | 400                          | 0                                   | 0 =Blank                              |

### Ponceau S

0.1% Pounceau in 5%acetic acid

(example Vf=50ml: add 0.05g of Ponceau S to 47.5ml of dH<sub>2</sub>O. In the hood, add 2.5ml of acetic acid).

Store at 4°C.